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Abstract 
The increase in the number of women in whom a diagnosis of ectopic 
pregnancy is made presents challenges to the gynaecologist. It is important to 
follow diagnostic protocols to ensure that cases are not missed. But because 
diagnostic tools, such as the use of serum hCG estimations, improves pick- 
up, clinicians need to be aware that surgery is not the only effective way of 
managing ectopic pregnancy and women can be offered management 
choices. 
Diagnosis of ectopic pregnancy is made by considering the clinical situation in 
conjunction with the ultrasound and biochemical (hCG or progesterone) 
findings. There is no test that conclusively proves that an ectopic pregnancy is 
present. Fetal fibronectin is explored as a possible diagnostic test as part of 
this thesis. Whilst there are appears to be some differences in the levels in 
different situations in early pregnancy, the assay, which detects the FDC-6 
epitope of the fetal form of fibronectin and is in widespread use in later 
pregnancy, is fundamentally flawed, as it is not specific to the fetal form of 
fibronectin and detectable levels can be found in the cervixes of non-pregnant 
women, as the presence of blood leads to a positive result. It is not possible to 
show whether or not fetal fibronectin is a useful tool in the diagnosis of ectopic 
pregnancy with the available assay. 
A series of questionnaires were used to assess the availability of Early 
Pregnancy Units and women's experiences of the diagnostic and 
management of ectopic pregnancy. I demonstrated that women can weigh 
different choices, where the choices offer complex advantages and 
disadvantages, and value involvement of management decisions. 
An audit of the use of hCG estimations within St. James's University Hospital 
was used as a basis of a protocol for the management of ectopic pregnancy. 
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Chapter 1- Introduction 
1.1 Ectopic Pregnancy 
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Figure 1.1 Sites of ectopic pregnancy (Tay, Moore, Walker, 2000) 
An ectopic pregnancy is one that implants outwith the uterine cavity. The vast 
majority occur in the Fallopian tube, mostly in the ampullary region, some in the 
ovary and cervix and rarely in the abdominal cavity. The reason that ectopic 
pregnancy is important is that is carries significant morbidity and mortality. If the 
ectopic pregnancy erodes through the Fallopian tube, there is damage to the tube 
itself and potential rupture of the adjacent blood vessels, which can lead to severe 
maternal illness and death. The numbers of women that die of this condition has 
stayed relatively static over the last 12 years (Table 1.1) 
OVary 
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Table 1.1 "Why Women Die" figures from the maternal mortality reports 1988- 
99. The numbers for ectopic pregnancies are estimated. 
Preg 1000 Ectopic Ectopics Deaths Deaths 
/1000 preg /1000 ectopic 
88-90 2,886 24,775 9.6 15 0.5 
91-93 3,137 30,160 9.6 9 0.3 
94-96 2,914 33,550 11.5 12 0.4 
97-99 2,873 31,946 11.1 13 0.4 
Deaths resulting from ectopic pregnancy now contribute the fourth highest cause of 
maternal mortality after pulmonary embolus, preeclampsia and sepsis. When 
ectopic pregnancy occurs, the mortality rate has remained static at around 4/1000. 
(RCOG Press, 2001) (Table 1.1) The aim of modern management is to achieve a 
diagnosis prior to the rupture of the Fallopian tube, when the morbidity is less and 
the treatment less invasive. 
1.2 Incidence of EctoDic Preanancy 
The incidence of ectopic pregnancy has risen steadily in recent decades. Although 
recently some countries are now seeing a fall, the incidence is still much greater 
than in the 1960's and 70's. The reasons for this increase are multifactorial, but it is 
partly as the result of an improvement in diagnosis of the condition following the 
introduction of high-resolution ultrasound scans and serum hCG estimations for 
diagnostic purposes. However, the background upward trend has largely been 
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Figure 1.2 An unruptured ectopic pregnancy in the left fallopian tube. 
blamed on the changes in sexual practices, and the wide availability of reliable 
contraception, resulting in an increase in exposure to infective agents such as 
Chlamydia trachomatis. Although this is partly related to the acute disease, it is 
more probably linked to the tubal damage that may result. Indeed, in the countries 
in which a decline in the incidence of ectopic pregnancy is being observed, this fall 
has been attributed to the implementation of programmes aimed at preventing 
chlamydial disease. Since there is a lag period of around 10 years between the 
widespread introduction of such programmes and the observed reduction, the 
effect of tubal damage resulting from chiamydial infections would appear to be long 
term. Studies of the changes in the incidence of ectopic pregnancy in different 
countries are discussed below. 
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Figure 1.3 Adhesions seen at laparoscopy, probably caused by previous 
infection with Chiamydia Trachomatis. 
1.2.1 Canada 
The reported incidence of ectopic pregnancy in Southern Canada in 1998 was 15.7 
per 1,000 reported pregnancies (Orr and Brown, 1998). In Keewatin, in the arctic 
territories of Canada, the incidence of ectopic pregnancy was lower at 9.6 per 
1,000 reported pregnancies. The fertility rate is higher in the northern regions of 
Canada, and the spacing between pregnancies less. Perhaps the delay in 
becoming pregnant after the onset of sexual activity, that results from the 
separation of sexual activity from reproduction, might mean that tubal damage 
occurs before pregnancy is achieved in cultures where fertility rates are lower and 
spacing between pregnancies greater. It is interesting that the rates of gonorrhoea 
. ý+'" R 
ý. ` 
ý.. 
ý. 1 
.A ýý ýý 
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and chlamydia in the Northern Canada are respectively 27- and 22-fold those 
found in Southern Canada, which would be expected to increase the incidence of 
ectopic pregnancy, since pelvic inflammatory disease is considered such an 
important aetiological factor for ectopic pregnancy. Other factors such as age at 
pregnancy and genetic differences may play a role. 
1.2.2 Finland 
A large increase in the incidence of ectopic pregnancy was noted in Finland 
between 1967 and 1984 (Mäkinen, 1987), the zenith of the increase was found in 
1987 and since then the incidence has decreased (Mäkinen, 1996). These data 
showed a population-based incidence of 159 per 100,000 women in 1984,176 per 
100,000 women in 1988 and 155 per 100,000 women in 1994. Although these 
figures use a different denominator, they show the same recent decline in the 
incidence of ectopic pregnancy found in Sweden, described below. Mäkinen et al. 
(1998) postulated that the peak of the incidence of ectopic pregnancy was a result 
of the large cohort of "baby-boomers" reaching the peak of their fertility leading to 
distortion of the figures. 
1.2.3 France 
Coste et al. (2000a) analysed data from the Auvergne ectopic pregnancy register. 
They observed a global decline in the incidence of ectopic pregnancy between 
1992 and 1997. To determine the reasons behind this decline, they divided the 
cases of ectopic pregnancy into a group that was caused by reproductive failure 
Chapter 1- Introduction 6 
and another group that was caused by contraceptive failure. Consistently, 3/4s of 
cases secondary to contraceptive failure were in women using intra-uterine devices 
(IUDs). Over the period studied, there was a decline in the use of IUDs and an 
increase in the use of contraceptive pills in France, this lead to a decrease in the 
number of ectopic pregnancies secondary to contraceptive failure, resulting in a 
reduction in the total number of ectopic pregnancies. The number of ectopic 
pregnancies resulting from reproductive failure remained constant. 
1.2.4 India 
A lower incidence is reported in India, although here too, the incidence is rising. In 
the fifteen-year period between 1959 and 1973, the incidence was 2.7 per 1,000 
pregnancies. In the five years between 1988 and 1993 the incidence was 6.3 per 
1,000 pregnancies (Arora et al., 1998). This may reflect a lower incidence in this 
population where sexual relations outside of marriage are less common, but it 
might also show that in an environment where there is not universal free health 
care that many ectopic pregnancies resolve without requiring medical intervention. 
1.2.5 Ireland 
The incidence of ectopic pregnancy at the National Maternity Hospital doubled 
from 1995 to 1996 (4.8 to 8.3 per 1,000 pregnancies, respectively). This coincided 
with the introduction of serum hCG testing and a protocol for the diagnosis of 
ectopic pregnancy (Ong and Wingfield, 1999). There was no increase in the 
incidence of ruptured ectopic pregnancy or blood transfusion in these two years, 
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and indeed these were required no more frequently than in 1986 when the 
incidence of ectopic pregnancy in the same unit was 1.8 per 1,000 pregnancies. 
The authors suggested that there was not so much an increase in incidence of 
ectopic pregnancy than an increase in its diagnosis. 
1.2.6 Norway 
Skjeldestad of aL, (1997a) noted a four-fold increase in the incidence of ectopic 
pregnancy in a stable Norwegian population between 1970 and 1993. Storeide et 
al. (1997) observed a different Norwegian population over a similar time - 1976 
and 1993. They again noticed an increase in the incidence of ectopic pregnancy. 
This increase was greater in older women; in women of less than 30 years the rate 
per 1,000 reported pregnancies increased by 25% from 9.4 to 11.8; in women of 
more than 35 years of age the rate per 1,000 reported pregnancies increased by 
98% from 20.7 to 40.9. Compared with the 15 to 19 year old age group, the over 
35's had an eight-fold increase in the risk of ectopic pregnancy. This was explained 
as an "accumulation of risk factors" in the older age group. 
1.2.7 Sweden 
In Sweden there has been a widespread implementation of a screening 
programme for chlamydia. This has lead to a decrease in the incidence of new 
chlamydial infections between 1985 and 1995. As a result, the incidence of ectopic 
pregnancy has fallen by 45% (Egger et al., 1998). 
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1.2.8 United States 
The incidence of ectopic pregnancy has been seen to increase in recent decades: 
Table 1.2. Incidence of ectopic pregnancy in the United States Rubin et a/., 
1983; **Centers for Disease Control, 1993; -*Rajkhowa et al., 2000 
Year Incidence - US (UK figures for 
comparison) 
1970 4.5 per 1,000 
. 
3.51 per 1,000 
pregnancies re nancies*** 
1978 9.4 per 1,000 
* 
5.59 per 1,000 
pregnancies re nancies*** 
1992 19.7 per 1,000 
** 
12.4 per 1,000 
pregnancies re nancies*** 
This has a knock-on effect on hospital admissions with the number of 
hospitalisations for ectopic pregnancies increasing from 17,800 in 1970 to 88,400 
in the United States in 1989. (Anonymous, 1995a) 
1.2.8 United Kingdom 
Figures for the incidence of ectopic pregnancy between 1966 and 1970 were 
published by Beral, (1975) and Rajkhowa et al., (2000) continued this to 1996 
(Figure 1.4) 
This suggests that the incidence of ectopic pregnancy might have reached its peak 
in the UK in the early 90's, and when information from the next decade is available, 
it will be possible to see whether the decline seen in some other countries, is 
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evident in the UK as well. If the incidence has indeed peaked, this is at a lower 
level than in the US or Scandinavia. 
Data is missing for 1986 to 1988; this represents a change in the method of 
collecting data. It is possible that the apparent increase in incidence might be an 
artefact of data collection, rather than a true rise in incidence. Data from other 
countries would, however, support at least some of this rise being genuine. 
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Figure 1.4. Rise in incidence of ectopic pregnancy in the UK 1966-1996. 
1.3 Presentation of Ectopic Pregnancy 
It can be seen that the presentation and diagnosis of ectopic pregnancy has varied 
with place and time. Early diagnosis is important because it can reduce morbidity, 
but will result in an increase in the reported incidence. However, traditionally, most 
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women with ectopic pregnancy have only presented when acute symptoms are 
apparent and so it is seen as a gynaecological emergency. 
In one study, 96% of subjects presented with abdominal pain and 83% with vaginal 
bleeding (Aboud and Chaliha, 1998). Overcoming the failure to recognise the 
symptoms of ectopic pregnancy would seem to be the greatest challenge in 
reducing the associated mortality and morbidity. Another difficulty with the 
diagnosis of ectopic pregnancy arises, not so much from recognising the 
symptoms, but from the possibility that ectopic pregnancy can be present in 
asymptomatic women with apparently normal periods. A pregnancy test is simple 
to perform, and should be performed in any woman in whom pregnancy is a 
possibility, even when symptoms do not suggest a pregnancy related problem. A 
negative test almost certainly rules out an ectopic pregnancy. 
1.4 Epidemiolo 
Cagnacci et al. (1999) found a seasonal variation in the incidence of spontaneously 
conceived ectopic pregnancy, the frequency being significantly higher from 
November to January and May to July than it was from February to April and 
August to October. Lemus (2000) reports that no such seasonal variation is found 
after assisted conception. This would suggest a changing behaviour pattern in the 
spontaneously conceived group. 
Many risk factors for ectopic pregnancies have been implicated in its aetiology: 
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1.4.1. Pelvic Inflammatory Disease: 
Pelvic inflammatory disease is estimated to cost the United State $4.2 billion each 
year (Quan, 1994). Barlow et al. (2001) found evidence of past or present infection 
with chiamydia in 50% of women presenting with ectopic pregnancy using PCR on 
fresh tissue specimens. Chlamydia could be found in the endometrium, ovary and 
Fallopian tube at the time of surgery. 
Gaydos et al. (1998) assessed risk factors for chiamydia infection in US military 
recruits and found the following risk factors were independently associated with 
infection: 
ever having had vaginal sex (OR for infection 5.9) 
being 25 years of age or less (OR 3.0) 
being black (OR 3.4) 
having had more than one sexual partner in the last 90 days (OR 1.4) 
having had a new sexual partner in the last 90 days (OR 1.3) 
A Swedish Study (Egger et aL, 1998) looked at the incidence of both chlamydia 
infection and ectopic pregnancy. They found a strong and significant correlation in 
the 20 to 24 year old group (correlation coefficient= 0.93, p<0.001), which was lost 
in the older 35-39 year old group (correlation coefficient=0.07, p=0.8). A further 
study from Sweden (Kamwendo et aL, 2000) found a 10-year lag between a 
reduction in the incidence of pelvic inflammatory disease and any resultant 
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decrease in the ectopic pregnancy rate. This work suggests that current infection 
with chlamydia is important in the aetiology of ectopic pregnancy, but the 
association of the risk of ectopic with this primary chiamydial infection remains with 
this cohort for up to ten years. 
Recurrent chiamydial infections further increase the risk of ectopic pregnancy 
(Hillis et al., 1997). Compared to women who had had a single chlamydia infection, 
women with two infections had an elevated risk of ectopic pregnancy, OR 2.1 (95% 
Cl 1.3-3.4) and with three or more infections the risk rose further, OR 4.5 (95% Cl 
1.8-5.3). 
Urbach and Cohen (1999) examined the role of previous perforation of the 
appendix in the aetiology of ectopic pregnancy, as infection and adhesion 
formation associated with the complications of appendicitis were thought to be 
responsible for some tubal damage. They found only four original studies. These 
gave risks of adverse fertility outcome, following a perforated appendix, of between 
1.6 and 4.8 compared to women who had not had an appendicitis. They concluded 
that the trials were so poorly designed that the results were not reliable and felt a 
properly designed trial would be necessary to examine what role, if any, perforation 
of the appendix had in predisposing to ectopic pregnancy. 
1.4.2. Influence of Contraceptive Practice on Incidence 
This relates to methods that prevent intra-uterine pregnancies, but may have less 
of an effect on extra-uterine pregnancies, such as the intra-uterine contraceptive 
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device. This will not increase the incidence of ectopic pregnancies in the population 
but means there is a higher incidence of ectopic when pregnancy occurs. 
Xiong et al. (1995) performed a meta-analysis of case-control studies of the 
relationship between intrauterine contraceptive devices (IUD) and ectopic 
pregnancy. Between 1970 and 1994, sixteen such studies were found. They found 
no increase in the risk of ectopic pregnancy when current IUD users were 
compared with non-pregnant controls (pooled OR: 1.06,95% Cl 0.91-1.24). Past 
IUD use only mildly increased the risk (OR 1.40,95% Cl: 1.23-1.59). 
In France, figures obtained from the Auvergne Register associate 25-30% of all 
ectopic pregnancies with the use of IUDs (Bouyer et al., 2000). This reflects the 
high prevalence of usage of this method of contraception in France. In the UK this 
figure is lower, with only 14% of ectopic pregnancies being associated with the use 
of IUDs (Aboud, 1997). However, women using IUDs have a lower rate of ectopic 
pregnancy than women who are not using any form of contraception, which means 
the risk of ectopic pregnancy, as well as intrauterine pregnancy, is lower in IUD 
users (Ory, 1981; Sivin, 1991; Rossing et al., 1993; Skeldestad, 1997). But, as 
IUDs protect against intrauterine pregnancy more effectively than extra-uterine 
pregnancy, failure of this method of contraception is more likely to result in an 
extra-uterine pregnancy. Women using other forms of contraception that prevented 
ovulation or conception, such as the combined oral contraceptive or barrier 
methods, had a lower risk of ectopic pregnancy than non-contraceptors and users 
of IUDs (Rossing et al., 1993). 
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Bouyer et al., 2000a found that women who experienced pelvic pain or discomfort 
in the month following insertion of the IUD had a higher risk of ectopic pregnancy, 
presumably, because these were the women who got pelvic inflammatory disease 
as a result of coil insertion. IUDs tend to be used more in women who are 
approaching the end of their reproductive life. On one hand, this group has the 
highest incidence of ectopic pregnancy, but on the other, it might be the increased 
usage of IUDs for contraception that goes some way to explaining the high risk in 
this group. 
Women who have an ectopic pregnancy with an IUD in-situ have a different long- 
term prognosis. Women who conceived with an IUD in-situ had a rate 69.2% of a 
subsequent live birth, whilst those who did not had a subsequent 38.0% live birth 
rate (Sandvei et al., 1987). Ego et al., (2001) reported a similar finding, with 81 % of 
women IUD associated ectopics achieving on-going intra-uterine pregnancies 
within two years of trying to conceive, but only 67% in the group that conceived 
their ectopic pregnancy in the absence of an IUD. This is explained by the higher 
rate of a history of pelvic inflammatory disease and infertility of the group in whom 
an ectopic pregnancy was found in the absence of an IUD. Bernoux et al. (2000) 
found a similar pattern, with IUD users having an 87% 1-year cumulative rate of 
intra-uterine pregnancy after ectopic, with the cumulative rate in non-users being 
60%. However, they also found a big difference in the recurrent ectopic rate; 28% 
of the IUD non-users had recurrent ectopic pregnancy, whilst none of the IUD 
users had had a further ectopic pregnancy. 
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Wollen et al. (1984) examined the endosalpinx of healthy, non-pregnant women 
and found that users of IUDs had only half the area of ciliated epithelium compared 
to tubes of other women. The significance of this is unclear in the light of later 
evidence suggesting a lower risk of ectopic pregnancy in IUD users than in women 
not using contraception. 
Skjeldestad et al. (1997b) found no increase in the incidence of ectopic pregnancy 
in women who had undergone therapeutic termination of pregnancy. Multiple 
therapeutic terminations did increase the risk, although it might be expected that 
this group would be higher risk of sexually transmitted diseases. This finding was 
confirmed in a similar study by Atrash et al., 1997. 
1.4.3 Assisted Conception 
The results form the registry of the American Society for Reproductive 
Medicine/Society for Assisted Reproductive Technology for 1993 (Anonymous, 
1995b), found a rate of ectopic pregnancy of 1.2% for all IVF transfers and of 4.4% 
for all established cycles. Mol et al. (1997) found a 5.1 % risk of ectopic pregnancy 
after IVF-ET, Strandell et aL (1999) found a rate of 4%. These rates are more than 
twice those found after natural conceptions. 
Ribic-Pucelj et al. (1995) found the main risk factor for ectopic pregnancy after IVF- 
ET was a history of tuba) factor infertility. This was confirmed by Strandell et al. 
(1999) and Lesny et a/. (1999), who found the OR of having an ectopic pregnancy 
when tubal infertility was present was 5.41 (95% Cl 1.96-14.91), but also that 
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ectopic pregnancy was more likely when the embryo transfer was difficult, and 
particularly so if there were also tubal damage present. 
Aboud (1997) found 15% of women with ectopic pregnancy had a prior history of 
infertility. 
1.4.4 Influence of Maternal Age on Incidence 
The relationship between maternal age and ectopic pregnancy is frequently 
reported. Older women have a greater risk of any pregnancy being ectopically 
sited. Simms et al. (1997), reported that women over 40 have a 14 times greater 
risk of ectopic pregnancy than the under sixteens. This trend was seen in UK 
women as well, Rajkhowa et al. (2000), found the incidence of ectopic pregnancy 
in the 35-44 year old group to be more than double that of the 15-24 year old 
group. Coste et aL (1994) found a steep rise in the rate of ectopic pregnancy per 
1000 live births after the age of 35. When they looked at the rate of ectopic 
pregnancy as a proportion of women of reproductive age, the rate rose steadily 
until 35 years, at which point it began to decline. 
Sobande (2000) found that the risk of a second ectopic pregnancy increased with 
maternal age and with the interval between the ectopic pregnancy and the next 
conception. Women with a greater number of pregnancies before the ectopic 
pregnancy were less likely to have a second ectopic. 
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1.4.5. Miscarriage 
Some authors have found an association with a prior history of spontaneous 
miscarriage (Honore, 1979; Bouyer et al., 2000). Analysis of ectopic pregnancies 
shows them to have the same rate of karyotypic abnormality as intra-uterine 
pregnancy (Goddijin et al., 1996; Block et al., 1998; Coste et al., 2000b). 
1.4.6 Tubal Surgery 
Pisarska et al. (1998) reported an odds ratio for ectopic pregnancy following tubal 
surgery of 21.0 compared to those women in whom this was not a risk factor. 
However, caesarean section is not associated with any increase in risk of 
subsequent ectopic pregnancy (Kendrick et al., 1996). 
1.4.7 Sterilisation and its Reversal. 
Peterson at al. (1997) followed up women who had undergone a sterilisation 
procedure and found a 10-year cumulative probability of ectopic pregnancy of 7.3 
per 1,000 procedures. The annual rates of ectopic pregnancy were no lower 
between 4 and 10 years post-procedure than they were in the first three years. 
1.4.8 In-utero Exposure to Diethylstilboestrol (DES) 
Pons et al. (1988) reported a 15% incidence of extra-uterine pregnancy in DES- 
exposed women. More recently Kaufman et al. (2000) reported ectopic pregnancy 
in 4.2% of DES-exposed women compared to 0.77% of unexposed controls. 
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1.4.9 Smoking 
Castles et al. (1999) found an increased risk of ectopic pregnancy associated with 
smoking, with an odds ratio of 1.77 of ectopic pregnancy in smokers compared to 
non-smokers. Smoking also decreased the subsequent rate of intra-uterine 
pregnancy at two years after an ectopic pregnancy (51 % in smokers, 60% in non- 
smokers, p= 0.07) (Ego et al., 2001). 
1.4.10 Vaginal Douching 
Zhang et al. (1997), found vaginal douching to be associated with an increase in 
the incidence of ectopic pregnancy due to an increase in the risk of pelvic 
inflammatory disease. 
1.4.11 Previous Ectopic Pregnancy 
9.8% (Job-Spira et al., 1996) or 10.2% (Ego et aL, 2001) of women who have one 
ectopic pregnancy will have further ectopics. Each time a woman has an ectopic 
pregnancy, her chance of a future intra-uterine pregnancy decreases. Ego et al. 
(2001) found a 58% rate of ongoing intra-uterine pregnancy in women who desired 
a further pregnancy within two years of a first ectopic pregnancy. If she had had 
two previous ectopic pregnancies, the rate was only 29% at the same point in time. 
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1.5 Importance of Diagnosis and Management on Morbidity and 
Mortali 
A summary of the figures for maternal death, compiled for the Confidential 
Enquiries into Maternal Deaths, was shown in Table 1.1. The rates have not 
changed over the last 12 years. In the two most recent reports, most fatal cases 
are not diagnosed in either primary care or Accident and Emergency departments. 
The majority of women who had some sort of medical attention prior to death had 
reported symptoms suggestive of gastrointestinal or urinary tract disease. Early 
pregnancy deaths were the second leading cause of maternal death in the most 
recent report, and ectopic pregnancy taken in isolation was the fourth leading 
cause. 
This is the same as is found in other countries. Ectopic pregnancy is reported as 
the second leading cause of maternal death in Japan (Shinagawa et al., 1983). In 
Jamaica and Hong Kong it is the third leading cause, with a rate of 10.8 deaths 
related to ectopic pregnancy per 100,000 live births in Jamaica and 5.0 per 
100,000 live births in Hong Kong (Walker et al., 1986; Duthie et aL, 1989). Goldner 
et al. (1993) found ectopic pregnancy to be responsible for 13% of pregnancy 
related deaths in the United States. The case fatality fell from 3.55 per 1,000 
ectopic pregnancies in 1970 to 0.38 per 1,000 ectopic pregnancies in 1989, which 
is similar to the UK. 
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Schneider et al. (1977), in his study population in the United States, found that 
older women were more likely to die from the complications of ectopic pregnancy. 
Deaths were characterised by a marked delay between onset of symptoms and 
both presentation and diagnosis. 
Dorfman (1983) noted a doubling in the number of hospitalisations for ectopic 
pregnancy during the 1970's, with a mortality rate of 0.8 per 1,000 ectopic 
pregnancies. Black women and "other races" had 3.2 times the relative risk of 
dying as a result of ectopic pregnancy than white and Hispanic women. In Dorfman 
et aL's (1984) paper they found that 85% of ectopic pregnancy related deaths were 
due to haemorrhage, with abdominal and interstitial pregnancies presenting later 
and, therefore, being more likely to result in death. They concluded that more 
prompt diagnosis and management might have prevented half of deaths related to 
ectopic pregnancy, and the woman seeking medical attention at an earlier stage 
might have prevented one third. 
Rubin et al. (1983) noted a 75% reduction in the mortality from ectopic pregnancy 
between the year 1970 and 1978 in the United States. They, too, found that white 
women were less likely to die from ectopic pregnancy than non-white women. This 
might be because of issues of access to health care, or of language problems. The 
issue of language was also discussed as a barrier to diagnosis in the 1994 -1996 
Confidential Enquiries (The Station&ry Office, 1998). Duthie et al. (1989) observed 
a 72% decrease in the number of deaths due to ectopic pregnancy between 1961 
and 1985 in the Hong Kong population. 
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What can be seen from data on maternal deaths related to ectopic pregnancy is 
that many of them might be avoided by increased awareness of the condition 
amongst women of childbearing age. In addition, increased awareness, and 
guidelines for the diagnosis and management of ectopic pregnancy, amongst the 
professionals who are responsible for the care of these women, is needed if the 
number of deaths is to be reduced to a minimum. 
Whilst death resulting from ectopic pregnancy is the most important adverse 
outcome, it is rare. However, ectopic pregnancy is associated with long-term 
morbidity: infertility and recurrence of ectopic pregnancy. These issues are 
discussed further in following chapters. 
Ectopic pregnancy remains a leading cause of maternal mortality; eight of the 
thirteen maternal mortalities in the 1997 to 1999 triennial report, occurring in 
women with ectopic pregnancy, were considered to be associated with 
substandard care (RCOG Press, 2001). When discussing how to improve the 
management of ectopic pregnancy, where and how the diagnosis of ectopic 
pregnancy is made needs to be considered: 
1.5.1 Where the Diagnosis is Made. 
Early Pregnancy Units (EPU) have evolved, firstly, from the recognition that some 
women required more than evacuation of their uterus when miscarriage was 
diagnosed (Turner et al., 1991; Bradley and Hamilton-Fairley, 1998), and secondly, 
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from the realisation that they provided an efficient and cost effective means of 
dealing with common gynaecological complaints (Bigrigg and Read, 1991; Wren 
and Craven, 1999). Efficiency brings benefits to those providing the service: most 
women can be seen in normal working hours, reducing the burden upon the on-call 
doctors; ultrasound scanning is available at presentation; efficient use is made of 
theatre-time; in-patient stay is reduced, both before diagnosis and whilst awaiting 
treatment. But there are benefits for the patients as well; they are seen by 
dedicated staff who can provide ongoing support for the psychological recovery 
from miscarriage; the advice they receive is consistent; these units are easily 
accessible whether the patient is referred by her GP or the casualty officer, or she 
makes direct contact with the unit herself (Walker and Shillito, 1997). 
The EPU was established at St. James's University Hospital in 1994. In the 
following year, 30% of women with pregnancies seen through this hospital 
experienced early pregnancy bleeding. 57% of women reporting early pregnancy 
bleeding to the EPU had a viable pregnancy on initial ultrasound scan. 3.4% of 
these women had an ectopic pregnancy that required intervention (Walker and 
Shillito, 1997). 
EPUs are the ideal setting for patients who might potentially have an ectopic 
pregnancy to be reviewed and a management plan made. The patient's symptoms 
can be screened when the initial contact, usually by telephone, is made with the 
unit. Those with worrying symptoms can be fast-tracked for urgent review. Women, 
who have had an ectopic pregnancy in the past, can contact the unit as soon as 
Chapter 1- Introduction 23 
pregnancy is diagnosed to allow serum monitoring until the site of the current 
pregnancy can be established with the help of ultrasound examination. The results 
of ultrasound scans and serum monitoring can be reviewed by nursing and medical 
staff with specialist knowledge of early pregnancy complications, reducing the 
opportunities for the diagnosis to be missed. Once an ectopic pregnancy is 
diagnosed, the management options can be discussed with the patient, rather than 
just an automatic listing for "laparoscopy ? proceed". With the provision of protocols 
and guidelines for management, early pregnancy complications can be largely 
managed by specialist nurses with senior medical back-up, which removes the 
problem of management being decided by the more inexperienced junior medical 
staff. Within such a structure, proper training in early pregnancy complications can 
be offered to junior obstetricians and gynaecologists. 
1.5.2 How is the Diagnosis Made. 
This is not just the availability of appropriate investigations, both ward-based and 
surgical, but also the ability of the nursing and medical staff to interpret and act 
upon these results. Protocols aid in the diagnosis of early pregnancy complications 
giving guidelines to practitioners who have a general, rather than an expert 
understanding, and they also allow nurses to manage early pregnancy 
complications independently of doctors. 
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1.5.2a Clinical Findings 
Ectopic pregnancy is a well known complication of early pregnancy, the first 
description recognisable as an ectopic pregnancy was that of Abulcasis AD936- 
1013, (Dimitry and Reid, 1993). The classically described symptoms are of pain, 
bleeding and amenorrhoea; but this presentation has not held true with time. In 
recent years more sensitive pregnancy tests have meant that women can confirm 
their pregnancy at a much earlier gestation and greater access to early pregnancy 
assessment means that many ectopic pregnancies are picked up in women who 
are, as yet, largely asymptomatic. This is proposed as one of the reasons why the 
incidence of ectopic pregnancy might be rising, with ectopic pregnancies that 
would have resolved without diagnosis now diagnosed and treated. Earlier 
presentation means that the classical triad of the symptoms of ectopic pregnancy is 
seen less frequently. 
When hCG levels were tracked in asymptomatic women prior to performing an 
ultrasound scan, 64% of women with ectopic pregnancies and 40% with 
spontaneous miscarriages became symptomatic during the period of observation 
(Shepherd et al., 1990). Reliance on symptoms alone would be misleading, as 
16% of women with normal intrauterine pregnancies also reported the same 
symptoms and 36% of women with ectopic pregnancies reported none; patient 
reported symptoms are an unreliable predictor of ectopic pregnancy. In women 
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with symptoms suggestive of ectopic pregnancy after ! VF-ET (Mol et al., 1997), just 
over half were eventually diagnosed with ectopic pregnancies. 
At the other extreme, some women present with major haemorrhage. This 
haemorrhage can be life-threatening. In some cases, it happens so suddenly that it 
is unlikely that earlier diagnosis would have been possible. In others, increased 
awareness amongst women of reproductive age, and better management by the 
doctors attending them, might have prevented a medical emergency, which, at its 
worst, is a cause of maternal death. A recent estimate by Bajekal et aL (2000) puts 
8-10% of women with ectopic pregnancy presenting with signs of shock requiring 
immediate treatment. 
Unilateral pain might be a symptom indicating tubal rupture, but tubal rupture is not 
always associated with major haemorrhage; some women with tubal rupture will 
have little in the way of active blood loss, as demonstrated by occasional cases of 
abdominal pregnancies reaching viability. Equally, every case of major 
haemorrhage is not associated with tubal rupture and large quantities of intra- 
abdominal blood can be seen with an intact tube. Tubal abortion is also associated 
with unilateral, sometimes severe, abdominal pain, and yet, tubal abortion often 
leads to spontaneous resolution of the ectopic pregnancy. With a low specificity for 
complicated ectopic pregnancy, abdominal pain and/or tenderness would not be a 
contraindication to medical management if there were no evidence of 
cardiovascular compromise. A symptomatic patient might, however, prefer surgical 
management, as this will lead to a more rapid resolution of her symptoms. But, if 
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the patient's clinical state allows, paired hCG estimations 48 hours apart might 
prevent unnecessary intervention for a spontaneously resolving tubal abortion. 
Equally, clinical examination might not help with diagnosis. If no suspicious signs 
are found, this does not exclude ectopic pregnancy. There is also the danger that 
pelvic examination might precipitate tubal rupture and haemorrhage. 
Mol et al. (1999a) felt that digital vaginal examination was unnecessary when a 
combination of trans-vaginal ultrasound and hCG estimations was used. They also 
looked at factors predictive of tubal rupture and/or active bleeding (Mol et a/. 
1999b). Abdominal pain was the most sensitive predictor with a sensitivity of 95%. 
But again, the specificity was low at 37%. 
Pain that is described as moderate to severe, lateral or sharp, is more predictive of 
ectopic pregnancy than centralised pain. On examination, peritoneal signs, cervical 
excitation pain, and lateral or bilateral abdominal or pelvic tenderness increased 
the risk of ectopic pregnancy (Dart et at, 1999). Although the authors found these 
factors predictive, the outcomes were so variable that they concluded no 
constellation of findings could confirm or exclude a diagnosis of ectopic pregnancy 
with a high degree of reliability. 
If pelvic examination is considered unnecessary in most cases of suspected 
,p Aw'ý, c pregnancy, this will limit the opportunity to take endo-cervical swabs to screen for 
chlamydia in a population that is at higher risk of being infected. This problem 
could be overcome by using urine PCR testing for chiamydia and, as it is more 
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acceptable to the patient, its introduction is likely to result in more patients being 
tested. 
1.5.2b Ultrasound 
The presence of an intrauterine pregnancy largely excludes ectopic pregnancy. A 
fetal heart beat is always found when the mean sac diameter exceeds 18mm 
(Cacciatore et al., 1990a). As a result of the public inquiry called by South 
Glamorgan Health Authority (Hately et al., 1995) it was recommended that on 
trans-vaginal scan, a 20mm mean gestation sac diameter be the cut-off for 
diagnosing a failed pregnancy when neither yolk sac nor fetal pole was found. 
Trans-vaginal ultrasound will detect a yolk sac or fetal pole up to one week earlier 
than trans-abdominal ultrasound (Weston, 2001). Trans-vaginal ultrasound 
appears to be an acceptable investigation with 88.1 % of women agreeing to the 
examination in one study, the common reasons for refusal were fear of miscarriage 
or discomfort (Braithwaite and Economides, 1997). Trans-vaginal scanning may be 
the more comfortable option, as the bladder is not required to be full. 
The presence of an intrauterine gestation sac generally excludes an ectopic 
pregnancy, although the level of hCG at which an intrauterine gestation sac should 
always be seen is not established (Lipscomb at al., 2000). It is probably difficult to 
give a fail-safe level because of differences in the assay between units, and the 
differences in level that can be found in the same individual in one day. 
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There are two situations when the apparent appearance of an intrauterine sac can 
be misleading, firstly, in the presence of a heterotopic pregnancy, and secondly, 
when a pseudogestation sac is seen. 
Heterotopic pregnancy is the co-existence of an intrauterine pregnancy and an 
ectopically sited pregnancy. It is said to occur once in every 7000 pregnancies 
(Mehta et a!., 1997) and the incidence is higher after assisted conception where 
more than one embryo is replaced, often in women with pre-existing tubal disease. 
To diagnose heterotopic pregnancy, a high index of suspicion is required. If a 
heterotopic pregnancy is suspected and the woman's symptoms give concern, a 
laparoscopy is the only means of diagnosis - hCG levels will be misleading as they 
are partly made up by the viable pregnancy which will give normally rising levels on 
serial measurement even if the ectopically placed trophoblast is non-viable. 
Ultrasound is likely to be unhelpful unless an adnexal mass contains a fetal heart 
pulsation or yolk sac. Mol eta!. (' 997a) found that in women who had undergone 
IVF-ET, the presence of an intrauterine gestation sac virtually excluded a 
heterotopic pregnancy if the woman was asymptomatic. In the presence of 
symptoms of pain and bleeding, an intrauterine gestation sac reduces the 
probability of a heterotopic pregnancy from 53% to 17%. 
A pseudogestation sac is a fluid collection found within the endometrial cavity in 
ectopic pregnancies. Various ultrasound findings have been described to help 
differentiate the early gestation sac from the pseudogestation sac. The normal 
early pregnancy is eccentrically placed within the endometrium, the 
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pseudogestation sac central within the cavity. An intrauterine sac displays the 
intradecidual sign - the presence of an oval or round fluid collection within the 
decidua with an echogenic rim (Mehta et al., 1997). The double decidual sac sign 
is the appearance of two concentric rings and is specific for an intrauterine 
pregnancy (Bradley at al., 1982; Nyberg at al., 1983). However, in up to a third of 
normal early gestations the double ring sign is not seen (Weston, 2001). Nyberg et 
a/. (1988) found pseudogestation sacs in only 2 out of 26 ectopic pregnancies in 
their prospective study of trans-vaginal ultrasound findings in early pregnancy 
complications. In both cases, the pseudogestation sac was clearly within the 
endometrial cavity, which should have differentiated it from a true gestation sac. 
Cacciatore et al. (1990b) claimed that an adnexal mass was a reliable sign of 
ectopic pregnancy with a specificity of 99%, an adnexal mass was not seen in only 
8% of ectopic pregnancies in their series. However, in Ankum et al. 's (1993) 
experience, an ectopic pregnancy (defined as either an adnexal gestation sac, with 
or without a fetal pole or fetal heart pulsation or an adnexal mass with associated 
fluid in the Pouch of Douglas) was found with trans-vaginal ultrasound in only 56% 
of cases of ectopic pregnancy. 
Mol et aL (1998a) looked at the predictive value of various ultrasound findings for 
ectopic pregnancy. They diagnosed ectopic pregnancy on the basis of ultrasound 
findings alone if a yolk sac, a fetal pole or fetal cardiac activity were seen within the 
adnexa. When an intrauterine gestation sac was not found on the initial trans- 
vaginal ultrasound, additional findings increased the likelihood of an ectopic 
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pregnancy. If an adnexal mass was found, the likelihood ratio was 3.6 for the 
presence of an ectopic pregnancy. Fluid in the Pouch of Douglas was a little more 
predictive with a likelihood ratio of 4.4. When both findings were combined, the 
likelihood ratio for an ectopic pregnancy increased to 9.9. However, in 3% patients 
where an intrauterine pregnancy was diagnosed on initial trans-vaginal ultrasound, 
a final diagnosis of ectopic pregnancy was made. In women with an empty uterus 
and the presence of additional ultrasound findings, the likelihood ratio for ectopic 
pregnancy increased strongly when serum hCG was >1500miu/ml (3`d IS). If no 
additional ultrasound findings were present, the likelihood ratio for an ectopic 
pregnancy increased strongly when the serum hCG was >2000miu/ml (3`d IS). 
Fluid in the Pouch of Douglas can be a normal finding in early viable intrauterine 
pregnancies. In Nyberg et aL's 1988 series, small to moderate amounts of fluid 
were found in 22% of women with normal intrauterine pregnancies. Adnexal 
masses are likewise not always abnormal. A collapsing or haemorrhagic corpus 
luteum cyst will be reported as such if an intra-uterine pregnancy is found, but the 
same finding raises suspicion of ectopic pregnancy if the uterus is empty. 
The thickness of the endometrium on trans-vaginal ultrasound has been examined 
as a further means of differentiating between intrauterine and extra-uterine 
pregnancies. Spandorfer and Barnhart (1996) proposed that the endometrial stripe 
thickness was dependent upon the hormonal milieu, and therefore a thicker 
endometrial stripe would be found in normal early pregnancy and a thinner 
endometrial stripe in an abnormal pregnancy. Their retrospective study found that 
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no ectopic pregnancies were found if the endometrial stripe thickness was >13mm, 
no normal intrauterine pregnancies were found if it were <6mm. In all cases the 
hCG level was <1500miu/ml. Using receiver-operator curves, they used a cut-off of 
8mm. This detected 71% of ectopic pregnancies, although it did not discriminate 
between ectopic pregnancy and abnormal intrauterine pregnancy and would seem 
to offer little advantage over other investigations for ectopic pregnancy. 
Others have not supported their findings. Levgur et al. (2000) found that 
endometrial stripe thickness did not vary with gestation. They compared ectopic 
pregnancies with normal intrauterine pregnancies, and, whilst they found that the 
endometrial thickness was less in ectopic pregnancies (9.9mm +/- 5.9) than in 
normal pregnancies (12.6mm+/- 5.3), the range of measurements obtained was 
similar, 2 to 24mm in the ectopic pregnancy group and 4 to 26mm in the normal 
intrauterine pregnancy group. 
Mehta et al. (1999) found endometrial thickness unhelpful in the differential 
diagnosis of early pregnancy problems, as there was no difference in the 
endometrial thickness in ectopic pregnancy (mean 9.0mm, range 2 to 20mm) and 
spontaneous miscarriage (mean 8.4mm, range 2 to 18mm). Endometrial thickness 
was assessed when an empty uterus was found and was not correlated with the 
level of hCG. 
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1.5.2c hCG 
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In 1976, Braunstein et al. used newer assays, specific to the ß-subunit of hCG, to 
describe the pattern of serum hCG throughout pregnancy. They showed the 
exponential rise in levels in early first trimester, which has subsequently been 
exploited to differentiate normal from abnormal early pregnancy. 
Kadar et al. (1981) proposed the concept of the discriminatory level of hCG; that is, 
the level of hCG when an empty uterus is likely to represent an ectopic pregnancy, 
rather than an early intrauterine pregnancy. This was based on the findings of 
trans-abdominal ultrasound and they suggested an hCG level of 6500miu/mI. 
With increasing use of trans-vaginal ultrasound, where the greater magnification 
and the closer proximity of the transducer to the uterus improve resolution, the 
contents of the uterus can be determined at an earlier stage. This has lead to a 
reduction in the discriminatory hCG level. 
Cacciatore et al. (1990a) found the following hCG levels with progressive changes 
on transvaginal ultrasound: 
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Table 1.3 hCG levels related to ultrasound findings 
Serum hCG (miu/ml) Gestational age (days) 
Mean Range Mean Range 
Intrauterine sac 730 432-935 31.2 30-33 
Yolk sac 4310 120-7280 36.0 34-38 
Fetal heart beat 12050 9280-22950 41.1 39-43 
They suggested a level of 1000miu/mI as the cut-off at which the absence of a 
gestational sac implied an ectopic pregnancy (Cacciatore et al. 1990b). They used 
the 2 "d International Standard (2"d IS) for the measurement of hCG, the 3Id 
International Standard (3`d IS) is now more widely used and produces values 1.5 to 
2 times that of the 2"d IS (Buster and Carson 1997). They equated Cacciatore et 
al. 's cut-off level of 1000miu/ml to a level of 1800miu/ml on the 3rd IS. They also 
noted that multiple pregnancies had higher levels of hCG for equivalent gestations, 
hence they set their discriminatory zone above the level at which they felt confident 
that an intrauterine gestation sac should be seen. 
Ankum et al. (1993b) analysed the sensitivity and specificity of various ranges of 
single hCG estimations in the diagnosis of ectopic pregnancy when an empty 
uterus is found on ultrasound scan. All ranges of hCG levels approached a 
sensitivity of 1.00, but the specificity was poor at low levels of hCG. Even in the 
range of 3000 to 4500miu/ml, (equivalent to 3rd IS) the specificity was only 0.87. In 
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their conclusions, they felt that an hCG of 3,000miu/ml represented the best 
discriminatory zone. 
Unlike spontaneous conception, when assisted conception techniques are used 
the gestation of the pregnancy is usually accurately known. 4.5% of clinical 
pregnancies after IVF-ET are ectopic pregnancies (Marcus and Brindsen, 1995). 
Marcus et a!. (1995) found that they could predict 90% of ectopic pregnancies by 
day 23 post embryo transfer, on isolated hCG results alone. However, 10% of 
women with ectopic pregnancies had hCG levels of <10miu/ml, and were thought 
not to be pregnant (it is not clear whether treatment for ectopic pregnancy was 
required in these cases). 22.5% of women with ectopic pregnancies, had hCG 
levels comparable with viable singleton pregnancies and, by the author's own 
admission, this demonstrated the limitation of a single hCG level. 
In the series described by Mehta at al. (1997) of women with hCG levels 
>2000miu/ml (3d IS), suspected of having an ectopic pregnancy who underwent 
laparoscopy, 33% were eventually found to have normal intrauterine pregnancies. 
On review, six of the seventeen could have been said to have a weak intradecidual 
sign. They suggested, to avoid unnecessary intervention, a second hCG level 
would be desirable and they also concluded that there were limitations to the use 
of hCG estimations. 
The doubling rate of hCG has also been examined as a predictor of ectopic 
pregnancy; non-viable trophoblast, whether that is an ectopic pregnancy or a non- 
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viable intrauterine pregnancy, has a prolonged doubling time. Zegers-Hochschild at 
al. (1994) found that the doubling time for hCG between 11 and 23 days post- 
ovulation in normal pregnancy, was 1.43 days. Daya (1987), found the doubling 
time gradually increased throughout first trimester with the hCG levels plateauing 
at 9 weeks gestation. Pittaway at al. (1985) found a doubling time of 1.4 days 
between days 28 to 35 post last menstrual period (Imp), 2.7 days between 35 to 42 
days post Imp and 3.3 days between days 41-49 post Imp. The hCG level in viable 
intrauterine pregnancies in first trimester can therefore be said to double 
approximately every 48 hours. Although a doubling time of greater than 48 hours 
will, therefore, distinguish most ectopic pregnancies, it is not reliable in isolation. As 
Yao and Tulandi (1997) state, 15% of normal pregnancies have an abnormal hCG 
rise, O'Leary et al. (1996) found that with normal intrauterine pregnancies, the rise 
in hCG will be at least 66% over 48 hours. Neither does a normal rise always 
exclude ectopic pregnancy, as well implanted ectopic trophoblast can result in 
normal levels of hCG, at least in the early stages. In Shepherd at al. 's (1990) 
series, 64% of women with asymptomatic ectopic pregnancies initially exhibited a 
normal doubling of hCG and 15% persisted with a normal rise. 
Mol et al. (19988) observed that an ectopic pregnancy was never observed when 
the hCG level fell by >50% over 48 hours, although their definition of ectopic 
pregnancy, in this case, did not include ectopically situated non-viable trophoblast. 
They found serial values of hCG more discriminatory than single values, p=0.0003 
for absolute value versus absolute difference. The measurement that was of most 
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diagnostic value was that taken 4 days after the baseline value. Unlike ultrasound 
characteristics, patient characteristics of abdominal pain and vaginal bleeding had 
no influence on the diagnostic performance of hCG measurements. 
A single hCG estimation has little value in predicting ectopic pregnancy; paired 
levels are also of little value without also considering the clinical presentation and 
ultrasound appearances. 
1.5.2d Progesterone 
Progesterone has similar limitations to hCG, in that it will not differentiate between 
an ectopic pregnancy and a non-viable intrauterine pregnancy. It has the 
advantage over hCG that its levels inAfirst nine weeks of pregnancy remain 
fW_ 
constant (O'Leary et al., 1991) and so a single sample is of value. In first trimester, 
hCG reflects function of the trophoblast and progesterone function of the corpus 
luteum. Levels of progesterone, like hCG, are lower in abnormal pregnancy when 
compared to normal pregnancy. But also, as with hCG, normal levels of 
progesterone do not exclude ectopic pregnancy, as there is substantial over-lap 
between levels found in extra-uterine and normal pregnancies. This explains the 
wide range of suggested "critical" progesterone levels to discriminate between 
intrauterine and extra-uterine pregnancies, with levels of progesterone ranging 
between 21-80nmol/I (Yeko et al., 1987; Buck et al., 1988; Hahlin et al., 1990). 
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O'Leary et al. (1996) suggested that a combination of a single hCG and 
progesterone level provides better discrimination: hCG <3000miu/ml had a 
sensitivity of 74% and a specificity of 88%, in combination with a progesterone 
level of <40nmol/I, the sensitivity was 88% with a specificity of 82%. Whether this 
offers any advantage for the additional expense is unclear. Neither was this 
combination compared to the use of serial hCGs, their argument being that serial 
hCG estimations are not appropriate in some cardiovascularly unstable women, 
although an additional serum investigation at presentation in such women is 
unlikely to alter management anyway. 
1.5.2e Diagnostic Laparoscopy 
In 1989', Vermesh felt diagnostic laparoscopy was indicated in all cases of 
suspected ectopic pregnancy, unless the woman's condition merited an immediate 
laparotomy. 
If diagnostic laparoscopy is required in every case of ectopic pregnancy, there is 
little to justify medical management of ectopic pregnancy as this exposes the 
woman to the risks of both types of management. 
There have been various attempts at producing diagnostic algorithms to allow 
diagnosis of ectopic pregnancy without recourse to laparoscopy. An early algorithm 
from Ankum et al. (19938) used daily hCG measurements and a discriminatory 
level of 1500miu/ml, but did not consider the rate of increase of the hCG level with 
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time as part of their diagnostic process. This algorithm had a sensitivity of 0.97 and 
specificity of 0.95, but 8.4% of patients did not complete the protocol because of 
signs of shock. 1% of the subjects had a diagnostic laparoscopy to confirm an 
ectopic pregnancy and were later found to have a viable intrauterine pregnancy. 
They felt that a higher discriminatory zone might have reduced the false positive 
rate, but were concerned that this would lead to too great a delay in diagnosis of 
ectopic pregnancy. Also, intrauterine pregnancies were diagnosed as ectopics 
because adnexal masses on ultrasound scan were misinterpreted as ectopic 
pregnancies. 
Stovall and Ling (19939) proposed that the introduction of diagnostic algorithms 
would lead to "the virtual elimination of diagnostic laparoscopy", earlier diagnosis of 
ectopic pregnancy, with fewer women experiencing tubal rupture and greater use 
of medical and expectant management. Their algorithm incorporated history and 
clinical findings, serum hCG and progesterone levels, colour flow vaginal Doppler 
flow sonography and endometrial curettage with a combination of medical, surgical 
and expectant options for management. 
Mol et aL (1999d) examined algorithms again to see if their predictive value could 
be improved by making them flexible. This model took into account the patients risk 
factors for ectopic pregnancy, so that the post-test probability of ectopic pregnancy 
would be greatest in those women with the greatest pre-test risk factors. They 
concluded that incorporating probabilistic decision rules into algorithms improved 
the diagnosis of ectopic pregnancy. 
Chapter 1- Introduction 39 
If a miscarrying pregnancy is medically treated as an ectopic pregnancy, it is 
unlikely that this will lead to an adverse outcome, but it is unacceptable to 
medically treat a viable intrauterine pregnancy as an ectopic pregnancy. 
1.5.2f Diagnostic Curettage 
Lipscomb et al. (2000) argued that there is a greater role for diagnostic curettage in 
excluding non-viable intrauterine pregnancy if hCG levels are <2000miu/mI. This is 
not withstanding the extra expense of an additional surgical procedure and the 
delay whilst the curettings are analysed histologically. Pisarska et al. (1998) use 
curettage as a first line a diagnosis for non-viable pregnancies, proposing that a 
drop in the serum hCG level of 15% or more following a diagnostic curettage is 
indicative of miscarriage as opposed to ectopic pregnancy. If the presence, but not 
the site, of non-viable trophoblast has been determined, a single dose of 
methotrexate would be a possible treatment in either case, and would reduce the 
need for further surgical procedures. 
It is obvious that, although there is a great improvement in diagnostic methods, 
there is still no perfect approach. 
1.6 Fibronectins - is there a Role for Fetal Fibronectin in the 
Diagnosis of Ectopic Preanancv? 
Fibronectins are non-collagenous glycoproteins and are widely distributed 
throughout the body. They are present in varying forms at different sites; a soluble 
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form, produced in the liver, is found in the plasma, an insoluble form is found in the 
extra-cellular matrices. Fibronectins promote cell attachment to the substratum and 
are active in cell spreading and migration. 
Fibronectins have been demonstrated in the villous stroma and trophoblastic 
basement membranes (Rukosuev, 1992) and the walls of fetal blood vessels in first 
trimester placentae. In late pregnancy, fibronectins are found predominantly in the 
walls of fetal blood vessels. (Yamada et al., 1987) 
Fibronectins present only in fetal and malignant invasive cells, which have invasive 
as well as adhesive properties, have been described. (Borsi et al., 1987; 
Carnemolla et aL, 1989; Frank et al., 1994) An IgGI monoclonal antibody, FDC-6 
defines a unique domain on the oncofetal form of fibronectin which is not found on 
the normal adult form of fibronectin. (Matsuura and Hakomori, 1985) A single 
glycosylation at a defined threonine residue of the III CS region of fibronectin 
induces conformational changes in the peptide to form the specific oncofetal 
epitope recognised by the FDC-6 antibody (Matsuura et al., 1988). It is this FDC-6 
antibody that has been used to measure levels of fetal fibronectin in following 
chapters. 
Fetal fibronectin has already an established role in the diagnosis of later pregnancy 
complications. A diagnostic kit and a quantitative assay are available commercially. 
Its current use is discussed below, and part of this thesis seeks to explore its 
potential as a diagnostic aid with early pregnancy complications. 
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1.6.1 Fetal Fibronectin as a Predictor of Preterm Delivery 
The presence of the fetal form of fibronectin in the cervico-vaginal secretions as a 
predictor of pre-term labour was first proposed in 1991 (Lockwood et al., 1991). It 
was postulated that damage to the fetal membranes would release fetal fibronectin, 
which would then be found in the cervico-vaginal secretions. It was found that 
women who delivered at term rarely had concentrations of fetal fibronectin above 
0.05 µg/ml between 21 and 37 weeks gestation. 
Numerous studies have looked at fetal fibronectin levels in high risk subjects, 
(Nageote et at, 1994; Bittar et at, 1996; Leeson et at, 1996) low risk subjects 
(Morrison et at, 1993; Hellemans et at, 1995; Goldenberg et at, 1997; Crane et 
al., 1999; Goepfert et at, 2000; Heath et at, 2000; ) and symptomatic subjects 
(Goldenberg et al., 1996; Malak et at, 1996; Lukes et al., 1997; Peaceman et al., 
1997; Chuileannain et at, 1998; Joffe et at, 1999). All have found raised levels of 
fetal fibronectin to be predictive of premature labour, but as one author points out, 
there is no evidence that use of this test leads to any reduction in spontaneous 
preterm birth (Goldenberg et at, 1996). 
An overview (Chien et aL, 1997) of the use of fetal fibronectin to predict preterm 
labour identified 32 studies addressing the issue. 17 of these studies were selected 
for analysis (2 were eliminated because of inappropriate study populations, 6 for 
lack of original data, 2 for lack of relevant outcome measures being reported and 5 
because the same data was reported in more than one article). 
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They concluded that fetal fibronectin in the cervico-vaginal mucus has limited 
accuracy in predicting preterm labour as the likelihood ratios for positive and 
negative test results generated only minimal to moderate changes in the pretest 
probability of preterm birth. A negative result for fetal fibronectin would seem to 
have more significance than a positive. (Tables 1.4 and 1.5) 
Table 1.4. Summarises the results of the meta-analysis of the role of fetal 
fibronectin in the diagnosis of preterm labour - the effect on the likelihood 
ratios (LR) of positive and negative results. 95% confidence intervals in 
brackets. Positive result >0.05µg/ml of fetal fibronectin 
Group tested Outcome Pooled LR 
+ve swab 
Pooled LR 
-ve swab 
Symptomatic Delivery <34/40 2.6 (1.8 - 3.7) 0.2 (0.1 - 0.5) 
Delive within I week 5.0 3.8 - 6.4) 0.2 (0.1 - 0.4) 
Asymptomatic high risk Delivery <37/40 2.0 1.5 - 2.6 0.4 0.2 - 0.8 
Delivery <34/40 2.4 (1.8 - 3.2) 0.6 (0.4 - 0.9) 
Asymptomatic low risk Delivery <37/40 3.2 (2.2 - 4.8) 0.8 (0.7 - 0.9) 
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Table 1.5. Summarises the results of the meta-analysis of the role of fetal 
fibronectin in the diagnosis of preterm labour - the change in the pre-test 
probability of having a positive or negative result for pre-term delivery. 
Positive result >0.05pg/ml 
Group tested Outcome Pre-test 
probability 
+ve 
result 
-ve 
result 
Symptomatic Delivery <34/40 32.5% 55.6% 8.2% 
Delivery within 1 week 6.6% 25.8% 1.2% 
Asymptomatic high risk Delivery <37/40 31.5% 47.9% 16.6% 
Delivery <34/40 15.7% 31.0% 9.9% 
Asymptomatic low risk Delivery <37/40 25.0% 52.0% 22.0% 
1.6.2 Fetal Fibronectin in Pre-Labour Rupture of the Membranes 
Lockwood et al. also found high levels of fetal fibronectin in the amniotic fluid and 
in 93.8% of the cervicovaginal secretions of women with preterm rupture of the 
membranes (Lockwood et al., 1991). As a consequence, the presence of fetal 
fibronectin with the cervicovaginal secretions has been explored as a means of 
diagnosing pre-labour rupture of the membranes in equivocal clinical situations. 
Although it was a sensitive indicator of preterm rupture of the membranes, with 
98.2% of subjects having fetal fibronectin levels of greater than 0.05µg/ml, it was 
not specific with 19.4% of controls having similar levels (Eriksen of al., 1992). The 
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latter is not surprising, as it would be expected that elevated fetal fibronectin would 
be found, as some subjects will deliver prematurely despite intact membranes. 
If fetal fibronectin is detected when a diagnosis of pre-labour rupture of membranes 
is suspected, this finding does not appear to predict any difference in the outcome 
of the pregnancy - either in duration of the pregnancy or in complications of labour 
(Nisell et a/., 1996). 
1.6.3 Fetal Fibronectin in Post-Dates Pregnancy 
As the presence of fetal fibronectin in the cervicovaginal secretions is associated 
with preterm labour, the next logical step would seem to be to evaluate its role in 
the post-term pregnancy and whether it might predict those pregnancies that can 
be successfully induced. Lockwood et al. found that the presence of a positive fetal 
fibronectin swab between 39+0 and 39+6 weeks predicted delivery within the next 
ten days (Lockwood et al., 1994). Garite et al. (1996) found that women with levels 
of fetal fibronectin that were greater than 0.05µg/ml took less time to induce: 21.3 
hours with positive swabs and 31.1 hours with negative swabs (p=0.0001) and had 
a lower caesarean section rate: 15% of those with positive results and 27% of 
those negative results (p=0.05). 
1.6.4 Fetal Fibronectin in Early Pregnancy 
Since starting this study, two papers have been published on fetal fibronectin in the 
diagnosis of ectopic pregnancy (Ness et at, 1998; Nowacek at at., 1999). 
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Ness et al. compared the levels of fetal fibronectin found in women with a 
diagnosis of ectopic pregnancy (31 subjects) or threatened, incomplete or 
complete miscarriages (38 subjects) with normal early pregnancy (41 subjects). A 
further group consisted of those with pain or bleeding with an as yet undetermined 
diagnosis (45 subjects). They found that fetal fibronectin discriminated poorly 
between extra-uterine gestations and other early pregnancy complications, a level 
of 0.3µg/ml having a sensitivity of 0.94 and a specificity of 0.14. This should be 
considered against a background of a test being considered positive at a level of 
0.05µg/ml in later pregnancy and bedside tests are designed to give positive 
readings at this level. 
Nowacek et al. examined 46 subjects at high risk of ectopic pregnancy, or with 
signs or symptoms of ectopic pregnancy. 12 had a final diagnosis of ectopic 
pregnancy, 34 intrauterine pregnancies. Positive results (defined as fetal 
fibronectin levels of more than 0.051Ag/ml) were obtained in 41.7% of cases in 
which the diagnosis was ectopic pregnancy and 35.3% of cases where an intra- 
uterine pregnancy was diagnosed. 
The work on fetal fibronectin presented in this thesis will explore the predictive 
value of fetal fibronectin before a diagnosis can be made and study why the results 
are so variable. 
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1.7 Management of Ectopic Pregnancy 
Once a diagnosis of ectopic pregnancy has been made, it becomes important to 
consider what treatment options are available. The optimum treatment of ectopic 
pregnancy will depend on the outcomes required. At one extreme, any possible 
case should be treated aggressively and early to avoid maternal death. However, 
aIA 
although minimising maternal mortality iss important outcome, it is a rare outcome 
and overly aggressive management will increase mortality and morbidity resulting 
from unnecessary surgery. In both of the last Confidential Enquiries, a proportion of 
the deaths were caused by the surgical treatment of the ectopic pregnancies, 
rather than by misdiagnosis (The Stationery Office, 1998; RGOG Press, 2001). If a 
more considered approach to diagnosis is used, more normal and failing intra- 
uterine pregnancies can be differentiated from ectopic pregnancy without resorting 
to laparoscopy and a wider choice of management options can be offered to the 
woman in whom an ectopic pregnancy is confirmed. This thesis will discuss 
women's choices for the management of ectopic pregnancy and the short and 
long-term implications of these choices. 
1.7.1 Evolution of the Treatment of Ectopic Pregnancy. 
In 1888, Lawson Tait first described the surgical management of ectopic 
pregnancy, pioneering the then new concept that surgical intervention, in such 
cases, might be life saving. He saved the life of 38 out of 40 women with ectopic 
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pregnancy (Stromme, 1973). He used salpingectomy; his basic technique has 
remained largely unchanged. 
The first conservative surgical procedure for the treatment of ectopic pregnancy, 
with preservation of the fallopian tube, was described in 1953, (Stromme 1953). 
Laparoscopic management of ectopic pregnancy was first described in 1973, 
(Shapiro and Adler, 1973), and the first description of conservative laparoscopic 
surgery was in 1980, (Bruhat et al., 1980). 
The first reported case of ectopic pregnancy treated with methotrexate was by 
Tanaka et al. in 1982. This was a logical progression from the use of methotrexate 
in the management of trophoblastic disease. 
When surgery was first performed in the management of ectopic pregnancy, the 
aim was to preserve the woman's life. As time has gone on, there have been 
increasing efforts to try to reduce the morbidity associated with ectopic pregnancy. 
Ectopic pregnancy poses two main long-term problems: reduced subsequent 
fertility and an increased risk of a further ectopic pregnancy. Changes in 
management of ectopic pregnancy have centered around attempts to conserve the 
Fallopian tube in the hope that this will increase the chances of a spontaneous 
conception by leaving both tubes to function. The concern is that conservative 
methods of treating ectopic pregnancy also leave a damaged tube, increasing the 
risk of future tubal pregnancies in women who are already at greater risk of ectopic 
pregnancy. 
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Bouyer et al. (2000b) looked at 291 women who had attempted to conceive after an 
ectopic pregnancy. 66% had achieved a conception, 41% had had either a live 
birth or their pregnancy was ongoing at the time of survey, 15% had had a 
miscarriage and 10% a further ectopic pregnancy (that is 16% of women who had 
actually become pregnant had a further ectopic pregnancy). The 18 month 
cumulative spontaneous intrauterine pregnancy rates were 57% for radical surgery, 
73% for conservative surgery and 80% for medical treatment. When the figures 
were adjusted for confounding factors (e. g. age and education), there was no 
significant difference in subsequent intrauterine pregnancy rates for radical or 
conservative surgical treatment, although a similar trend was noted. If women with 
a prior history of infertility were considered, radical surgery gave a significantly 
lower subsequent pregnancy rate than conservative surgery, if there was no such 
prior history, no significant difference was found. 
1.7.2 Surgical - Laparoscopy v Laparotomy 
In the Cochrane Library review of management of ectopic pregnancy, Hajenius et 
a!. (2000) found three studies suitable for meta-analysis to compare tubal 
preservation at laparoscopy with laparotomy (Vermesh et a!. 1989b; Lundroff et al. 
1991; Murphy et al. 1992). This review concluded that conservative surgery was 
significantly less successful when it was performed laparoscopically than when it 
was performed at the time of laparotomy (RR 0.90,95% Cl 0.83,0.97) due to the 
higher rate of persistent trophoblast after laparoscopic management (RR 3.6,95% 
Cl 0.63,21). In the short term, laparoscopic management was less costly than 
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open surgical management because blood loss and analgesic requirements were 
lower; also operative time, hospital stay and convalescence were shorter. The cost 
reduction for conservative laparoscopic surgery will, however, be offset to some 
extent, by the cost in medically treating persistent ectopic pregnancy. In the paper 
by Lundroff et al., the majority of their patients with persistent trophoblast were 
treated surgically, which further reduces any saving made by treating ectopic 
pregnancy by laparoscopy. 
In the long-term, conservative laparoscopic management offered similar tubal 
patency rates, similar intrauterine pregnancy rates and a non-significant reduction 
in the repeat ectopic pregnancy rate as conservative management at laparotomy 
1.7.3 Surgical - Salpingectomy v Salpingotomy 
One of the problems encountered in comparing conservative and radical 
management of ectopic pregnancy is whether the two groups are similar. Smaller, 
unruptured and less symptomatic tubal pregnancies are likely to be selected for 
conservative surgery, whereas more complicated ectopic pregnancies will require 
salpingectomy. Similarly, for an ectopic pregnancy to be medically managed, the 
rise in hCG will be smaller and the levels lower - representing less viable 
trophoblast - than unsuitable cases requiring surgery. 
Yao and Tulandi (1997) reviewed current management of ectopic pregnancy. They 
reviewed nine studies that compared the reproductive outcome of women 
undergoing conservative and radical surgery. There was a total of 528 women in 
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the conservative and 1,246 in the radical group. Of those desiring fertility, 53.0% in 
the conservative group and 49.3% in the radical group subsequently achieved an 
intrauterine pregnancy, whilst 14.8% and 9.9% respectively had a further ectopic 
pregnancy. The studies considered were not strictly comparable, and Yao and 
Tulandi felt that they could only conclude that "conservative surgery may provide a 
subsequent intrauterine pregnancy rate that is at least comparable to or possibly 
higher than that after radical surgery. Unfortunately, the recurrent ectopic 
pregnancy rate may also be higher after conservative surgery". They felt a trial, 
randomising women with ectopic pregnancy to either salpingectomy or 
salpingotomy, was necessary to determine whether salpingotomy offered any long- 
term advantage when a diagnosis of ectopic pregnancy was made. Such a trial has 
still not been performed. 
Shy 
Data published after the Yao and Tulandi has been contradictory. A retrospective 
n 
cohort study (Mol et al., 1998b) found a two-year cumulative pregnancy rate of 62% 
in women who had undergone conservative surgery for ectopic pregnancy and 
30% in women who had undergone radical surgery. A study of laparotomy versus 
laparoscopic management of ectopic pregnancy (Fernandez et al., 19988) found 
the opposite, with a 75% two-year cumulative pregnancy rate following radical 
surgery and a 40% rate following conservative surgery or medical management, 
although the follow-up was shorter (eighteen months) in the latter group. 
It might be thought that the relatively small difference in the intrauterine pregnancy 
rate, between salpingectomy and salpingotomy, is a result of any intra-uterine 
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pregnancy being conceived largely through the unaffected tube, with the conserved 
tube contributing little to the intra-uterine pregnancy rate after salpingotomy. The 
higher repeat ectopic pregnancy rate after salpingotomy being a result, therefore, 
of those conceptions that are achieved through the damaged tube. In Yao and 
Tulandi's review, data from 176 women in whom conservative surgery had been 
performed in a solitary fallopian tube, found similar pregnancy rates to women with 
both tubes present at the start of surgery, with 54.5% of those attempting to 
conceive achieving an intrauterine pregnancy whilst 20.5% had recurrent ectopic 
pregnancies. This confirms that damaged tubes do not inevitably lead to ectopic 
pregnancy and successful intra-uterine pregnancy can be achieved. 
Other factors are likely to be more important than the method of treatment of 
ectopic pregnancy in determining the chances of a successful intrauterine 
pregnancy in the future. The subsequent pregnancy rate is lower in women with a 
history of prior infertility (Sultana et al., 1992; Ory at al., 1993). Pouly et a/. (1991) 
found a lower intrauterine pregnancy rate in women in whom there was evidence of 
damage to the contra-lateral tube at the time of surgery for ectopic pregnancy. 
The risk of persistent trophoblast, i. e. incomplete elimination of all active 
trophoblastic tissue, is a potential complication when conservative surgery is used 
in the treatment of ectopic pregnancy. Any conservative procedure requires post- 
operative surveillance of serum hCG levels. The risk of persistent trophoblast 
appears to be higher with smaller ectopic pregnancies (i. e. <2cm diameter), earlier 
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therapy (<42 days from LMP), initial hCG levels of >3,000miu/ml and implantation 
medial to the salpingotomy site (Seifer, 1997). 
In Yao and Tulandi's review (1997) of the management of ectopic pregnancy, they 
reported rates of persistent trophoblast following conservative surgery of between 
3 and 20%. Overall, patients treated with conservative surgery at laparotomy had a 
3.9% rate of persistent trophoblast, and in equivalent women treated 
laparoscopically the rate was 8.3%. Persistent trophoblast, and its treatment, did 
not appear to have any detrimental effect on subsequent pregnancy rates. 
Graczykowski and Mishell (1997) proposed prophylactic methotrexate after 
conservative surgery to reduce the risk of persistent trophoblast. The same 
argument can be used against this treatment regime as laparoscopic infiltration 
with methotrexate, the patient is electively exposed to the side effects and risks of 
two procedures. However, methotrexate successfully reduced the incidence of 
persistent trophoblast and the duration of hCG monitoring post-operatively. 
Methotrexate can be used more selectively after salpingotomy, being given when 
hCG levels do not support resolution of the trophoblast. This limits the number of 
women exposed to dual management and avoids the necessity for a second 
surgical procedure. In their series, Hoppe of at (1994) successfully treated all 19 of 
their patients with persistent trophoblast with single dose, systemic methotrexate. 
Ben-Arie et al. (2001) reported disseminated intra-abdominal implants after 
laparoscopic salpingectomy. In this case, the woman re-presented with a 
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haemoperitoneum three weeks after her surgery. Disseminated peritoneal implants 
have been found after salpingotomy as well (Giuliani et aL, 1998). 
Dwarakanath et al. (1996) looked at the management of persistent ectopic 
pregnancy following conservative laparoscopic surgery. In their experience, they 
found further surgical intervention was not required in women whose post- 
operative hCG levels rose unless they became symptomatic. They do not state 
whether the hCG levels eventually fell, or how long this process took. They did not 
use methotrexate in the management of persistent trophoblast, if it had been used, 
it might have reduced the length of follow-up and might have been a less invasive 
alternative for those who eventually became symptomatic and required surgery. 
Radical surgical treatment is considered unlikely to result in residual trophoblastic 
tissue but this assumption does not always hold true, 1 of 39 women having 
laparoscopic salpingectomy required intervention for persistent trophoblast (Mol et 
al. 1997b). In this non-randomised comparison of salpingectomy and salpingotomy, 
the spontaneous intrauterine pregnancy rates within three years were 39% and 
47% respectively. 
Suturing the tube after salpingotomy might affect future fertility. Tulandi and 
Guralnick, (1991) found the intrauterine pregnancy rate was higher in women 
whose tubes were left unsutured during the first twelve months after surgery. This 
advantage appeared to be short lived, with similar cumulative intra-uterine 
pregnancy rates at two years. 
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"Milking" of the ectopic gestation sac through the tube describes the technique 
whereby attempts are made to expel the trophoblast through the tubal ostium 
without incising the tube. It is associated with continued bleeding fromthe 
implantation site and a persistent ectopic rate of 33.3%, Vermesh (1989). 
Therefore, unless a tubal abortion is found at the time of surgery, this technique is 
not to be recommended. 
1.7.4 Medical - Methotrexate 
Various agents have been used to treat ectopic pregnancy medically - RU486, 
prostaglandins F-2a and E-2, potassium chloride, hyperosmolal glucose - 
however, the agent with the greatest use, remains methotrexate. 
Various criteria to predict the success of methotrexate have been considered - the 
size of the ectopic mass on ultrasound scan (in Lipscomb of a/., 1999, they allowed 
up to 4cm diameter), the initial hCG and progesterone levels, the presence of fetal 
heart activity and the presence of pelvic fluid. Lipscomb et al. (1999) considered all 
these factors in 350 women undergoing a single dose regime of methotrexate, and 
hCG level at the start of therapy was the only factor that had any significance 
(p<0.001) in predicting success. With initial values of hCG of <1000miu/ml the 
success rate was 98% (95% Cl 96-100), of 1000-1999miu/ml, 93% (95% Cl 85- 
100) and of 2000-4999miu/ml, 92% (95% Cl 86-97). 
Tawfiq et al. (2000) found a cut-off for successful medical treatment with an hCG 
level of 4,000miu/ml or less; at levels greater than this there was a 65% failure 
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rate. They do not quantify the success rates at lower levels. They also found that 
medically treated women who presented with a history of pain and vaginal bleeding 
had a lower (unquantified) success rate. 
Methotrexate has been given by various routes: local infiltration, either 
laparoscopically or ultrasonically guided, or parentally, either as single or multiple 
dose regimes. 
Parental regimes might be either multiple or single dose. Multiple dose regimes n 
consist of repeated injections of methotrexate with citrovorin rescue. A commonly 
used regime is methotrexate 1mg/kg intramuscularly on alternate days with 
citrovorin 0.1 mg/kg, until either the hCG level falls by more than 15% in 48 hours, 
or, four doses of methotrexate have been given (Pisarska et al., 1998). Single dose 
regimes have been developed as the side effects are considerably less, and 
citrovorin rescue is not required. The most frequently used regime is 50mg/m2. The 
single dose regime requires repeat administration of methotrexate in some cases, 
but only if the levels of hCG are not falling adequately. Levels that fail to fall by 
15% between days 4 and 7 post methotrexate require a second dose of 
methotrexate. 
Single dose intra-muscular regimes would seem to have similar long-term 
outcomes as surgical treatment. In the Yao and Tulandi review (1997), three 
prospective trials (Stovall and Ling, 1993b; Glock et al., 1994; Gross et al., 1994) 
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with a total of 172 patients, found 58% of patients had subsequent intrauterine 
pregnancies and 9% had recurrent ectopic pregnancies. 
Hajenius et al (1997) compared multiple dose methotrexate and laparoscopic 
salpingotomy and found similar outcomes by randomly assigning patients to one or 
other of the treatments. All laparoscopically confirmed ectopic pregnancies were 
included. In the methotrexate group 82% required no further treatment, 4% 
required an additional course of methotrexate and 14% surgical intervention. This 
compared to 72% who required no further treatment after salpingotomy, 20% 
requiring post-operative methotrexate and 8% requiring surgical intervention. 
Ipsilateral tubal patency was confirmed in 55% and 59% of the patients 
respectively. 
There have been no randomised comparisons of single dose and multiple dose 
regimes, although one unit reported a 96.0% success rate with a multiple dose 
(Stovall et aL 1991) and 91.5% success rate with a single dose regime (Lipscomb 
et al., 1998). This is despite a liberalisation of the treatment criteria after initiating 
the single dose regime. 
In their Cochrane Library review, Hajenius et a!. (2000) found that multiple dose 
regimes were as effective in eliminating ectopic pregnancy as laparoscopic 
salpingotomy, with similar long-term outcomes. They did not feel that single-dose 
treatment was sufficiently effective when compared to laparoscopic salpingotomy. 
However, multiple dose regimes are considerably more expensive and are 
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associated with a greater impairment in quality of life. They concluded that multiple 
dose methotrexate had a place in the management of ectopic pregnancy in 
haemodynamically stable women, unlike single dose therapy. There was no direct 
comparison of single and multiple dose regimes; the comparison was indirect, both 
regimes being compared independently to laparoscopic salpingotomy. 
Fernandez et al. (1998b) randomised women with ectopic pregnancy to either 
laparoscopic salpingotomy or medical treatment. The preferred route was local 
infiltration of methotrexate under ultrasound guidance, single dose systemic 
methotrexate only being used when the ectopic pregnancy could not be safely 
accessed with ultrasound guidance. hCG levels were not the primary means of 
determining suitability for inclusion. 88.2% of the methotrexate group were 
successfully treated and 95.9% in the surgical group. The lower rate of success in 
the medically treated group was largely down to the greater rate of persistent 
ectopic pregnancy. The subsequent spontaneous intrauterine pregnancy rate was 
higher, and the repeat ectopic rate lower, in the medically treated group. 
Saraj et al. (1998) randomised women with a diagnosis of ectopic pregnancy to 
single dose systemic methotrexate or laparoscopic salpingotomy. Resolution of 
ectopic pregnancy was similar in both groups, 94.7% in the methotrexate group, 
15.8% requiring a second dose seven days post-treatment, and 91.4% in the 
surgically managed group. Subjects with all levels of hCG were included, and 
those requiring a second dose of methotrexate had higher initial mean hCG levels 
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than those subjects in which a single dose was successful (4830 +/- 1588miu/ml 
and 2133 +/- 393miu/ml respectively). 
A further study of single-dose systemic methotrexate and laparoscopic 
salpingotomy by Sowter et al. (2001a) included all women with a diagnosis of 
ectopic pregnancy whose initial hCG was <5000miu/ml and an adnexal mass of 
less than 3.5cm on ultrasound scan. In the methotrexate group, 64.7% were 
successful with a single dose of methotrexate, 20.5% required one or more 
additional doses and 14.7% required surgical management. In those treated 
surgically, 82.1 % were successfully treated at the time of laparoscopy, in 10.7% an 
ectopic pregnancy was not found and 7.1% had persistent trophoblast. They 
concluded that single dose methotrexate is less effective than laparoscopic 
salpingectomy. 
In the Cochrane review, Hajenius et a!. (2000) considered the three trials discussed 
above (Fernandez et a!., Saraj et al. and Sowter et al., ) to be robust enough to 
allow comparison. It is these trials that lead them to conclude that single dose 
methotrexate is not as effective as either treatment with multiple dose methotrexate 
or laparoscopic salpingectomy. However, as can been seen, one of the trials was, 
in fact, a comparison of ultrasound infiltration and laparoscopic salpingectomy and 
none of the trials limited cases to lower levels of initial hCG, in which medical 
treatment has been shown to be more effective. Future reproductive performance 
was similar in the two groups and a non-significant lower rate of repeat ectopic was 
found in the medically treated group. 
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Bouyer et al. (2000) found a higher intrauterine pregnancy rate in women treated 
medically over those treated surgically. However, women treated medically were 
better educated and the numbers much smaller, suggesting some bias in the 
selection of patients for medical treatment. In a similar study (Dias Pereira et al., 
1999), salpingotomy was compared with a multiple dose methotrexate regime no 
significant difference in subsequent intrauterine pregnancy or ectopic pregnancy 
rates was found. 
Olofsson et aL (2001) found a similar probability of intrauterine pregnancy in the 
subsequent 2.5 years following medically treated pregnancies as after surgery. The 
study was not randomised and did not differentiate between different surgical 
techniques. 
Pharmacokinetic studies comparing systemic and local methotrexate have shown 
that the maximum plasma concentration and area-under the curve are similar in 
local and systemic regimes (Schiff at al., 1992; Fernandez et al., 1994). 
Fernandez et al (1995), found similar short-term outcomes when laparoscopic 
salpingotomy was compared with ultrasound guided infiltration with methotrexate 
combined with aspiration of the gestation sac. They looked at resolution of the 
ectopic pregnancy; the trial did not examine subsequent fertility rates. 
In their Cochrane Library review, Hajenius et al. (2000) concluded that their was no 
place for local infiltration with methotrexate, either at laparoscopy or under 
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ultrasound guidance, as these methods are significantly less successful than 
surgery at eliminating ectopic pregnancy. 
When methotrexate is administered locally at laparoscopy, the patient is exposed 
to both the risks of surgery and the risks of medical management. Ultrasound 
guided local infiltration does not expose the patient to the additional operative risk, 
but, unlike parental administration, it is operator dependent. 
A 
The use of methotrexate is associated with an increase in size and vascularity of 
the ectopic pregnancy (Atri et aL, 1992); this is a normal finding post-methotrexate 
and does not denote treatment failure. It is for this reason, that repeat ultrasound is 
not recommended until hCG returns to non-pregnant levels. Levels of hCG can be 
expected to rise between days 1 and 4 post-methotrexate. Stovall and Ling (1993) 
found a transient rise in the hCG in 86% of subjects between days I and 4. 
Treatment of ectopic pregnancy with methotrexate leads to pain in a substantial 
proportion of women around 3-4 days after treatment. Predicting women who are 
at risk of haemorrhage is, therefore, problematic. Lipscomb et al. (2000) followed 
258 women who had single-dose methotrexate. 21.7% had concerning symptoms, 
of these 14.3% required surgery, although this is only 3% of the cohort. They 
suggest that early surgical intervention is not indicated in haemodynamically stable 
women with severe pain following treatment single-dose methotrexate. 
Patients having either expectant or medical treatment (or conservative surgical 
treatment) must be warned that tubal rupture might occur until there is complete 
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resolution of the trophoblast. It is, therefore, important that they attend for tracking 
of hCG levels and that methotrexate/repeat methotrexate is considered if the levels 
fail to decline. Tubal rupture can occur at any time whilst viable trophoblast 
remains. Lipscomb et al. (2000) record a case of tubal rupture 42 days after 
treatment with methotrexate. 
In Lipscomb et al. 's 1999 paper, they found the mean for hCG levels to return to 
non-pregnant levels after medical treatment was 33.6 days, with the longest being 
109 days. 17.5% of their patients required more than one dose of methotrexate, 
though it must be remembered that they treated any suitable case regardless of 
initial hCG level. 
Perdu et a!. (1998) gave mifepristone in combination with methotrexate, resulting in 
a substantially reduced failure rate, with only 3.3% of those receiving medical 
management failing to resolve. This was against a failure rate of 26.2% in those 
treated with methotrexate alone, which might be explained by medical treatment 
being offered to all suitable women with hCGs of 10,000miu/ml or less. Also, the 
trial was not randomised - the control group being historical. 
There are various potential side-effects of high dose methotrexate, for example, 
bone marrow suppression, acute and chronic hepatotoxic effects, stomatitis, 
gastritis, pulmonary fibrosis, alopecia and photosensitivity (Pisarska et al., 1998). 
These are unlikely with single dose regimes and any additional risk in multiple dose 
regimes can be minimised by the use of citrovorin rescue. Life-threatening 
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neutropenia has been reported in patients given methotrexate as treatment for 
ectopic pregnancy, in one case using multiple dose, the other a single dose regime 
(Isaacs et al., 1996). Transient pneumonitis has also been described following local 
er infiltration of an ectopic pregnancy (Schoenfeld et al., 1992) and use of a parental 
single dose methotrexate regime (Horrigan et al., 1997). Interestingly, in the case 
reported by Horrigan et al., the patient had had uncomplicated medical 
management of a previous ectopic pregnancy. 
Ben-Shlomo et al. (1997) found multiple ovarian cysts (maximum diameter 9.4cm) 
in 15% of women who had local methotrexate infiltration of ectopic pregnancy. 
Similar cysts were found in just 1.8% of women after salpingotomy. 
1.7.5 Expectant Management 
The rise in incidence of ectopic pregnancy might, in part, be explained by an 
increase in its early diagnosis. Ectopic pregnancies, that might have spontaneously 
resolved in the past, are now treated because pregnancy, and hence its 
complications, can be diagnosed at much earlier gestations than was previously 
possible. The pressure to treat all ectopic pregnancies comes from the morbidity 
and mortality from the uncontrolled bleeding associated with some cases of ectopic 
pregnancy. For these reasons, many women with ectopic pregnancy may be over 
treated. 
In 1955, Lund described the expectant management of 119 patients with ectopic 
pregnancy. 57% did not require surgical intervention. Of those patients in whom 
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expectant management failed, many had significant symptoms with 
haemoperitoneum or collapse. Subsequently, 46% of those desiring a further 
pregnancy achieved an intrauterine pregnancy, 15% had a further ectopic 
pregnancy. However, this management required a protracted hospital stay, which 
would be financially unacceptable today, even if patients tolerated it. 
Ylöstalo et al. (1991) observed 48 women with ectopic pregnancy selected for 
expectant management. Ectopic pregnancy was diagnosed when hCG level fell 
between samples taken 48 hours apart, there was no evidence of an intrauterine 
pregnancy and any adnexal mass was less than 4cm on ultrasound and no signs 
of rupture or acute bleeding. 23% of all cases of suspected ectopic pregnancy 
fitted these criteria. Spontaneous resolution occurred in 65%. 
Shalev et al. (1995) expectantly managed all ectopic pregnancies in which the hCG 
level was seen to decline in consecutive samples taken 48 hours apart. Women in 
whom an ultrasound scan demonstrated an adnexal fetal heart pulsation or a 
haemopertitoneum of >100mis were excluded. The ectopic pregnancies were 
confirmed at laparoscopy. 46.7% of cases were successfully expectantly managed, 
60% of cases where the initial hCG was <2000mi/ml, whereas 93.3% failed if the 
initial hCG was >2000miu/ml (i. e. 1 of 28 cases succeeded). In one woman, tubal 
rupture occurred when the hCG level was <10mlu/ml. Their fertility rates following 
expectant management were similar to those after surgical management, with 
recurrent ectopic pregnancy rates of 12.5% and ongoing pregnancy rates of 45.8% 
at one year. 
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Ylöstalo et al. (1992) considered expectant management if the initial hCG levels 
were declining and an adnexal mass of <4cm on ultrasound. 26% of all their 
ectopic pregnancies were suitable for expectant management, in 69% spontaneous 
resolution occurred. Shalev et al. (1995) argued that this higher success rate might 
be because a proportion of their adnexal masses were not ectopic pregnancies. 
But to treat a woman expectantly and to add in the risk of a laparoscopic 
assessment of the ectopic pregnancy, increases the overall risk of this course of 
management without any improvement in her chances of a successful pregnancy 
in the future. 
In the study by Fernandez (1988), 10 out of 14 ectopic pregnancies resolved 
spontaneously. These pregnancies were carefully selected at laparoscopy. This 
illustrates the problem with all non-surgical treatments of ectopic pregnancy: if the 
diagnosis, or in this case assessment, of the tubal pregnancy cannot be made by 
non-surgical means, little advantage is offered to the patient, whilst they are 
exposed to the risk of a second operative procedure if the initial management fails. 
Banerjee et al. (2001) followed all women in whom the location of pregnancy could 
not be determined at initial presentation. All these women were managed 
expectantly until an intrauterine gestation sac was found, or a deterioration in the 
clinical state, or hCG levels failed to fall. 69% of these pregnancies resolved 
spontaneously and a serum progesterone level of 20nmolJ or less had a positive 
predictive value of 97% for spontaneous resolution. 
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Strobelt et al. (2000) found similar rates of subsequent intrauterine pregnancy in 
women with successful expectant management of their ectopic pregnancy as those 
whose primary treatment was surgical (63% v 51 %, p=0.37). Those women who 
failed expectant management and required surgery as a secondary procedure also 
had similar rates of subsequent intrauterine pregnancy as those who had primary 
surgical management (54% v 65%, p=0.44). 
1.7.6 Impact on Quality of Life 
Nieuwkerk et a!. (1998a) compared women who had medical treatment with those 
having laparoscopic salpingostomy. They found that medical treatment of ectopic 
pregnancy had a greater negative impact on physical, role and social functioning; 
they had worse health perceptions, greater pain, depression and physical 
symptoms, less energy and overall, a worse quality of life, than those treated 
surgically. This study is limited by the fact that all women had a diagnostic 
laparoscopy to confirm the ectopic pregnancy, the avoidance of a surgical 
procedure being one of the attractive features to women who choose medical 
management, and also that a multiple dose methotrexate regime was used. 
In a paper, by the same authors, published simultaneously, (Nieuwkerk at al., 
1998b) patient treatment preferences were explored. Treatment with methotrexate 
was portrayed as better preserving tubal patency than salpingostomy, at the 
expense of more initial intervention. Few patients would trade any gain in tubal 
patency, if treatment with methotrexate were preceded by diagnostic laparoscopy. 
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However, most patients preferred treatment with methotrexate, even without any 
improvement in tubal fertility, if this avoided a diagnostic laparoscopy. 
1.7.7 Financial Implications 
In their paper evaluating the economic implications of radical and conservative 
surgery, Mol et a/. (1997`) concluded that conservative surgery has an additional 
economic cost that can only be justified if a higher rate of future intrauterine 
pregnancy leads to at least an equivalent reduction in the cost of investigation and 
management of subsequent infertility. All surgery was laparoscopic. Patients 
undergoing salpingectomy had a marginally shorter (non significant) in-patient stay 
(2.8 v 3.0 days). Persistent trophoblast was found in 1 of 39 women who 
underwent salpingectomy and 17 of 76 women undergoing salpingotomy. 
Treatment was not determined by randomisation. Salpingectomy took significantly 
longer to perform (77 versus 64 minutes, p=0.018). But because of the need for 
routine hCG surveillance and the greater number of women who required 
treatment for persistent trophoblast, the short-term unit cost of salpingotomy was 
greater. (Women undergoing salpingectomy routinely had two post-operative hCG 
levels taken). They demonstrated that an increase of 2.2% in the subsequent 
intrauterine pregnancy rate for salpingotomy over salpingectomy was cost effective 
when the additional costs of future assisted conception techniques are considered. 
The same authors made an economic comparison of multiple dose systemic 
methotrexate and laparoscopic salpingotomy (Mol et al., 1999c). Treatment with 
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methotrexate was more expensive (US$5721 for medical treatment, versus 
US$4066 for laparoscopic salpingostomy). Their trial required laparoscopic 
confirmation of the ectopic pregnancy before treatment. If this could be avoided, 
medical management with a multiple dose regime became the cheaper option 
when starting hCG levels were less than 1500miu/ml, single dose regimes were 
marginally cheaper still, despite the greater rate of second interventions when hCG 
level failed to fall. When initial hCG levels were greater than 3000miu/ml, 
methotrexate became a more expensive option, even in the absence of a 
diagnostic laparoscopy. 
Sowter et aL (2001b) compared the direct and indirect cost of treatment for patients 
treated in their trial of single dose methotrexate versus laparoscopic management 
of ectopic pregnancy. In subjects suitable for inclusion in the trial, the mean direct 
costs were half that of surgical treatment for methotrexate (NZ$3083 and NZ$1470 
respectively) and the indirect cost for women treated surgically were also greater 
than with medical treatment, though the difference was not as great (NZ$1899 and 
NZ$1141 respectively). As subsequent reproductive outcome appears similar in 
groups of women treated medically and by laparoscopic salpingotomy, the long 
term costs of recurrent ectopic pregnancy and assisted conception are likely to be 
similar. 
Lecuru et al. (2001) prospectively costed the treatment of women undergoing 
medical and surgical treatment of ectopic pregnancy. Single dose methotrexate 
was given to women whose hCG level was <5000miu/ml. Those women who 
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did not wish to have medical management, or were unsuitable, had laparoscopic 
salpingotomies. There were similar outcomes in both groups, but hCG follow-up 
took longer in those medically treated. However, significant savings were still made 
with medical management because of the reduced hospital stay. Laciano et al. 
(2001) estimated a saving of US$3,000 for each patient treated medically, rather 
than surgically. 
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Chapter 2- Aims and Objectives 
2.1 Aims and Objectives 
1. To evaluate the diagnosis and management of ectopic pregnancy 
locally and nationally 
Two questionnaires were designed to look at the service available for the 
diagnosis and management of ectopic pregnancy, both from the point of view of 
those who deliver the service, and from that of the patients who access the 
service. 
The first questionnaire was designed to assess the facilities for the diagnosis 
and management of ectopic pregnancy throughout the United Kingdom and 
Northern Ireland. Questionnaires were sent to all units with an acute 
gynaecological service asking about Early Pregnancy Units: 
- their opening hours 
- diagnostic facilities, particularly pertaining to the use of ultrasound and serum 
hCG 
- how ectopic pregnancy is managed within the unit, their ability to deliver 
laparoscopic management of ectopic pregnancy and willingness to consider 
medical management 
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A second questionnaire was designed in conjunction with the Ectopic 
Pregnancy Trust to survey the experiences of women, as patients, who had had 
an ectopic pregnancy: 
- who made the diagnosis 
- how long it took for the diagnosis to be made 
- the choices that were offered for management 
- information they were given about their diagnosis and its implication for the 
future 
2. To look at changes in the diagnosis and management of ectopic 
pregnancy between 1993 and 1999 
This compromised an audit of practice at St. James's University Hospital in 
1993, before the introduction of serum hCG estimations and 1999, when hCG 
estimations were an established component in the diagnosis of ectopic 
pregnancy. 
3. To discuss the impact that any changes in diagnosis and management 
of ectopic pregnancy might have on service provision 
4. To develop a protocol for the management of ectopic pregnancy to be 
used within St James's University Hospital that can be used by both 
medical and nursing staff 
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Ectopic pregnancy has a measurable mortality and is also responsible for much 
short-term and long-term morbidity. An examination of the literature was made 
to determine the optimal diagnostic protocol and recommendations for 
management to prevent maternal death and reduce morbidity to a minimum. As 
specialist nurses are often the practitioners who manage patients until a 
diagnosis is made, a protocol should support them in this practice, giving clear 
guidelines within which they can work, and at what point a senior doctor should 
be involved. A protocol should also aim to make the best use of resources, 
limiting unnecessary use of ultrasound scans and biochemical testing. It should 
also encourage good practice in the management of ectopic pregnancy, making 
clear the full range of medical and surgical options and in what circumstances 
they should be employed. 
S. To consider scope for changes in the diagnosis and management of 
ectopic pregnancy 
Review of the literature for the design of the protocol will consider the medical 
experience of diagnosis and management of ectopic pregnancy. This will also 
be considered from the perspective of the patient 
Experiences with the ROCET trial, a pilot trial to compare conservative and 
radical surgical treatment for ectopic pregnancy, will be discussed. This pilot did 
not offer an answer to what was the optimal mode of surgical management, but 
was revealing in what it showed about the choices the women made about their 
management. 
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Conjoint Analysis is a tool used in Transport Studies to observe how people 
trade choices off against each other. It was used here to see if women were 
prepared to trade choices for the management of ectopic pregnancy. 
This is also covered, in part, by the Ectopic Pregnancy Trust questionnaire 
regarding women's experiences of ectopic pregnancy. 
6. To explore fetal fibronectin in early pregnancy, its potential as a 
diagnostic test for ectopic pregnancy and its use in differentiating 
between ectopic pregnancy and other complications of early 
pregnancy 
Even with effective protocols for the diagnosis and management of ectopic 
pregnancy, there will still be cases in which the diagnosis is delayed or when a 
diagnostic laparoscopy is performed in the absence of an extra-uterine 
pregnancy. At present, making a diagnosis means deciding which is most likely 
out of a range of possibilities. If a test were to be devised that could 
discriminate between abnormal and normal early pregnancy and between intra- 
and extra-uterine pregnancy, mortality and morbidity related to ectopic 
pregnancy and its treatment, might be reduced. 
Measurement of fetal fibronectin in the endo-cervical and vaginal secretions is 
well established in the diagnosis of complications of pregnancy in the third 
trimester. A commercially available assay is used. Fetal fibronectin is produced 
by trophoblast and so it is also found the endo-cervical and vaginal secretions 
in first trimester. I aimed to assess its potential as an aid to the diagnosis of first 
trimester complications. 
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"I wished to establish levels of fetal fibronectin in normal early pregnancy. 
9 Miscarriage is an important differential diagnosis with ectopic pregnancy. 
I aimed to see if fetal fibronectin might be used to differentiate between 
viable early pregnancy and non-viable early pregnancy, at gestations too 
early for this distinction to be made by ultrasound. 
"I next aimed to measure levels of fetal fibronectin found in ectopic 
pregnancy. With information about the levels found in ectopic pregnancy 
and levels found in the two situations that are part of the differential 
diagnosis of ectopic pregnancy, the role of fetal fibronectin in 
differentiating between these situations would be assessed. 
" As further evaluation of the assay, situations such contamination with 
blood and samples taken in the non-pregnant state would be examined. 
Chapter 3- Management of Ectopic Pregnancy 74 
3. Local and National Management of Ectopic Pregnancy 
3.1 Assessment of Current Local and National Management of 
Ectopic Pregnancy 
In order to assess how to improve management guidelines, it was important to 
investigate current practice in the management of ectopic pregnancy and where 
this is deficient. There are three components to this assessment: local, national, 
and the patient perspective. 
(i) audit of practice within St. James's University Hospital (SJUH). 
(ii) the current practice of UK units in the diagnosis and management of ectopic 
pregnancy using a national postal questionnaire to assess practice in the 
diagnosis and management of ectopic pregnancy that was sent to all UK 
units offering a gynaecological service. 
(iii) the experiences of women in whom an ectopic pregnancy has been 
diagnosed. The Ectopic Pregnancy Trust Questionnaire of Women's 
Experiences of Ectopic Pregnancy was designed in conjunction with the UK 
based charity The Ectopic Pregnancy Trust (EPT) and distributed, by them, 
to women who had experienced ectopic pregnancy. 
Examples of the questionnaires used are given in Appendices 1 and 2. 
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3.2 Audit of the Management of Ectopic Pregnancy in St. 
James's University Hospital (SJUH)I 1993 and 1999. 
Although there was an early pregnancy unit established before 1994, it was not 
until then that the use of serum hCG estimations was introduced. This innovation 
should have improved the diagnosis of ectopic pregnancies, with fewer women 
having the diagnosis missed and presenting with collapse, whilst at the same 
time, reducing the number of unnecessary laparoscopies in women with normal 
intra-uterine pregnancies and miscarriages. Use of serum hCG levels also opens 
up different possibilities for management of ectopic pregnancy, allowing doctors 
to consider expectant or medical management. 
Since its introduction, there has been concern that too many levels are being 
carried out since it is the "easy option". This leads to normal early pregnancies 
being tracked and doctors requesting a repeat sample after 48 hours when a 
diagnosis should have been possible. 
The impact of this change was assessed by auditing the management of ectopic 
pregnancy before and after introduction of this service. 
3.2.1 Method 
There was an assumption that all women with ectopic pregnancy would end up 
with a laparoscopy and/or tissue being sent to pathology. However, women who 
had a laparoscopy but the diagnosis was negative would not be coded as ectopic 
pregnancies and would have no tissue sent. Therefore I studied: 
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(a) all emergency laparoscopies (le laparoscopies done outside 
scheduled operating lists) 
(b) all surgical procedures coded for ectopic pregnancy in 1993 and 
1999. 
In SJUH, all surgical procedures are Reed coded and stored on a database for 
the administrative purposes. This provides a simple way of identifying women 
who have had either a diagnostic laparoscopy or surgical procedures for the 
management of ectopic pregnancy as acute cases. A search was performed for 
all procedures that were coded as including salpingectomy, salpingotomy, 
salpingostomy, salpingoophorectomy or ectopic pregnancy. A second search was 
also performed for all laparoscopies performed on acute lists. For all the 
procedures to be found, this would require that codings are reliably and 
accurately entered. In order to check this, the theatre books from all the theatres 
where gynaecological and acute cases were carried out were checked for two 
months of the years in 1999 (1993 theatre books being unobtainable) and the list 
appeared to be complete and reliable. 
Second approach was to look for specimens sent for pathological assessment. 
All tissue is "SNOMED" coded according to the findings. I performed a search 
looking for all samples coded as ectopic pregnancy, or trophoblast and fallopian 
tube. However, this gave a poor return with only a handful of cases. 
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A computer-generated list of all these cases was produced and a large proportion 
of cases that were obviously unrelated were then removed - for example, "total 
abdominal hysterectomy and bilateral salpingoophorectomy". The notes of the 
remaining cases (acute laparoscopies and other procedures that could possibly 
have been performed for ectopic pregnancy) were retrieved from the medical 
records library. There was one group of patients that might be underrepresented 
in this sample, women who had negative diagnostic laparoscopies on scheduled 
lists. However, since most acute cases are done on designated acute lists in 
SJUH, this number is likely to be small. 
Medical management of ectopic pregnancy was not available in this unit in 1993 
and only routinely used in 1999. These cases are not Reed coded in the same 
fashion, as they do not usually have a surgical procedure, however, all such 
cases from 1999 were known through the records of the Early Pregnancy Unit 
(EPU). 
Therefore, all the cases of ectopic pregnancy from both years were retrieved and 
most of the cases of suspected ectopic that went for laparoscopy. These cases 
were examined to evaluate the impact of hCG estimations on the diagnosis and 
management of ectopic pregnancy. The number and timing of estimations, the 
length of pre- and post-operative stay, the findings at laparoscopy and final 
diagnosis were all recorded and compared. 
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3.2.2 Results 
3.2.2a Diagnosis 
In 1993 there were 158 emergency laparoscopies for suspected ectopic 
compared with 88 in 1999. Figure 3.1 shows the final diagnosis reached in 
women requiring an acute diagnostic laparoscopy for both years. 
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Fig. 3.1 final diagnosis in women having acute diagnostic laparoscopies, 
comparing 1993 and 1999 
Compared with 1993, the number of ectopic pregnancies diagnosed in 1999 was 
similar (fig. 3.1). However, the total number of emergency laparoscopies in 1993 
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wo almost double that in 1999. The difference between the two years wo. ý due 
two distinct groups (fig. 3.2) 
(i) fewer women with viable intra-uterine pregnancies and miscarriages were 
subjected to laparoscopies (48 laparoscopies in 1993 and 11 in 1999). 
(ii) there has been a decline in acute laparoscopies done in non-pregnant 
woman over this time. 
1993 
 ongoing 
 miscarriage 
Oectopic pregnancy 
O other 
1999 
Fig. 3.2 Final diagnosis as a proportion of all acute laparoscopies 
3.2.2b Length of in-patient treatment 
Figure 3.3 shows the period of time, in days, that women spent as in-patients 
before they were taken to theatre. 
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Figure 3.4 shows the number of women (all cases) with a particular length of stay 
expressed as a percentage as all cases. 
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Figure 3.4 Length of pre-operative stay for all diagnostic laparoscopies, 
expressed as a percentage of all cases 
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Fig. 3.5 Length of inpatient pre-operative stay, ectopic pregnancies only, 
expressed as a percentage of all ectopic pregnancies 
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Fig. 3.6 Length of total hospital stay, ectopic pregnancies only, expressed 
as a percentage of all ectopic pregnancies 
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3.2.2c Management of ectopic pregnancy 
The majority of surgery is still radical with 87.3% of women in 1993 and 87.1% of 
women in 1999 having the tube containing the ectopic pregnancy removed. 
There was an increase in the number of women requesting bilateral 
salpingectomy, with three in 1993 and seven in 1999. With small numbers from 
just two years it is difficult to attach too much significance to this change, 
however, bilateral salpingectomy is a management option discussed with women 
who have ectopic pregnancies whilst undergoing assisted conception, and this 
might have brought about the increase. 
Table 3.1 How ectopic pregnancies were managed in 1993 and 1999 
Management 1993 (%) 1999 (%) 
salpingectomy 
salpingotomy 
bilateral salpingectomy 
"milking" of ectopic 
salpingoophorectomy 
52 (82.5) 46 (74.2) 
7(11.1) 4(6.5) 
3 (4.8) 7 (11.3) 
1 (1.6) 1 (1.6) 
01 (1.6) 
methotrexate 103 (4.8) 
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Table 3.2 Route of surgical management of ectopic pregnancy 
Route 1 1993 1999 
laparotomy 1 63 (100%) 34 (69.3%) 
laparoscopy 10 15 (30.6%) 
Whilst all ectopic pregnancies were managed by laparotomy in 1993, the number 
of laparoscopic procedures in 1999 remains low, with only 30.6% of ectopic 
pregnancies being managed laparoscopically within the unit (Table 3.2). This was 
partly related to the problem of a lack of appropriately trained personnel. 
Table 3.3 Site of ectopic pregnancy 
Site 1 1993 1999 
right side 34 40 
left side 
3.2.2d Use of serum hCGs 
26 18 
The purpose of the study was to investigate if any change in practice is 
associated with the use of serum hCG estimations. It certainly would appear it 
has made an impact on the accuracy of the diagnosis since there was a reduction 
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in the number of women with normal pregnancies and miscarriages who under- 
went laparoscopy. 
Table 3.4 The number of women undergoing laparoscopy who were found 
to have an ectopic pregnancy (positive result) 
Positive 
Negative 
Total 
1993 1999 
63 (PPV - 40%) 62 (PPV - 70%) 
94 26 
157 88 
Figure 3.7 demonstrates how many pre-operative hCG levels were taken for 
those pregnant subjects in whom the outcome was known. In only 17 (23.0%) 
was the optimum number of two hCG levels taken. 
Conservative management runs the risk of persistent trophoblast and it is 
recommended that all such cases should be tracked post-operatively until non- 
pregnant levels of hCG are reached. In this study only 3 of the 4 women 
undergoing a conservative surgical procedure had follow-up hCGs. 
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Fig. 3.7 The number of diagnostic preoperative hCG levels taken according 
to pregnancy outcome 
3.2.3 Discussion 
It is clear that there are less laparoscopies being carried out and more are 
positive for ectopic pregnancy implying increased accuracy of diagnosis. This 
difference is split evenly between those who are non-pregnant and those who 
have miscarriages or viable pregnancies. There are two factors that may have 
lead to this reduction. Firstly, a negative pregnancy test will exclude ectopic 
pregnancy in most cases removing the need for laparoscopy, and secondly the 
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diagnosis prior to laparoscopy was more accurate making more of the remaining 
laparoscopies positive. The use of serial hCG may be the reason for this. 
Although bed occupancy in this population has decreased between 1993 and 
1999 (fig. 3.3), this is because of the reduction in the total number of acute 
laparoscopies. When length of pre-operative stay as proportion of cases is 
considered (fig 3.4) it can be seen that there is a tendency towards women in 
1999 having a longer stay before surgery, but this did not reach significance. The 
difference is only a matter of an extension of two days. However, there was not a 
large number of patients who were admitted for a long period before surgery. 
If just the population in whom a diagnosis of ectopic pregnancy was made is 
considered, the length of pre-operative stay is again shown to have increased 
slightly between 1993 and 1999 (fig. 3.5). This might be because doctors are 
waiting for serial hCG estimations before taking the patient to theatre. In a cardio- 
vascularly stable woman with few symptoms, this may be an inappropriate use of 
beds. Protocols giving guidance as to when hCG levels can be tracked on an out- 
patient basis may result in a reduction in pre-operative stay. Designated theatre 
time would lead to a further reduction, as patients do not have to wait for time on 
the acute list. However, this does not appear to be a significant problem and 
there is a reduction in the total length of stay between the two years. 
Figure 3.6 shows a decline in the total length of stay between 1993 and 1999. 
This is statistically significant (X2 p<0.001). Since this is only slightly due to 
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pre-operative stay, it is likely to be because of increased use of laparoscopic 
surgery to manage ectopic pregnancy and a reduced post operative stay. 
There appears to be a predominance of right-sided ectopic pregnancies in the 
St. James's population (Table 3.3), although this reaches significance (X2 p<0.01), 
a preference for the right tube is not supported in the literature and conclusions 
should not be drawn from such small numbers. 
Of those who did have a laparoscopy, the diagnosis of ectopic was more likely in 
1999, with the positive predictive value rising from 40% in 1993 to 70% in 1999 
(X2 p<0.001) (Table 3.4) 
This means that clinical and biochemical management allows a more accurate 
diagnosis, opening up the possibility of an alternative management approach 
without laparoscopy. Medical management is successful in the majority of cases if 
the starting hCG is less than 2000miu/mI (Lipscomb et al.; 1999). In the 
St. James's study, 22 women (29.0%) had hCG levels of <2000 when they were 
taken to theatre; these could have been offered medical management. Half of 
these went to theatre without the hCG level being known and none had any 
cardio-vascular compromise. There was no hurry to carry out the laparoscopy 
and if the result had been reviewed as part of the decision making process this 
might have been avoided. 
In 1999, despite the widespread availability of hCG estimations to help diagnostic 
accuracy, a further 18 women (32.3%) had no pre-op level taken. Not only does 
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this mean less management options are available for discussion, but if 
laparoscopy were to be negative an important stage in considering the differential 
diagnosis would have been omitted. It might also be possible that a laparoscopy 
is carried out too early in pregnancy, and although present, the ectopic pregnancy 
is as yet too small to be visualised (Lipscomb et al., 2000). 
The more levels that are taken before the woman is taken to theatre, the more 
likely it is that the woman has a miscarriage. 
Therefore, it is the under usage of hCG levels that is most striking, 48 cases 
(64.9%) of cases having too few levels taken to be of value in determine 
diagnosis and management options. In particular, a spontaneously resolving 
ectopic pregnancy will be over-treated if paired samples are not obtained. 
However, a negative level will exclude an ectopic and may explain the reduction 
in non-pregnant laparoscopies. As 30% of the laparoscopies were still negative it 
suggests that improving the uptake of hCG use may help to reduce this level 
further. 
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3.3 National Postal Questionnaire to Assess Practice in the 
Diagnosis and Management of Ectopic Pregnancy. 
In order to assess whether the practice in SJUH is comparable with the national 
practice in the UK, a national survey was carried out. 
3.3.1 Method 
The aim of the questionnaire was to gather information on the early pregnancy 
assessment service offered by every gynaecology unit in the UK. Specific 
questions were directed at the availability of Early Pregnancy Units (EPUs) and 
the management of Ectopic Pregnancy. 
A draft questionnaire covering areas of interest - availability of an early 
pregnancy assessment service, and facilities for diagnosis and treatment, was 
designed. This questionnaire was piloted locally, to correct any obvious 
deficiencies of clarity and content, and a final version produced. 
It was assumed that most units with an acute gynaecological service will have 
junior doctors in training, and so can be identified from the RCOG list of District 
Tutors. In June 1999, the questionnaire was sent out to every UK District Tutor for 
obstetrics and gynaecology. 
3.3.2 Results 
A total of 262 questionnaires were sent out and 155 (59.2%) were returned. Five 
units did not have any acute gynaecological service. Of the 107 units who did not 
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send a reply to the questionnaire, it is possible that more of them did not provide 
facilities for early pregnancy assessment, which led them to be less inclined to 
reply to the questionnaire. I did not follow up the initial questionnaire to 
investigate this. This left 150 units providing care for those with problems of early 
pregnancy and the results of the analysis of these is presented. 
3.3.2a Availability of Early Pregnancy Assessment Services. 
Units were asked if they had a specific provision for women with early pregnancy 
problems to be assessed without requiring admission. This can take several 
forms, from a dedicated early pregnancy unit to a dedicated space on a ward. 
The important thing is that time and facilities are set aside for women to be 
referred directly for assessment. Overall, 127 (84.7%) units had a dedicated early 
pregnancy assessment service. The other 15.3% provided acute gynaecological 
care with no dedicated services for early pregnancy. 
Table 3.5 Number of days the service was open each week (126 
respondents) 
1234567 
no. 10123 95 5 20 
0 0.8 1.7 1.7 76.0 4.1 15.7 
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Those units with EPUs were asked to indicate their availability, both the number 
of days per week that they were open, and how many hours they were open each 
day. 
Average hours open - weekdays 
Only 99 units gave sufficient information to estimate the average number of hours 
they were open and the results are shown in figure 3.8. 
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Fig 3.8 Chart to demonstrate the number of hours units were open on 
weekdays (99 responses) 
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Average hours open - weekends 
Of the units that are open at the weekend, only 9 of the 25 gave enough 
information to calculate the length of time they were open. 
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Fig 3.9 Chart to demonstrate the number of hours units were open at 
weekends (9 responses) 
3.3.2b Facilities for Diagnosis 
Units with access to trans-vaginal ultrasound 
Ultrasound is the basic tool for assessment of early pregnancy complications. 
Viable pregnancy and many miscarriages can be assessed by ultrasound alone. 
All units had access to ultrasound, and all except one had at least some access 
to trans-vaginal scanning. Availability of trans-vaginal ultrasound is fundamental 
in the diagnosis of ectopic pregnancy as its closer proximity to the pregnancy and 
greater magnification means a diagnosis can be reached at an earlier gestation. 
12345 
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Table 3.6 Units with access to trans-vaginal ultrasound (148 responses) 
TV US Number % 
Yes 127 84.7% 
Limited 20 13.3% 
No 1 0.6% 
No response I21.3% 
Investigation of Suspected Ectopic Pregnancy 
Table 3.7 Availability of ultrasound and biochemical investigations in the 
diagnosis of suspected ectopic pregnancy 
Serial use Single use Nil available No response 
ultrasound 
Serum hCG 
progesterone 
129 (86%) 19(12.7%) 2 (1.3%) 
141 (94%) 4(2.7%) 2 (1.3%) 3 (2%) 
11(7.3%) 6 (4%) 47 (31.3%) 86 (57.3%) 
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If ultrasound cannot confirm a normally placed viable pregnancy or miscarriage, 
further investigation is required. Serum hCG estimations are the main-stay of 
further investigation. 
Only 91 (60.7%) of units had a protocol for managing ectopic pregnancy. This 
survey showed that 113 (75.3%) would be willing to consider out-patient 
management until diagnosis was confirmed but 27 (18%) would admit all possible 
ectopic pregnancies (10 (6.7%) did not reply). 
3.3.2c Treatment of Ectopic Pregnancy 
Surgical management 
Surgery remains the mainstay of management of ectopic pregnancy. This will be 
discussed at length in chapter Q, but questions were included in this 
questionnaire about the treatment offered by the units when ectopic pregnancy is 
diagnosed. Laparoscopic management is considered to be the gold standard for 
the surgical management of ectopic pregnancy. Whilst all units offer surgical 
management, not all offer this laparoscopically 
Availability of Laparoscopic Management of Ectopic Pregnancy 
" EP always managed laparoscopically when appropriate 12 (7.9%) 
" EP sometimes managed laparoscopically when appropriate 116(77.3%) 
" EP never managed laparoscopically when appropriate 19 (12.79161) 
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" No reply 3 (2%) 
Table 3.8 Reasons given as to why not all (appropriate) ectopic pregnancies 
are not managed laparoscopically (120 responses): 
Reasons given Number 
Trained staff not always available 118 
Facilities only available out of hours 5 
Facilities only available in normal hours 8 
No reply 130 
The questionnaire asked for the number of consultants and middle grades in 
each unit, and whether there were trained in the laparoscopic management of 
ectopic pregnancy. Overall, less than 50% of consultants and middle grade 
doctors were reported to be appropriately trained: 
9 656.2 consultants in 121 units = 5.4 per unit 
o 295 (45.0%) manage EP laparoscopically = 2.4 per unit 
" 667 middle grades in 108 units = 6.2 per unit 
o 332 (49.89) manage EP laparoscopically = 3.1 per unit. 
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Medical Management 
Table 3.9 Units using medical management of confirmed ectopic pregnancy 
(147 responses) 
Number (%) 
Confirmed ectopic pregnancy 
Persistent ectopic pregnancy only 
No use 
No reply 
142(28.0%) 
18 (12.0%) 
87 (58.0%) 
3 (2.0%) 
Table 3.10 The agents used for medical management (60 respondents with 
some units using more than one agent) 
Agent I Number 
Systemic MXT 57 
Local MXT 5 
Mifepristone 1 
misoprostol I 
KCI 1 
PGF2a 1 
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Medical management of ectopic pregnancy is an alternative in certain cases of 
ectopic pregnancy. Using this method, the women can avoid the need for surgery 
and sometimes admission. 
3.3.2d Follow-up and Support 
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Figure 3.10 Advise given to women about timing of next pregnancy 
following an ectopic pregnancy (149 responses) 
The questionnaire asked about the post-operative discussion and support offered 
to patient. Discussion of the operative findings was almost universal with 149 
units saying this is part of their care. Discussion of the implications for fertility was 
less common, with only 58.0% of units providing this, and in 17.3% this 
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discussion would only take place post-operatively and not at follow-up in the 
outpatients. The implication for fertility is an important area for women who have 
had an ectopic. In total, 69.3% of units offered outpatient follow-up after an 
ectopic pregnancy. 138 (92.0%) of units recommended a scan in any future 
pregnancy. 
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Fig 3.11 Who provides counselling following an ectopic pregnancy? (101 
responses) 
44 (29.3%) of units offered no access to counselling for women who had had an 
ectopic pregnancy. However, it is important to be critical of what is meant by 
counselling, as only 67 (44.7%) of units had access to counsellors with any 
training. 
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73 (48.7%) of units provided information leaflets about ectopic pregnancy to 
women before discharge, 63 produced their own leaflets about ectopic pregnancy 
and 10 used externally produced leaflets. 61 (40.7%) did not. The remainder did 
not give this information. 
33 units knew of support groups for women who had had an Ectopic Pregnancy 
in their area, 142 units were aware of the Miscarriage Association and 39 units 
were aware of the Ectopic Pregnancy Trust. 
3.3.3 Discussion 
That there are 84.7% of units with some form of EPU is very encouraging, but it is 
not possible to say whether this would be true of the UK as a whole. 
Over 95% of the units were available for at least 5 days although only 19.8% 
provided some sort of weekend service. It can be seen that the majority of units 
(59.8%) are open for half a day or less, though most of the rest offer an all day 
service (fig. 3.8). As most hospitals provide only emergency cover at weekends, it 
is not surprising that EPUs have reduced hours of opening at this time. 
The majority of units (94%) employ the use of serial hCG sampling. Only a small 
proportion use progesterone in the investigation of ectopic pregnancy (11.3%), 
but it is interesting that 7.3% claim to use serial progesterone levels, when this 
offers no advantage over a single estimation. 
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Wider use of protocols might improve both diagnosis and use of resources. Both 
ultrasound and serum investigation of ectopic pregnancy are expensive 
resources, and review of early pregnancy complications is often left to the most 
junior doctors on call. Without clear guidelines about what action should be taken, 
and when this is appropriate, there can be a tendency to delay diagnosis by 
arranging a further scan or blood test. These women are often admitted to 
hospital. Protocols not only guide the safe use of resources, but also facilitate 
appropriate and prompt diagnosis and who should be admitted and who can be 
managed as an outpatient. They can be followed by specialist nurses, only 
referring to senior doctors when cases lie outside the scope of protocols. These 
nurses provide expertise and continuity for patients, as they are likely to be 
continuing to care for the patient day by day, rather than passing decisions on. 
If an empty uterus is found, a large proportion of women will subsequently be 
found to have an ongoing pregnancy, or to have miscarried. The decision as to 
whether these women require admission is important as this has a considerable 
effect on resources if all these women are inpatients until a final diagnosis is 
reached. 
Admitting women does not prevent catastrophic haemorrhage, but allows rapid 
treatment should this occur. The risk of complications during outpatient 
management can be reduced by careful patient selection, consistency of advice 
and direct admission to the wards if symptoms cause concern. Catastrophic 
haemorrhage can also occur after a patient is discharged home following 
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conservative treatment (conservative surgery, medical or expectant management) 
and the same conditions should apply. A seven-day hCG service is required, so 
that women who require treatment are not left at home over weekends when they 
will find it most difficult to access medical care. 
Very few units (7.9%) were able to offer a complete service for the laparoscopic 
management of ectopic pregnancy. The main reason for this would seem to be a 
lack of trained personnel (Table 3.8) 
28.0% of units said they currently considered medical management for ectopic 
pregnancy (Table 3.9). However, poor design of the questionnaire at this point 
means it was impossible to tell whether this is an occasional event, or a standard 
part of practice. It would have been useful to know how many times the units had 
used medical management in the preceding year. 
Where medical management is offered, systemic methotrexate is the agent of 
choice and this was the one generally used by units responding to the 
questionnaire. 
Following an ectopic pregnancy, many women have questions that were not 
answered at the time of diagnosis; they also require information about what was 
found and advice for the future. Specialist clinics in the Early Pregnancy Units 
might be a more appropriate setting for follow-up after an ectopic pregnancy than 
general gynaecology out-patient clinics. 
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There was no consensus of advice on the timing of the next pregnancy after an 
ectopic pregnancy. If the woman has waited for a period before conceiving, it 
allows a more meaningful expected gestation to be determined, which is 
important information when assessing the likelihood of an empty uterus 
representing another ectopic pregnancy. Advice to wait until psychologically 
prepared is sensible, as women described the fear of being unable to conceive at 
the same time as described fear conception, in case it is a further ectopic 
pregnancy. 
Counselling is something doctors are expected to do, often without training, and 
is often understood as giving information. Although this is an important part of 
post-operative care, being able to listen and facilitate problem solving is also an 
important aspect for some women, as they acknowledge the loss of their 
pregnancy, the threat to life posed by ectopic pregnancy, try to address their fears 
about infertility and discuss the possibility of another ectopic pregnancy. 
Chapter 3- Management of Ectopic Pregnancy 103 
3.4 Ectopic Pregnancy Trust Questionnaire of Women's 
Experiences of Ectopic Preanancy. 
A third method of assessing the early pregnancy care provided for ectopic 
pregnancy is to ask the women themselves. This allows a different view to be 
obtained. There are obvious biases, as there are with hospital questionnaires, but 
the combination of approaches should give a good overview of practice 
throughout the country. Because of links with the Ectopic Pregnancy Trust, a 
questionnaire was sent to all women who contacted them. 
3.4.1 Method 
A questionnaire was designed in conjunction with the Ectopic Pregnancy Trust 
(EPT). The EPT is a national organisation providing support and information to 
people affected by ectopic pregnancy. Areas of interest to the EPT and to me 
were listed. I produced a draft questionnaire covering these areas and ensuring 
that medical aspects were presented in an accurate form. The questionnaire was 
then re-organised into a final draft within the EPT by its officers, who are lay- 
women who have experienced an ectopic pregnancy. They ensured that the 
questionnaire was presented in a way that would be accessible to a non-medical 
person. I then checked this final draft from a medical point of view. 
The questionnaire covers many aspects of ectopic pregnancy, and as the two 
parties involved in the design required different things from the data, some of the 
results are difficult to interpret, reflecting this dual authorship. For example, I felt 
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data on the risk factors for ectopic pregnancy would be difficult to relate to the 
time of the ectopic pregnancy through the use of this questionnaire, but this area 
was still covered despite this limitation because it was of interest to the EPT 
members. There is a compromise between what information is wanted, and what 
it is possible to obtain. 
The questionnaire also provided free space for women to write about the impact 
ectopic pregnancy has had on themselves and their relationships. The responses 
to this part of the questionnaire are not discussed in this thesis. 
The questionnaire was sent to all the women on the mailing list of the EPT in 
June 1999. The population to whom the questionnaire was sent is self-selected, 
being those women who had approached the EPT for advice/support. The 
response was good, although around 100 further replies were sent in after the 
data base had been analysed and, therefore, are not included in the analysis that 
follows. 
The responses from all the questionnaires -w are entered into a data-base which 
I designed for this purpose. I entered all the results personally, to ensure 
consistency. 
3.4.2 Results 
400 questionnaires were sent out, 221 replies with 263 ectopic pregnancies were 
received and added to the data base. Most (70.1%), but not all, of the ectopic 
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pregnancies had occurred in the three years prior to the questionnaire being 
distributed. Information giving the year of first ectopic pregnancy was available on 
174 women and is shown in figure 3.12 below. In 18.9% of cases, women had 
contacted the Trust about ectopic pregnancies that had occurred 5 or more years 
before. 
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Fig 3.12 Year in which respondents experienced their first ectopic 
pregnancy (174 responses) 
Most of the women had had a single ectopic pregnancy, 14.4% had experienced 
two or more ectopic pregnancies, one woman had five. A woman who has had 
more than one ectopic pregnancy might be more inclined to contact the EPT, and 
it is possible that women who have had multiple ectopic pregnancies are over 
represented. However, this is unlikely, since a large number of women sort help 
1946 1978 1980 1983 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 
year of ectopic pregnancy 
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soon after their first ectopic pregnancy, and a recurrence risk of around 15% is 
compatible with these figures. 
Table 3.11 Number of ectopic pregnancies experienced by respondents (221 
responses) 
Number of EP I Number 
I ectopic pregnancy 1 189 (85.5%) 
2 or more 1 32 (14.4%) 
3.4.2a Background of respondents - 
Ethnic Origin 
The respondents were asked to indicate their ethnic group. 93.7% of this 
population described themselves as white (Table 3.12). This is similar to the 
general population as the most recent UK census found 92.1% of the population 
described themselves as white (ONS; 2001). 
Age 
In 168 women it was possible to calculate their age at the time of their first 
ectopic pregnancy. This is shown in figure 3.13. 
If the number of ectopic pregnancies in each age group is taken as a proportion 
of the number of maternities for the triennia of 1994-1996 (The Stationary Office, 
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Table 3.12 Racial Group (216 responses) 
Ethnic group I number 
European 207 
Black Afro-Caribbean 4 
Indo-Asian 2 
Mediterranean 1 
"other - white" 2 
did not state 5 
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Fig. 3.13 Calculated age of respondents at the time of their first ectopic 
1998) the incidence of ectopic pregnancy is seen to increase with age of the 
population of respondents (Table 3.13 and fig. 3.13): 
19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 
age at first ectopic 
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Table 3.13 Number of ectopics pregnancies in respondents per thousand 
maternities according to age. Figures for number of maternities taken from 
the 1994 - 1999 Confidential Enquiries into Maternal Deaths. 
age ectopics % of all Maternities 
ectopics (x 1000) 
<25 19 11.3 590.4 
25- 
29 
30- 
34 
35- 
39 
40+ 
% of all 
aternities 
ectopics per 
1000 maternith 
26.9 0.032 
51 30.4 738.4 33.6 0.069 
64 38.1 610.7 27.8 0.105 
26 15.5 220.0 10.0 0.118 
8 4.8 37.8 1.7 0.210 
OR 
9ý5%CI 
0.466 
(0.272- 
0.798) 
1 
1.518 
(1.035- 
2.227) 
1.710 
(1.042- 
2.808) 
3.046 
(1.350- 
6.872) 
0.25 
0.2 
0.15 
2L E 
0 .00.1 ä cc E 
005 
0 
<25 25-29 30-34 35-39 40+ 
= age group 
Fig 3.14 Number of ectopic pregnancies as a proportion of total maternities 
in the same age-group 
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Risk factors for ectopic pregnancy 
Table 3.14 "Have you suffered from or received treatment for any of the 
following conditions prior to your first ectopic pregnancy? " Risk factors 
identified by respondents (221 responses). 
Risk factor I Number I% 
miscarriage 44 19.9 
progestogen only pill 30 13.6 
termination of pregnancy 30 13.6 
AMC" 29 13.1 
fertility treatment 28 12.7 
appendicitis 24 10.9 
caesarean section 20 9.0 
intra-uterine device 20 9.0 
pelvic infection 19 8.6 
abdominal surgery 18 8.1 
chlamydia 12 5.4 
endometriosis 12 5.4 
tubal surgery 7 3.2 
sterilisation 4 1.8 
none of the factors identified 80 36.2 
The respondents were given a list of possible risk factors. As this was not timed 
against their ectopic pregnancy, it was difficult to assess the significance of some 
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of the risk factors. This information would be better assessed by structured 
interview. 
Eighty women ticked none of the boxes identifying risk factors, some of these 
women may have simply omitted this question, but this might mean that up to 
36.2% did not have any of the risk factors for ectopic pregnancy suggested in the 
questionnaire. 
Twenty-four had had an appendicectomy, in eight this was the only factor they 
identified. 
Smoking 
Table 3.15 "Do you smoke? " Smoking status of respondents (219 
responses). 
. 
Smoking status I number 
non-smokers 136 
ex-smokers 33 
current smokers 50 
not stated 2 
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3.4.2b Knowledge about Ectopic Pregnancy 
An important component in reducing both number of mortalities resulting from 
ectopic pregnancy, and the number of women ý+ who present with cardio- 
vascular collapse secondary to ectopic pregnancy, is education of the population 
at risk of ectopic pregnancy. If women are aware of ectopic pregnancy and its 
symptoms, potentially they will present earlier. The respondents were asked 
whether they were aware of ectopic pregnancy before they were affected 
themselves. 
Table 3.16 "Before your first ectopic pregnancy, did you know what an 
ectopic pregnancy was? " Women's knowledge of ectopic pregnancy before 
their first experience of ectopic pregnancy (221 responses). 
Number % 
Women with no prior knowledge of ectopic pregnancy 62 28.1 
Women with prior knowledge of ectopic pregnancy 149 67.4 
Women who did not know another with ectopic 106 48.0 
Women with 1st degree relative with ectopic 5 2.3 
Women with other relative with ectopic 19 8.6 
Women with friend with ectopic 84 38.0 
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3.4.2c Clinical Diagnosis of Ectopic Pregnancy 
The total number of ectopic pregnancies (263) was considered. 
Table 3.17 "By which Health Care Professional were you first seen? " The 
first Health professional respondents saw at the time of the Ectopic 
Pregnancy (252 responses). 
Who I Number 
General Practitioner (G. P. ) 176 66.9 
Casualty doctor 33 12.5 
Gynaecologist 20 7.6 
Collapsed - did not know 13 4.9 
Midwife 2 0.8 
Emergency doctor 2 0.8 
Assisted conception unit 2 0.8 
Practice nurse 1 0.4 
Chest physician 1 0.4 
Don't know 2 0.8 
Not stated 11 4.2 
Was the patient known to be pregnant at first presentation? 
18 did not know they were pregnant and were not asked about the possibility of 
pregnancy or had a pregnancy test performed. Only 110 had a pregnancy test 
performed, the rest, 132, did not. Of those that did not have a pregnancy test 
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performed, many women had already performed this themselves before they 
presented to a doctor, and a repeat test is not generally required. The information 
was not available in the other 21 ectopic pregnancies. Therefore, of the women 
who gave this information, the diagnosis of pregnancy was not considered by 
either the patient or the doctor in 12.7% of women. 
Presenting symptoms 
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Fig. 3.15 "What symptoms did you have when you were first seen by a 
Health Care Professional? " Presenting symptoms of ectopic pregnancy - 
more than one symptom was described by many respondents 
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Did the woman suspect an ectopic pregnancy when she first presented? 
184 women did not suspect the diagnosis when they first presented. In 12 of 
these cases, the woman had previously had an ectopic pregnancy. 60 women did 
suspect the diagnosis. In 37 cases, this was the first ectopic pregnancy, in 23 the 
woman had had an ectopic pregnancy before. In 19, no information was given. 
Involvement of Early Pregnancy Units 
Only 74 women were seen in EPUs and 166 women reported that they were not. 
23 did not answer the question but may not have known. 
Initial diagnosis 
The women were asked what diagnosis was made when they first presented for 
medical advice. (More than one initial diagnosis was considered in some cases). 
Overall, in 51.8% of women, where an initial diagnosis was stated, ectopic 
pregnancy was considered. 
Of those women first seen by their G. P., the diagnosis of ectopic pregnancy was 
made in 74 out of 172 women (43.0 %). 
In those women first seen by a casualty officer, an ectopic pregnancy was 
diagnosed in 14 out of 31 cases (45.2%). 
In those women first seen by a gynaecologist, an ectopic pregnancy was 
diagnosed in 13 (65.0%) out of 20 cases. 
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Table 3.18 "What was the initial diagnosis? " Diagnosis made at first 
presentation (231 respondents gave at least one diagnosis). 
Initial Diagnosis Number 
Ectopic Pregnancy Suspected 118 
? miscarriage 44 
Various gastro-intestinal problems 23 
Recalled after managed as miscarriage 18 
Normal pregnancy 9 
Menstrual disturbance 9 
Managed as a miscarriage, but not recalled 8 
"Womb infection" 4 
Ovarian cyst 4 
Other 14 
Not stated 32 
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Time the woman first noted symptoms to diagnosis 
Most women presented between 6 and 8 weeks gestation. In only 36.3% of 
cases was the diagnosis of ectopic pregnancy made within the first week of 
symptoms. However, 15 women reported symptoms before their menstrual 
period was due. Seven of these women stated that the diagnosis was made at 
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Fig. 3.16 "At what stage of your pregnancy did your symptoms first 
appear? " (219 responses) "How many weeks pregnant were you when 
diagnosed you're your ectopic pregnancy? " (232 responses) Chart 
demonstrating the time at which symptoms first appear and time at which 
the diagnosis of ectopic pregnancy is made. 
this time which seems unlikely. Because of the way the questionnaire was set-up, 
it is not possible to verify this early diagnosis or the reliability of the respondent's 
memory about the length of pregnancy in relation to last menstrual period. 
123456789 10 11 12 13 
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In cases where the information was given (215), 73.9% were diagnosed as 
having an ectopic pregnancy within three weeks of first seeking medical advice, 
with 22.3% in the second and 36.3% in the first week. 
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Fig. 3.17 Delay in weeks between first noting symptoms and the diagnosis 
of ectopic pregnancy being made calculate from those questionnaires 
where both onset of symptoms and time of diagnosis were given 
Time the woman first presented to medical services to diagnosis 
Of those women who gave the information, 56.5% had a diagnosis of ectopic 
pregnancy made at their first visit to their General Practitioner, and 70.6% at the 
first visit to hospital. 
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Fig. 3.18 "Please state how many times you visited your GP and/or hospital 
before your ectopic pregnancy was considered. " Number of visits made to 
medical practitioners before the diagnosis of ectopic pregnancy was made 
3.4.2d Diagnostic Tests 
Respondents were asked what diagnostic tests were performed both in Primary 
Care and hospital. 
In general practice, vaginal examination was the only investigation performed in 
32 cases. In hospital practice, this was the case in just 5 women. 68 women 
reported not having an ultrasound scan performed when they first presented to 
hospital. What the questionnaire does not establish is whether a scan was 
organised at the first visit. 
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Table 3.19 "What tests were carried out and by whom. " Diagnostic tests 
performed in General Practice and in hospital. Some respondents had more 
than one test performed (263 responses). 
Test General Practice Hospital 
no test 180 30 
vaginal examination 43 98 
urine pregnancy test 46 143 
serum hCG - single 8 71 
serum hCG - serial 0 50 
ultrasound Scan 1 195 - TA 45 
-TV55 
- both 95 
3.4.2e Treatment of Ectopic Pregnancy 
Treatment options for ectopic pregnancy are discussed at length in Chapter Q, 
The questionnaire on women's experiences included questions on whether these 
options were discussed. 
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Treatments offered to patients 
In 227 pregnancies the management options were discussed pre-operatively. 91 
women felt that management was not discussed with them because they were in 
a collapsed state. 
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Fig. 3.19 "Were you given any options as to the treatment of your ectopic 
pregnancy. " Respondents' recollection of the management options 
discussed once a diagnosis of ectopic pregnancy was made (227 
responses). 
Actual treatment 
Chapter q will discuss, in detail, what should be considered optimal 
management of ectopic pregnancy, so there will be only a brief comment here. In 
general, respondents described the management of the first ectopic pregnancy. 
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Details of the treatment received from 217 first ectopic pregnancies were 
analysed. 
Of those who had surgical management and gave information on the route (177 
respondents), 80.2% had management by laparotomy and 19.8% had 
laparoscopic management. 
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Fig. 3.20 "What treatment did you actually receive for your ectopic 
pregnancy? " Actual management of ectopic pregnancy. Chart 
demonstrates both the procedure performed and the route by which it was 
performed (221 responses). 
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Table 3.20 Number of respondents with conservative (tubal preservation) 
and radical (tubal excision) treatment of their first 
ectopic pregnancy. Surgical and non-surgical treatments considered (221 
responses). 
treatment ( Number (%) 
salpingectomy 168 (76.0) 
salpingotomy 33 (14.9) 
others (tube preserved) 8 (3.6) 
not known to the woman 12 (5.4) 
Tubal rupture 
Table 3.21 "Did your tube rupture? " The number of ectopic pregnancies 
that were ruptured at the time of treatment 
Rupture I Number 
Yes 115 
No 77 
did not know 26 
not stated 3 
not applicable 4 
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Subjects were asked for each pregnancy whether or not the tube had ruptured by 
the time of surgery. There were 227 responses from the 263 ectopic pregnancies. 
Side affected by ectopic pregnancy 
The side in which the ectopic pregnancy was found was stated in 227 
pregnancies. 
Table 3.22 "Which tube was affected? " The side in which the ectopic 
pregnancy was found (217 responses). 
Side Number 
right 107 
left 91 
don't know 8 
both 5 
not applicable 6 
3.4.2f information, Follow-up and Support 
Communication of the diagnosis and its implications are an important part of the 
management of ectopic pregnancy. Adequate information and effective 
communication can lessen many of the long-term psychological sequelae. 
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Table 3.23 "Once diagnosed, was ectopic pregnancy fully explained to 
you? " Respondents' level of satisfaction with the explanation of their 
diagnosis once ectopic pregnancy was suspected (215 responses). 
Number (%) 
Generally satisfied 146 (66.1) 
Generally dissatisfied 69 (31.2) 
Not stated 6 (2.7) 
Table 3.24 "If you were given any information, how was this communicated 
to you? " Means of communicating treatment for ectopic pregnancy (182 
responses). 
Number (%) 
Verbal 
Written 
143 (64.7) 
39 (17.6) 
not stated 1 39 (17.6) 
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Table 3.25 "Do you feel you were given an adequate explanation of the 
treatment? " Respondents' satisfaction with the explanation of the treatment 
for ectopic pregnancy given to them after the procedure (209 responses). 
Number (%) 
generally satisfied 140 (63.3) 
generally dissatisfied 69 (31.2) 
not stated 12(5.4) 
Risk of future ectopic pregnancy 
Adequate management of ectopic pregnancy should include information about 
future pregnancies because of the higher risk of a further ectopic pregnancy. This 
should include information about early pregnancy assessment to establish 
location of the pregnancy. 
At the time of their first ectopic pregnancy 167 (75.6%) women were warned that 
they were at risk of a further ectopic, 53 (24.0%) were not. In one (0.4%) the 
warning was not applicable. 
161 (72.9%) women were advised to have an early pregnancy ultrasound to 
confirm a pregnancy was intrauterine, 55 (24.9%) were not so advised, 4 (1.8%) 
did not state and in one (0.4%) this was not applicable. 
Chapter 3- Management of Ectopic Pregnancy 126 
31 (14.0%) women were neither told of the risk of a future ectopic pregnancy, nor 
advised to have an early pregnancy ultrasound scan in subsequent pregnancies. 
Information about ectopic pregnancy 
Hospitals are generally not able to provide ongoing support for those women who 
have psychological sequelae after an ectopic pregnancy. It is important that 
women should have information about support groups that are available to fulfill 
this need as required. As discussed above, there is also some information that 
should always be conveyed to women for their future safety. 
Table 3.26 "Were you given written information about ectopic pregnancy 
prior to leaving the hospital? " Leaflets given on discharge after an ectopic 
pregnancy (221 responses). 
leaflet I Number of women 
hospital designed on ectopic pregnancy 20 
Miscarriage Association leaflet on ectopic pregnancy 12 
Ectopic Pregnancy Trust leaflet on ectopic 4 
pregnancy 
ectopic pregnancy leaflet - unknown 32 
leaflet on miscarriage 2 
hysterectomy 1 
post-pregnancy exercise I 
no written information given 145 
don't know 4 
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46 (20.8%) were given information about support groups available to them, 68 
(30.8%) were given written information about ectopic pregnancy before leaving 
hospital (Table 3.23). 
Table 3.27 "Pregnancies you have had. " Obstetric history of respondents 
(221 responses). 
Women with no living children 96 (43.4 ä) 
Ectopic pregnancy only 57 (25.8%) 
Ectopic pregnancy and termination of pregnancy only 10 (4.5%) 
Ectopic pregnancy and miscarriage only 28 (12.7%) 
Ectopic pregnancy and stillbirth only 1 (0.5%) 
Women with either living children or ongoing pregnancies at 
time of questionnaire 
125 
(56.6%) 
Currently pregnant 15 (6.8%) 
Livebirth after ectopic 18 (8.1 %) 
Livebirth before ectopic 71 (32.1961) 
Livebirth before and after ectopic 
_ 
21 (9.5%) 
3.4.2g Obstetric Outcome - 
All 221 respondents gave details of their obstetric history which is summarised in 
Table 3.27.167 (75.5%) women had not had an ongoing pregnancy since their 
ectopic pregnancy. They were asked to indicate the reasons. This is displayed in 
figure 3.21 with the responses of all 221 respondents. 
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Fig. 3.21 "Pregnancies you have had after this ectopic. " Obstetric history 
after an ectopic pregnancy (221 responses). 
3.4.3 Discussion 
Whilst, on first inspection, white Europeans appear to constitute the bulk of the 
respondents, in fact the proportion of white to non-white does reflect those of the 
UK population as shown in the last census. When considering ectopic pregnancy, 
it is of particular concern that all racial groups access services and information, 
as data suggest that ectopic pregnancy has a higher incidence in some minority 
groups, particularly black women (Gaydos et al.; 1998). The EPT is making 
efforts to target specifically this population with the appropriate leaflets etc. 
The results of the questionnaire also suggested an increase in incidence of 
ectopic pregnancy with age. Whilst this cannot be extrapolated to the entire UK 
population - perhaps younger women are under-represented, being less likely to 
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contact a support organization, it does fit with what is already known. As 
discussed in chapter 1, there is epidemiological data to support an increase in the 
incidence of ectopic pregnancy with advancing maternal age. 
Appendicectomy/appendicitis has not been proven to be associated with ectopic 
pregnancy (Urbach and Cohen; 1999). It would be expected that about 6% of the 
population could expect to have an appendicitis at some time in their life, with 
men have a slightly higher incidence, the ratio of women to men effected being 1 
to 1.4 (Al-Owran et a/.; 2003). The number of women found to have previously 
had an appendicitis is higher than would have been expected. Urbach and Cohen 
emphasise that it is the quality of the studies of the association of ectopic 
pregnancy with appendicitis that means reliable conclusions cannot be drawn, 
rather than that an association is not found. This study suggests more women 
than would be expected had had an appendicectomy. 
More than half (61.5%) of our respondents had never smoked. More women, and 
particularly younger women, are taking up smoking. Smoking is associated with 
an increased risk of ectopic pregnancy (Castles et al.; 1999), and it will be 
interesting to see if this trend has any impact on the incidence of ectopic 
pregnancy in future years. It is not possible to assess, because of the design of 
the questionnaire, whether the respondents were smokers at the time of their 
ectopic pregnancy/pregnancies. 
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Education of the fertile female population about ectopic pregnancy and its 
aetiology will hopefully reduce the incidence and serious complications of the 
disease. But if women are better placed to recognise ectopic pregnancy before 
serious complications arise, it must be possible for them to access assessment 
promptly. Allowing self referral by patients to Early Pregnancy Units is one step 
towards achieving this. 
67.4% of respondents had some knowledge of ectopic pregnancy before their 
own, first, experience of ectopic pregnancy (Table 3.16). However, knowledge is 
only one factor in early detection of ectopic pregnancy, as, in this survey, 16.4% 
of women did not recognise their second ectopic pregnancy. 
It is not surprising that the majority of women presented first in primary care. The 
next biggest group presents directly to casualty. Whether appropriate action is 
taken depends largely on whether this doctor considers ectopic pregnancy in the 
differential diagnosis. This can be facilitated by ongoing education of primary care 
and casualty doctors about the complications of early pregnancy, but also by 
providing a supportive early pregnancy service, which is easily contacted for 
advice and appointments, and has mechanisms in place for out of hours referrals. 
Both of the last two Confidential Enquiries into Maternal Deaths (The Stationary 
Office, 1998; RCOG Press 2001) have stressed that pregnancy should be 
considered in any fertile woman or girl and urine pregnancy test should be readily 
available in Primary Care and casualty departments. 
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In 12.9% of the ectopic pregnancies, the woman reports herself as being 
collapsed at the time of presentation. This is a very frightening experience and 
perhaps this group is over represented in our sample, as these women are more 
likely to require support. However, all the women presenting with self-reported 
sudden collapse experienced some other symptom before the collapse occurred, 
which opens the possibility of intervening sooner if patients are aware of what 
constitutes abnormal early pregnancy. 
Only 26.2% of women reported their period being late. This is surprising, but 
since no corresponding question was asked to whether the period occurred 
normally, this may be reporting bias as the respondents may have considered 
other symptoms much more relevant. However, this does emphasize the 
importance of remaining vigilant with women with suspicious symptoms, even in 
the absence of a late period. 
12.2% of women presented with vomiting and 19.8% with bowel symptoms. 
Another point that is emphasised in the two most recent Confidential Enquiries 
into Maternal Deaths is that a diagnosis of ectopic pregnancy should be 
considered in women presenting with gastro-intestinal problems. 
It is disappointing that so few women attended an Early Pregnancy Unit , but 
there are several possible reasons for this. In a reasonable number of women, 
the diagnosis was not considered and therefore an EPU referral would not occur. 
Women with severe symptoms, or women presenting out of normal working 
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hours would be admitted directly to the ward. It might also mean that the 
respondent did not identify the Early Pregnancy Service in the hospital to which 
they presented as a "unit". 
It would have been surprising if gynaecologists did not have a better success rate 
in diagnosis at first presentation than other doctors, as they have a narrower 
range of differential diagnoses to consider. Perhaps there should be more 
concern about the 35.0% of ectopic pregnancies missed by gynaecologists than 
those missed by other doctors, as wider use of pregnancy tests, easier access to 
early pregnancy assessment and ongoing support and education for Primary 
Care and casualty services can, potentially, have a big impact on missed 
diagnosis of ectopic pregnancy outside of gynaecology. 
It is important for General Practitioners to have easy access to early pregnancy 
assessment for their patients when the need arises. Perhaps women presenting 
to their GPs in early pregnancy could be given a card/leaflet with details of their 
local early pregnancy assessment service, allowing the patients to self-refer if 
problems arise. This serves the dual purpose of 
1. giving women important information in early pregnancy to increase 
their awareness of potential problems 
2. encouraging direct referral to an Early Pregnancy Unit if problems 
arise. 
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This system could be open to abuse, with patients self-referring inappropriately 
as they know that they will be seen, assessed and probably have an ultrasound 
scan. However, many women have concerns in early pregnancy and attend the 
GP and/or hospital services anyway; a simple triage service that can make a 
diagnosis and reassure if possible could be very beneficial by relieving other 
services of the need, and diagnosing the problems early when morbidity is low. 
There is a degree of delay in diagnosis, both from waiting for assessment through 
the early pregnancy service, and through the use of serum hCG estimations and 
ultrasound to establish diagnosis. Some degree of delay should not be seen as a 
failure if the woman is under review and acute admission, directly to the 
gynaecology ward, is possible if the woman's symptoms deteriorate. However, 
there is cause for concern in the 26.1% of women reported the diagnosis was 
delayed for more than three weeks. The long delays reported by some women 
are difficult to interpret as it would be expected that a tubal ectopic pregnancy 
might have either presented as an emergency or resolved in that time, although 
these women may have had atypical presentations resulting in delay. Rapid 
diagnosis is easier when the symptoms are typical of the disease. 
Again, it is not clear how many of the women presenting to hospital were not 
diagnosed as potentially having an ectopic pregnancy at their first visit because 
the results of serum hCGs were awaited. It is important that the woman is aware 
that a life-threatening condition is part of the differential diagnosis, and it is a 
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failure of communication if the doctor's suspicions have not been shared with the 
patient. 
Those women who reported that their General Practitioner did not investigate 
them will often have been managed appropriately as they do not investigate, 
rather refer the patient promptly for hospital assessment. Vaginal examination in 
the case of suspected ectopic pregnancy is inappropriate in Primary Care as 
there are concerns that vaginal examination can precipitate tubal rupture and 
haemorrhage, and Primary Care is not equipped to deal with this promptly. 
The low reported use of serum hCG estimations (Table 3.19) could be partly 
explained by the women not understanding why blood had been taken from them. 
Also, hCG estimation may not have been in use at the time of their ectopic 
pregnancy. 
The perception of not having their management option discussed because the 
respondents were collapsed before going to theatre is interesting. It may be there 
is a high proportion of severely ill, haemodynamically compromised women in this 
sample because it is these women that most require support from the EPT. But it 
might also be a reflection of the anxiety felt at this stage compounded by a sense 
of urgency on the part of the doctor. Only 34 women, when asked about 
symptoms at presentation, reported themselves to be collapsed, but 91 women 
offered this as an explanation as to why management options could not be 
discussed with them. It can be seen that few women were offered any options 
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(fig. 3.19). 31.2% had no discussion of management, and only 6.2% were offered 
any choice of management, and that was between salpingotomy and 
salpingectomy. Of the total number of women responding only 18.1% of women 
were offered laparoscopic management and only 16.4% actually underwent 
laparoscopic surgery. 
Ectopic pregnancies are included from several years ago when provision for 
laparoscopic management would have been less likely. This being said, this is a 
worrying small proportion of ectopic pregnancies being managed 
laparoscopically. A long elapse of time since the ectopic pregnancy might explain 
why other women could not recall what treatment they had received. 
Many respondents recall being told that their ectopic pregnancy had ruptured. 
This would limit the number of women in whom conservative surgery would be 
appropriate. The long length of time between onset of symptoms and the 
diagnosis being made in some of the respondents, might increase the number of 
women with tubal rupture. An earlier diagnosis prior to rupture would lead to 
greater treatment options as well as reduced morbidity. 
Not all the women remembered being given this advice. It maybe that some were 
also given appropriate advice that they subsequently forgot. If this is the case, it 
illustrates how important it is for women to be given advice in a form that they will 
retain, and written leaflets are ideal for this purpose. 
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Any written information that is given to women should be appropriate. The 
women who were given leaflets on miscarriage found this was inappropriate for 
their needs, and the women who were given leaflets on hysterectomy and post- 
pregnancy exercise found this distressing. 
There is reduced subsequent fertility in women who have had an ectopic 
pregnancy, and prior infertility is a predictor of poor subsequent fertility (Sultana 
et al., 1992; Ory et al., 1993). As most of the ectopic pregnancies occurred in the 
five years before the questionnaire was completed, it could well be that many of 
these women have gone on to have successful pregnancies, although most 
pregnancies are conceived in the first 18 months following the ectopic (Bouyer et 
aL; 2000b). Interestingly, 32.1% of women had experienced a miscarriage in their 
reproductive life to date. A miscarriage would be anticipated in 25% of women at 
some point in their reproductive life (Regan, 1997) suggesting that the population 
of women with ectopic pregnancy might be more prone to reproductive failure 
than would be expected. 
Management of the psychological sequelae is just as important as the choices for 
management at the time of diagnosis. The Ectopic Pregnancy Trust 
questionnaire gave respondents the opportunity to discuss the effect of ectopic 
pregnancy on their lives. The findings from this part of the questionnaire are not 
reported here, but several, consistent themes emerged: fear of another ectopic 
pregnancy - effecting sexual and interpersonal relationships, fear of never having 
a baby and problems relating to the realisation that ectopic pregnancy is a life- 
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threatening condition. As previously discussed, many women considered 
themselves to have collapsed at the time of presentation, although this might h. 
cardiovascular collapse and a medical emergency, it might also be a reflection of 
the fear of death that many women experience at some time during their ectopic 
pregnancy. 13.6% of the EPT women said they were too scared to try for another 
pregnancy. They also feel that hospital staff failed to acknowledge that they have 
lost a baby 
3.5 Summa 
This chapter has explored the experiences of women who have had ectopic 
pregnancies, the diagnostic facilities and tools available, their use in the United 
Kingdom and our local experience of the introduction of a diagnostic aid: serum 
hCG estimations. 
For an ectopic pregnancy to be diagnosed, it must first be recognised. The more 
familiar a person is with ectopic pregnancy, the more likely they are to consider it. 
An increased awareness of the condition, and its presentation, in the female 
population would enable affected women to seek help at an earlier stage, 
reducing mortality and morbidity, and increasing their management options. 
Practitioners who are more familiar with ectopic pregnancy are more likely to 
consider it in a differential diagnosis. The management of the complications of 
early pregnancy should be component of education programmes for Primary 
Care and Accident and Emergency staff, for whom pregnancy is only one of 
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many possibilities they must consider. In-house discussion of early pregnancy 
cases within gynaecology units is a means 
maintaining 
awareness amongst 
those doctors who most frequently encounter ectopic pregnancy. This can also 
be a forum for trouble-shooting in those cases providing the greatest diagnostic 
and management dilemmas. 
Once awareness is successfully raised, women in whom a diagnosis of ectopic 
pregnancy is suspected require rapid confirmation of the diagnosis, consistent 
and accurate information, a willingness to discuss management choices and 
access to ongoing support when that is required. Dedicated early pregnancy units 
are the ideal setting for this. 
Early Pregnancy Units are now widespread, though not universal, in the UK. 
They are a means of trying to fulfil all these needs in a single setting. These units 
should be accessible to the women themselves, either for advice or self-referral 
when appropriate, as well as to medical practitioners. In cases that are 
straightforward, a diagnosis and management plan can be initiated by specialist 
nurses following protocols. In cases that do not fit within the guidance of the 
protocol, help from senior doctors with an interest in early pregnancy should be 
sort. The protocol I developed within the unit as a result of the work in this thesis 
can be found in Appendix 14. It draws on the experiences of others, as discussed 
in the review of literature in Chapter 1. It is written to answer the particular needs 
of our unit, as discussed in this Chapter. It also discusses the options that can be 
offered to a woman with an ectopic pregnancy, an area covered in Chapter 9. 
Chapter 3- Management of Ectopic Pregnancy 139 
Ultrasound and serum hCG levels have proved to be major innovations, 
improving the diagnosis of ectopic pregnancy. However, diagnosis can often take 
several days. It is important that women in whom the diagnosis is suspected are 
aware of the complications that can arise within that time and have direct access 
to the early pregnancy assessment service or out-of-hours gynaecology service 
of the unit in which they are known. It is inappropriate, and could be dangerous, if 
further assessment and diagnosis are delayed because the women can only be 
seen in casualty or primary care. 
Use of hCG estimations has improved the management of ectopic pregnancy by 
increasing its detection and differentiating it from other early pregnancy 
complications. It has also reduced the morbidity (and mortality) associated with 
negative laparoscopies performed in women with miscarriages and normal early 
pregnancies. However, it is not the ideal test as it does not give a diagnosis at 
first presentation. Single estimation progesterone levels give a same-day answer, 
but poorly differentiate between normal and abnormal early pregnancy. The ideal 
test would both rapidly diagnose ectopic pregnancy but also accurately 
differentiate from miscarriage and normal early pregnancy. 
The following chapters describe evaluation of fetal fibronectin as a possible rapid 
diagnostic test differentiating ectopic pregnancy from early viable and non-viable 
intra-uterine pregnancies. This is then followed by an exploration of modern 
treatment options for ectopic pregnancy and the choices they offer to women 
regarding future fertility and further ectopic pregnancies. 
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Chapter 4- Fetal Fibronectin - the Assay 
4.1 Introduction 
One of the aims of the laboratory based work was to produce a normal curve of 
values of fFN in early pregnancy. This would require quantification of the levels 
of fFN found within the cervico-vaginal secretions. Leeson et al. (1996) sampled 
fluid obtained from the posterior fornix of the vagina, Morrison et al. (1993) and 
Hellemans et al. (1995) sampled the endo-cervix. Lockwood at al. (1991) 
sampled both and found there were more positive cervical than vaginal 
samples. I wished, in the first instance, to establish whether fFN was found in at 
both sites in early pregnancy, in the same subject, before embarking upon 
collection of samples for the quantitative assay. 
In clinical practice where the aim is to establish the risk of premature labour, the 
amount of fFN is of little relevance, a result is considered positive if levels are 
greater than 0.051Ag/ml. Women with uncomplicated pregnancies rarely had fFN 
above this level in the late second and early third trimesters (Lockwood et a/., 
1991). Therefore, a clinically useful test would only show a positive result if 
levels greater than 0.05µg/ml were present. A bedside test fulfilling this 
requirement is available (Adeza Biomedical, USA; Mast Diagnostics, UK). For 
this project I had access to diagnostic kits used in the development of this 
product and these were used to develop the sampling technique. 
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A commercially available ELISA kit was used for the quantification of levels 
(Adeza Biomedical, USA; Mast Diagnostics, UK). This ELISA assay contains 
monoclonal antibody FDC-6 sensitive to the oncofetal fibronectin not found in 
normal maternal tissues. This antibody is said to be highly specific to the fetal 
form of fibronectin. 
4.2 The Qualitative Assa 
A self-contained kit was supplied by Adeza Biomedical. This contained a sterile 
Dacron swab, a resealable tube containing extraction buffer and a single 
dipstick on which is mounted the fFN immunoassay. 
A sterile speculumwinserted to allow visualisation of the uterine cervix within 
the vault of the vagina. This .aWQ access to the cervix or posterior 
vaginal fornix. A swab gently inserted either into the endocervical 
canal or into the posterior fornix and gently rolled for 10 seconds. The swab w"A 
then withdrawn and immediately inserted into the tube containing the extraction 
buffer. The swabwzthen mixed vigorously for 10 seconds to allow the absorbed 
secretions to mix with the buffer. The swabv , sthen removed and disposed of. 
The fFN immunoassay dipsticW6then inserted into the buffer/secretions mix for 
10 minutes before removing it to read the result. 
A positive result is denoted by a double pink line and a negative result by a 
single pink line. 
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positive negative 
fig. 4.1 illustration of positive and negative results for qualitative assays 
Samples were taken from both the endocervix and the posterior fornix for a 
direct comparison in each woman sampled. 
4.3 The Quantitative Assay 
Swabs were taken in a similar way to those taken for the qualitative assay. 
However, in this case the swab was inserted into a transport tube containing the 
buffer and the shaft snapped. The shaft of the swab was inserted in the cap of 
the transport tube, which was then sealed for processing later. 
At the end of each collection session, the samples were processed in batches. 
The transport tubes were then gently vortexed for 30 seconds in a Gallenkamp 
mixer. Each swab was removed from its transport tube; the tip of the swab was 
squeezed against the transport tube to extract as much fluid as possible. 
The collection kits were supplied with there own filter systems - each sample 
having an individual filter, which fitted tightly into the transport tube, forcing the 
buffer/secretions mix through the filter membrane as the filter was pushed to the 
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bottom of the transport tube. The filtrate was then decanted into a 
microcentrifuge tube and stored in a -80°C freezer until use. 
When an assay was to be performed, the samples were defrosted in a 37°C 
water bath for ten minutes before use. The calibrators to be used in the assay 
were warmed, simultaneously, in the same way. 
Wash buffer (buffer salts, detergent and preservative - sodium azide) was 
prepared for use during the assay, 20mIs of concentrated wash buffer solution 
was diluted with ELGA water to make a 21 dilute solution of wash buffer. 
The ELISA assay wells were supplied in a resealable, airtight pack. At the start 
of the assay process the appropriate number of wells would be removed from 
the pack. The pack would then be resealed to store the remaining wells for 
future use. 
The calibrators were next removed from the water bath and gently mixed. 
Calibrator A contained fFN at a concentration of 1.0µg/ml 
Calibrator B contained fFN at a concentration of 0.54ml 
Calibrator C contained fFN at a concentration of 0.1 µg/ml 
Calibrator D contained fFN at a concentration of 0.054g/mI 
Calibrator E contained fFN at a concentration of O. Oµglml 
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100µI of each calibrator was pipetted into the wells, each calibrator being 
represented in duplicate. IOOµI of each patient sample to be tested was, 
likewise, pipetted into the wells. The plate was then covered and incubated at 
room temperature for one hour. A thermometer ensured that the room 
temperature remained between 20 and 25°C, as recommended in the 
directional insert accompanying the kits. 
The wells were next aspirated and washed three times using the diluted wash 
buffer solution. 
100µI of antibody conjugate (affinity-purified goat polyclonal antibody to human 
fFN conjugated to alkaline phosphatase in a buffer matrix with sodium azide as 
a preservative) was pipetted into each well. Again the wells were covered and 
incubated for 30 minutes at room temperature. 
The wells were again aspirated and washed three times with the diluted wash 
buffer solution. 
Each well requires 100µl of substrate (phenolphthalein monophosphate 
substrate in buffer with sodium azide as preservative). Once removed from its 
container, surplus substrate cannot be replaced. Therefore, the amount required 
was calculated in advance and just sufficient for requirements on that occasion 
removed. 
The wells were then covered and left to incubate for a further 30 minutes at 
room temperature. A colour change proportional to the amount of fFN develops 
over this time. Wells with no fFN appear clear, the well containing calibrator E is 
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used to assess the background colour change and any well in which the 
absorbency is less than, or equal to, this calibrator is considered to contain no 
fFN. A pink hue, of deepening intensity according to the amount of fFN present, 
develops in the other wells. 
1.2 
F. 0.8 to 
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Cu ö 0.4 
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0 
fFNmcg/mI 
fig. 4.2 example of fFN calibration curve obtained from assay 
The aspiration and washing stage is omitted on this occasion. 50µI of stopping 
solution (buffer containing a chelating agent) was added to each well. The plate 
was gently mixed to ensure even distribution of the colour in each well. The 
absorbance at 570nm was then read using a microtitre plate reader. 
0 0.2 0.4 0.6 0.8 1 1.2 
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As calibrator E contained no fFN the value obtained from the wells containing it 
represents background levels and reflects the microtitre plate reader's 
sensitivity. The value obtained from calibrator E must be subtracted from all the 
other values obtained. 
As each of the calibrators were measured in duplicate, the adjusted values of 
the two readings for each were added and divided by two to give the average 
result. 
The calibrators were then used to plot a calibration curve with the concentration 
of fFN in µg/ml along the x-axis and the absorbance at 570nm along the y-axis. 
A sample curve is shown above. (fig. 4.2) 
The curve was re-drawn with each assay run, and the fFN values for the 
samples tested in that run calculated from it. 
Over the course of the time the assays were performed, the calibration curves 
were seen to move towards the x-axis (fig. 4.3). This posed two problems: 
how reproducible were the results 
why was the curve changing 
Samples were retested on subsequent occasions to look for internal 
consistency. These are displayed in Appendix 3. 
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fig. 4.3 demonstration of change in calibration curve with time 
The reasons for this were discussed within the department and with Mast 
Diagnostics. 
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The assay was well within the expiry date, and the information from Mast 
Diagnostics reputed the assay to be very robust, not degrading for many 
months after the expiry date. 
My assay technique had been observed both by the research scientist in the 
department and by a research scientist from Mast Diagnostics. 
The temperature of the room and incubation stages was monitored throughout. 
The calibrators and samples were defrosted and warmed to the correct 
temperature. This did not lead to any improvement in the angle of the curve. 
Therefore, the remaining aspect to test was the durability of the kits. A kit from 
the batch that I had been using was tested against a kit from a more recent 
batch obtained from another group using the same assay as a means of 
identifying which component of the kit, if any, was causing the problems with the 
curve. The calibration curves were calculated with all possible combinations of 
calibrators, microtitre wells and substrates from both kits to identify the 
unreliable component. 
The results are demonstrated in figure 4.4. The "old" kit is represented by A, the 
"new" kit by B. The sequence of letters represents the calibrators, the substrate 
and the microtitre wells respectively as demonstrated in Table 4.1 
As can be seen from the graph, the greater the proportion of components used 
from kit A, the older of the two kits, the nearer to the x-axis the curves went. 
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fig. 4.4 Chart displaying the curves obtained when different combinations 
of the two ELISA kits were used 
In addition, when all the components came from kit A, there was no difference 
between calibrator D, containing 0.05µg/ml fFN and calibrator E which 
contained no fFN. 
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Kit components 
B-B-B calibrator B, substrate B, microtitre wells B 
B-A-B calibrator B, substrate A, microtitre wells B 
A-B-B calibrator A, substrate B, microtitre wells B 
B-B-A calibrator B, substrate B, microtitre wells A 
B-A-A calibrator B, substrate A, microtitre wells A 
A-A-B calibrator A, substrate A, microtitre wells B 
A-B-A calibrator A, substrate B, microtitre wells A 
A-A-A calibrator A, substrate A, microtitre wells A 
Table 4.1 explaining the key for fig. 4.4 
The conclusion from this was that, even within the stated shelf-life of the assay 
all components of the assay were degrading. 
This still left the task of validating the measured levels of fFN I had previously 
obtained - was the assay reliable despite the observed changes with time? 
Through the process of remeasuring the levels of fFN in samples previously 
tested, it was possible to establish that the levels obtained were consistent. 
Mast Diagnostics' advice for use of the assay, was that samples need only be 
tested singularly. Once there appeared to be a problem with the assay, samples 
were tested in duplicate. The absorbance for these samples is shown in 
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Appendix 4. The results are represented in fig. 4.5 below. This shows a good 
correlation between the values obtained. 
Part of the work in the following chapters looked at fFN in plasma. Some of 
these samples were tested in duplicate, these results are found in Appendix 5 
and a similar chart displaying these results is shown in fig. 4.6. These results 
are displayed separately to those obtained from the endocervical swabs as it is 
unclear exactly what the assay is detecting in plasma, and therefore how 
reproducible any result might be. However, again, a reasonable correlation is 
obtained. 
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Figure 4.5 Scatter-chart showing the values for samples tested in 
duplicate 
Correlation co-efficient = 0.99 
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Fetal Fibronectin - the Assay 152 
0.35 
0.3 
0.25 
N 
E 0.2 
0.15 
0.1 
0.05 
oý 
0 
Figure 4.6 Plasma samples tested in duplicate at a single assay run 
Correlation coefficient = 0.99 
Once it was noted that the curve was changing with time, samples were 
retested on subsequent occasions. The change in the angle of the curve could 
mean that the results were unreliable, or alternatively, similar values for the 
level of fFN are obtained regardless. Appendix 3 shows the results obtained 
from samples that were tested on more than one occasion to assess 
consistency of the assay despite the changes in the curve with time. Of 
particular note, all those samples tested on 3/6/99 with measurable levels of 
fFN, when the shape of the calculation curve was abnormal, were retested with 
the next run of the assay. A scatter-chart demonstrating samples tested on two 
occasions is shown in figure 4.7. The first two results (with the exception of 
those from 3/6/99) are shown. 
0.05 0.1 0.15 0.2 0.25 0.3 0.35 
duplicate sample I 
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Although the correlation is not as close as that obtained in figures 4.5 and 4.6 
there is still a reasonable correlation demonstrated and the levels of fFN 
obtained can be said to be representative of the levels of fFN in the samples, 
despite the changes in the curve with time. 
In the chapters that follow, the first result obtained is used as the value for fFN 
except as explained above for those samples obtained on 28/1/00 when the 
curve was so close to the x-axis, that the retested results were considered more 
reliable. 
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Figure 4.7 Scatter-chart showing samples tested on more than one 
occasion 
Correlation coefficient = 0.96 
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Chapter 5- Fetal Fibronectin in Normal Early Pregnancy 
5.1 Introduction 
In order to assess the normal range for fetal Fibronectin in cervical fluid in early 
pregnancy, samples were taken from women requesting termination of 
pregnancy. All referrals for termination of pregnancy to St. James's University 
Hospital are made through the Fertility Control Unit (FCU). Each woman is 
scanned to confirm viability and gestation before being councelled for 
termination. Although long term viability of these pregnancies can only be 
assumed, the majority would have survived as only 3% of pregnancies will 
miscarry if a viable fetus has been demonstrated ultrasonographically at 8 
weeks from last menstrual period (Kline et at, 1989). 
Mast Diagnostics had provided us with their unpublished data on levels of fFN 
throughout pregnancy. Their results implied that fetal fibronectin was found in 
measurable amounts throughout first trimester. Their data did not, however, give 
any indication of range, or indeed if fFN was present in the cervix of every 
subject. It was difficult to establish how many women had been sampled at any 
given timepoint. The basis of their work had been done in establishing the role 
of fFN in premature labour. The theory being that fFN was to be found in the 
cervico-vaginal secretions until the decidua capsularis fused with the decidua 
parietalis prior to 20 weeks gestation. 
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Fig. 5.1 values of fFN in normal pregnancy as defined by Mast Diagnostics 
If fFN were to be found in the later half of pregnancy, this would indicate 
disruption of the pregnancy and predict premature labour. Therefore we felt that 
if fFN is measured in the endo-cervical secretions of normal early pregnancy, 
abnormal amounts may indicate abnormal early pregnancy. Ectopic pregnancy 
is located outside the uterus and its greater distance from the cervix might 
mean smaller quantities of fFN would be found in the cervico-vaginal 
secretions. In miscarriage, it might be that poor trophoblast formation and 
implantation would lead to smaller measurable quantities of fFN, or perhaps the 
disruption of the early fetal membranes might lead to higher measurable levels. 
I had, therefore, first to establish my own normal curve for normal levels of fFN 
in early pregnancy. 
13579 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 
weeks gestation 
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5.2 The Qualitative assay 
5.2.1 Aims 
-A means of establishing the technique of obtaining samples within the 
setting of the FCU. 
- Whether positive and negative swabs were of value, the qualitative swabs 
becoming positive at a cut-off value. The value of the cut-off value was not 
clear from the manufacturers; previous work has tended to use 0.05µg/ml 
fFN as the cut-off for positivity. 
- To establish whether the endocervix or the posterior fomix had better pick-up 
of fEN. 
- To establish if fFN was picked up at one site, whether it would then be 
consistently found at the other. 
5.2.2 Method 
Prior to quantifying the levels of fFN in first trimester, the qualitative assay was 
used to establish whether fFN could be detected and whether the endocervix or 
posterior fomix was the best site. 
Each subject had a speculum examination performed prior to transvaginal 
ultrasound scan. A swab was taken from both the endo cervix and posterior 
fomix in each woman simultaneously. The swab was gently rolled within 
the endocervix and the posterior fomix of the vagina for 10 seconds. The assay 
was performed in the clinic and read after ten minutes as described in the 
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previous chapter. 21 women of varying gestations in first trimester had swabs 
taken. 
5.2.3 Results 
The results are shown below (Table 5.1 and figure 5.2). In all 8 (38%) were 
negative at both sites, less than half (10/21) positive at the cervix and only 6 
postive at both sites. 
Table 5.1 chart showing the positive and negative swabs in first trimester 
subjects (all gestations). Analysed using Fisher's Exact Test: 
high vaginal swab 
+ve -ve 
+ve 6 4 
m 
v 
-ve 3 8 
Positive Predictive Value (PPV) = 0.600 
Negative Predictive Value (NPV) = 0.727 
PPV = probability of the HVS being positive if the cervical swab positive 
NPV = probability of the HVS being negative if the cervical swab is negative 
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Fig 5.2 Chart showing any positive result against no positive result 
for each week of gestation 
Odds Ratio that either/both samples are positive against neither 
sample being positive (OR) = 4.00 (Cl 0.639 to 25.021) 
5.2.4 Discussion. 
1. Not all the swabs were positive for fFN, 8 (38%) were negative both at the 
endocervix and the posterior fornix. This differs from the results obtained 
from Mast Diagnostics which imply that positive results would be obtained in 
first trimester. 
2. Neither the endocervix nor the posterior fornix gave consistently more 
positive results, 9 (43%) had positive high vaginal swabs, 10 (48%) had 
positive endocervical swabs. In only 6 (29%) both swabs were found to be 
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positive. However, because the cut-off point was not clear, it might well be 
that low levels of fFN were present that were beneath the cut-off of the test. 
3. Because so many swabs were negative, it seemed less likely that the same 
high mean values for first trimester fFN would be obtained as have been 
demonstrated in the graph based on the data from Mast Diagnostics. 
4. Fisher's exact test gave a low PPV of 0.600 and low NPV of 0.727, the OR 
crossing unity, when positive high vaginal swabs were compared with 
positive endocervical swabs. Based on the results obtained from the 
qualitative swab, there did not appear to be an optimum site for sampling. 
5. The proportion of positive swabs was greater at earlier gestations, which 
again, was contrary to Mast's experiences. However, the small number of 
subjects sampled makes it difficult to know the significance of this. 
As these results did not correspond with those obtained from Mast, and there 
was so little information on exactly what the qualitative test represented, it 
seemed advisable to test using the quantitative assay from then on. 
5.3 The Quantitative Assay 
5.3.1 Introduction 
The decision was made to sample the secretions from the endocervix. The 
earliest work on fFN had used the endocervix as the sampling site, and 
Lockwood et a/ (1991) had found more positive results in the endo-cervical than 
the high vaginal samples. The amount of physiological discharge may have a 
dilutional effect on the fFN concentration, whether this is greater in the posterior 
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fornix where secretions will tend to pool, or in the endocervix where the 
secretions are produced, is not clear. 
The disadvantage of using the endocervix was that it is more likely to produce 
contact bleeding. As the assay is said to be specific to fetal fibronectin and not 
to cross react with other fibronectins - particularly those in the blood, this was 
not thought to be important at this stage. If blood contamination were to be a 
problem, it would limit the assay's usefulness as a test at any stage of 
pregnancy, as small or large blood loss is likely to accompany both early and 
late pregnancy complications. If blood contamination is present is likely to be in 
both the endocervix and posterior fornix, even if it is not visible macroscopically. 
If blood was macroscopically obvious in the samples this was recorded so any 
effect of blood on fFN levels could be explored in the light of the results 
obtained. 
5.3.2 Method. 
Samples were obtained from the endo-cervices of consenting subjects 
attending the Fertility Control Clinic. Each woman requesting termination of 
pregnancy has a transvaginal ultrasound scan performed to accurately 
establish the gestation of the pregnancy. Samples were taken prior to 
ultrasound scan, as transvaginal scanning was considered to be likely to disrupt 
the cervix and might not give a true picture of what the levels of fFN were. 
Therefore, at the time of sampling, the gestation of the pregnancy was not 
known. Samples were taken by gently rolling the swab in the endocervix for 10 
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seconds. Ninety-two women were sampled. The gestations of the pregnancies 
at the time of sampling are shown in fig. 5.3. 
25 
20 
15 
E 
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5 
0 
Fig. 5.3 Gestation at time of sampling of women with "normal" early 
pregnancy attending the FCU. 
5.3.3 Results 
The full table of assay results is found in appendix 6. It had been anticipated 
that it would be possible to translate these results into a similar curve to that 
shown in fig. 5.1 however, 57 of the 92 results (62%) fell into the group where 
fFN was found, but in such small amounts that the levels could not be 
determined (i. e. <0.05 µg/ml). In 17 out of 92 (18%) no fFN was detected. In 
only 18 of the 92 (20%) was fFN found in sufficient quantities to be measured 
accurately. Because of the number of results in which a level for fFN was not 
obtained it was not possible to produce a mean value. 
S to 66 to 77 to 88 to 99 to 10 10 to 11 11 to 12 12 to 13 13+ 
weeks gestation 
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QWFN not measurable 
 WN <0.05migrog/ml 
 fFN >0.05microg/ml 
less than 99 to 11 greater than 11 
weeks gestation 
fig 5.4 Levels of fFN found in samples taken from subjects attending the 
FCU in first trimester 
case control X2 
4 8.1351 10 5.8649 5.0175 
31 26.7297 15 19.2703 1.6285 
8 8.1351 6 5.8649 0.0054 
totals 43 31 6.6513 
2 d. f. P<0.05 
fig 5.5 X2 test comparing results obtained in pregnancies of less than 9 
weeks gestation with those of between 9 and 11 weeks. This reaches 
significance. 
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case control X2 
10 8.8571 4 5.1429 0.4014 
15 16.4490 11 9.5510 0.3475 
6 5.6939 3 3.3061 0.0448 
totals 31 18 0.7937 
2 V. not significant 
fig 5.6 X2test comparing results obtained in pregnancies of between 9 
and 11 weeks with those of > 11 weeks. This does not reach significance. 
case control X2 
8 5.4286 6 8.5714 1.9895 
9 10.0816 17 15.9184 0.1895 
2 3.4898 7 5.5102 1.0388 
totals 19 30 3.2178 
2 d. f. not significant 
fig 5.7 X2test comparing results obtained in pregnancies of between 9 
and 10 weeks with those of > 10 weeks. This does not reach significance. 
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For the purposes of comparison, if a value of 0.05µg/ml is assigned to those 
samples in which fFN is present, but at concentrations too small to be 
measured by the assay, the following curve is obtained for the mean value of 
fFN during first trimester fig 5.7. 
0.35 
0.3 
0.25 
s 0.2 
0.15 z it, 
0.1 
0.05 
0 
Fig 5.7 Showing mean values of fFN in samples taken in first trimester 
from women attending the FCU 
5.3.4 Discussion 
1. The information received from Mast Diagnostics, I had anticipated that much 
higher levels of fFN would be found, and I was surprised at how few had 
measurable quantities. 80% of the samples had little or no fFN present. This 
was in keeping with the findings using the qualitative assay when 71% were 
negative at one or both sites of sampling. 
2. If arbitrary values are attributed to those samples in which fFN is present, 
but the levels are too small to quantify, a curve for fFN in first trimester can 
be produced. However, when this curve is compared to that obtained by 
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Mast Diagnostics, the levels obtained are only 10% of those obtained by 
Mast. The levels of fFN obtained during my analysis are of a similar order to 
those obtained in first trimester by Ness et al. (1998) and Nowacek et al. 
(1999). In the paper by Nowacek et al., the same assay system was used; 
their confidence interval for fFN ranged to less than the 0.05µg lower limit of 
the assay, it would therefore seem likely that they attributed values in a 
similar way to figure 5.7. 
3. The biggest group is that in which small, but not measurable amounts of fFN 
are found. In this, first trimester would not appear to be much different to 
later pregnancy. 
4. When the different gestational bandings are compared, fFN in the 9 to 11 
week banding is statistically higher to the <9 week banding, p <0.05. The 
broad bandings of fFN in first trimester, figure 5.4, and the curve 
representing levels throughout first trimester, figure 5.7 support a rise in the 
level of fFN around 10 weeks gestation. In the curve obtained from Mast 
Diagnostics, the levels of fFN are at their greatest between 9 weeks and 13 
weeks. After 10 weeks, the differences do not reach significance, but the 
trend in fFN levels is downwards. 
5. In 20% of pregnancies, measurable levels of fFN were found. The 
significance of this is unclear, even supposing that it is a reflection of future 
pregnancy problems, given that the pregnancies were confirmed as viable at 
the time of sampling, only 3% (which is less than three pregnancies in this 
group) would have been expected to miscarry after sampling. 
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However variable the normal level of fFN in first trimester might be, it still 
remains a potentially useful diagnostic test in the complications of first trimester, 
if the levels obtained in abnormal early pregnancy are measurably different. 
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Chapter 6- Fetal Fibronectin in Recurrent Miscarriage 
6.1 Introduction 
Sporadic miscarriage is a common problem, if all conceptions are considered, 
more than half will miscarry, and, of the pregnancies that are clinically 
recognised, up to 20% will miscarry. Sporadic miscarriage usually occurs 
because the pregnancy is either structurally or karyotypically abnormal. These 
pregnancies could never have progressed to a normal outcome. Overall, 25% 
of women will have a sporadic miscarriage during their reproductive life. 
However, some conceptions will miscarry because of a recurring problem in 
early pregnancy, not because of fetal abnormality. There are well recognised 
causes for recurrent early pregnancy loss, for example, antiphospholipid 
syndrome (APS). With treatment, this might be overcome and the normal 
conceptus survives. In about half of these women with recurring early 
pregnancy loss, a cause can be identified. In the other cases the lack of an 
explanation does not exclude an underlying cause, and, indeed, a proportion of 
these women will go on to have repeated, further early pregnancy losses. It is 
likely there are other, as yet undetermined, causes for the loss of karyotypically 
and structurally normal pregnancies. 
St James's University Hospital has an Early Pregnancy Unit (EPU) that gives 
access to support for women with early pregnancy complications. 
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- The Early Pregnancy Assessment Service (EPAS) provides a 
diagnostic and support service to women with early pregnancy 
bleeding, pain etc, with direct access for patients as well as referral 
from GPs, midwives and casualty. 
- The Recurrent Miscarriage Clinic (RMC) provides investigation, 
treatment and early pregnancy support to women who have had two 
or more early pregnancy losses. Patients of the RMC contact the unit 
as soon as they have a positive pregnancy test. This means they are 
usually seen for the first time between 4 to 5 weeks after their last 
menstrual period (Imp). At this visit, pregnancy will be confirmed, the 
APS screen is repeated and swabs are taken to look for bacterial 
vaginosis (BV) and chlamydia. Patients of the RMC are, therefore, 
seen early in pregnancy and the practice of screening for BV provides 
an opportunity to take swabs for quantification of fFN up to two weeks 
before viability of the pregnancy can be established by ultrasound 
scan. Approximately 100 pregnancies in women with a history of 
recurrent miscarriage are supported through the RMC each year. 
I set out to see whether fFN might be used to predict which pregnancies would 
be ongoing before viability could be confirmed by ultrasound scan - abnormal 
levels of fFN might predict early pregnancy loss independent of the reason for 
the pregnancy loss. In pregnancies destined to miscarry, fFN might be reduced 
if the trophoblast were not adequately established, or, alternatively the 
disruption of the trophoblast accompanying miscarriage might lead to increased 
levels of fFN at the endo-cervix. In this context, fFN was to be assessed as a 
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predictor of successful pregnancy, rather than as a means of investigating the 
aetiology of recurrent miscarriage. 
During the time of the study, consenting women would have a swab taken to 
quantify the levels of fFN at the endocervix. These swabs would be taken 
before the first ultrasound scan was performed, ie before either the gestation or 
viability status had been determined. 
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6.2 Quantification of Levels of fFN Found in Preanant Women 
attending the Recurrent Miscarriage Clinic 
6.2.1 Method 
Women under the care of the miscarriage clinic are asked to contact the unit 
when they have a positive pregnancy test. At this point a repeat APS screen 
and screen BV and chiamydia can be performed allowing the fFN swab to be 
taken at the same time. All swabs were taken before the first ultrasound scan 
assessment for viability of the pregnancy, regardless of suspected gestation. 
The standard pattern of care for women under the care of the miscarriage clinic 
means that the pregnancies are followed on a weekly basis until the end of first 
trimester, the number of these pregnancies with first trimester complications is 
therefore known with a great degree of accuracy. 
Women were recruited when they first reported a positive pregnancy test. The 
project was discussed with them and their consent for participation obtained. 
The sample was taken by gently rolling the swab within the endocervix for 10 
seconds with the fFN sample collection kit. The fFN swab would be taken 
before the endocervical swab for chiamydia. The level of fFN was quantified, as 
described in chapter 4. 
6.2.2 Results 
Endocervical swabs were taken from 65 women attending the RMC. The 
gestation at sampling (by subsequent ultrasound scan) and the outcome at the 
end of first trimester were recorded. Four outcomes were considered: 
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ongoing pregnancy at end of first trimester 
first trimester miscarriage - fetal heart pulsation never seen 
first trimester miscarriage after fetal heart pulsation seen 
ectopic pregnancy. 
This is summarised in Table 6.1: 
171 
Table 6.1 Numbers of samples obtained in first trimester against outcome 
gestation at 
sampling 
ongoing miscarriage 
- FH never 
seen 
miscarriage 
after FH 
seen 
ectopic 
<4 weeks 1 
4-5 weeks 11 3 2 
5-6 weeks 16 7 2 
6-7weeks 9 1 2 2 
7+ weeks 8 1 
total 44 (67.7%) 12 (18.5%) 7(10.8%) 2 (3.196) 
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fFN mcg/mI 
Fig 6.1 Levels of fFN obtained for different pregnancy outcomes 
Figure 6.1 demonstrates the band into which the levels of fFN fell for different 
pregnancy outcomes. The levels are not displayed according to gestation as the 
numbers are small and a significant increase in fFN was not found before 9 
weeks of gestation in normal early pregnancy. None of these samples were 
taken after 9 weeks gestation. Appendix 7 gives the actual value and gestation 
of sampling for each specimen. The two ectopic pregnancies are not 
considered in the subsequent analysis in this chapter, firstly, because there 
were only two, and secondly, because ectopic pregnancy is considered in its 
own right in the next chapter. 
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100% 
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0% 
pregnancy outcome 
 >0.05 mcg/mI fFN 
00-0.05 mcg/ml fFN 
"O mcg/ml fFN 
Fig 6.2 The percentage of samples that had measurable, recordable but 
not measurable and non recordable levels of fFN according to outcome. 
Figure 6.2 illustrates the proportion of samples from women with each 
pregnancy outcome that had 
1. measurable levels of fFN (ie >0.05µg/ml) 
2. fFN found, but outside the measurable range (ie <0.05µg/ml) 
3. fFN not detected 
There is no significant difference in the levels of fFN for different outcomes of 
pregnancy. 
ongoing miscarriage no miscarriage FH 
FH seen seen 
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fFN level 0 0.05 use/ml >0.05 use/ml total 
ongoing 9 26 9 44 
misc. - no FH 4 35 12 
misc. - FH seen 2 4 6 
total 15 33 14 62 
X2 = 6.539 4 d. f. p=0.162, not significant 
Fig 6.3 X2 test comparin g all pregnancy outcomes with all bands of fFN 
result 
fFN level 0 to 0.05 u a/ml >0.05 ua/ml total 
ongoing 35 9 44 
misc. - no FH 7 5 12 
misc. - FH seen 6 6 
total 48 14 62 
XZ 4.364 2 M. p=0.113, not significant 
Fig 6.4 X2 test comparing all pregnancy outcomes with fFN <0.05µg/ml 
and >0.05pg/ml 
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fFN level 0 to 0.05 mcWml >0.05 mcalml total 
ongoing/FH seen 41 9 50 
FH never seen 75 12 
total 48 14 62 
XZ = 3.101 1 d. f. p<0.1, significant 
Fig 6.5 X2 test comparing pregnancies in which a FH was seen at some 
point in 1'd trimesters and pregnancies in which a FH was never seen 
against measurable and non-measurable levels of tN 
fFN level 0 to 0.05 mcalml >0.05 mc&ml total 
ongoing 35 9 44 
miscarriage 13 5 18 
total 48 14 62 
X2 = 0.392 1 M. p=0.531, not significant 
Fig 6.6 X2 test comparing viable pregnancies and non-viable pregnancies 
against measurable and non-measurable levels of tFN 
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6.2.3 Discussion 
There is no significant difference between levels of fFN found in the endocervix 
of women in whom the pregnancy was found to continue and those in whom the 
pregnancy failed although there was an increase in the level of fFN if no FH 
was seen. However, fFN cannot be used to predict the outcome of pregnancy 
before viability is confirmed. The number of patients in the miscarriage group is 
small compared to those in the ongoing pregnancy group, but this is as would 
be expected, viable pregnancy being the outcome in the majority of patients, 
even in a recurrent miscarriage population. 
This is a big disappointment. The only possible trend - higher levels of fFN in 
Aft 
pregnancies in which a fetal pole never becomes established wassexpected if 
fFN production is greater in well established pregnancies, but is of no clinical 
value as even in this situation, 9/14 pregnancies continued to term. 
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Chapter 7- Fetal Fibronectin in Ectopic Pregnancy 
7.1 Introduction 
When a woman presents with a complication of early pregnancy her distress is 
likely to be compounded if diagnosis is delayed. Unfortunately, delay is usually 
a feature of the diagnosis of ectopic pregnancy. When an ultrasound scan 
shows an empty uterus, this might represent a normal early pregnancy, an 
ectopic pregnancy or a miscarriage. These women have to wait for the results 
of serial serum hCG testing before they can be told whether the pregnancy is 
ongoing and if it is not, whether treatment is required. Early Pregnancy Units 
are an efficient way of investigating and initiating management of early 
pregnancy complications (Bigrigg and Read, 1991) but they do not remove this 
delay. 
Ultrasound scan can only make a definitive diagnosis of ectopic pregnancy 
when an adenexal fetal heart pulsation or yolk sac is seen. Such a definitive 
diagnosis will only be made in only a small proportion of ectopic pregnancies - 
Leibman et al. (1988) and Timor-Tritsch et al. (1989) suggested this was up to 
20%, but when Mol et al. looked at the predictive value of ultrasound findings in 
1998", a definitive diagnosis of ectopic pregnancy by ultrasound alone could 
only be made in 9.0% of their patients. 
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If a test could be developed that would differentiate an ectopic pregnancy from 
early normal pregnancy and miscarriage, not only would this remove the anxiety 
and uncertainty that surrounds suspected ectopic pregnancy, but it would widen 
the therapeutic choices. Medical management is more successful at lower 
levels of serum hCG (Lipscomb et al., 1999), but ultrasound does not 
discriminate well between normal and abnormal pregnancy at these lower 
levels. It is particularly important to exclude normal early pregnancy if medical 
management is to be considered - it is unlikely that the women will suffer 
adverse consequences if a miscarriage is treated with methotrexate, but it is 
imperative that normal early pregnancy is not so treated. 
If fetal fibronectin is found at the cervix in a normally situated early pregnancies, 
whether viable or non-viable, its absence, or presence in reduced quantities, 
might represent an ectopic pregnancy that is located at site distant to the cervix. 
The benefits of a test that can that can give a diagnosis of ectopic pregnancy at 
the time of presentation are not just of swifter diagnosis, but also allow the 
option of medical management to be considered at lower levels of hCG when 
the chance of success is at its greatest. 
Ness et al. (1998) looked at fFN in women who presented with pain and 
bleeding in early pregnancy. They found fFN levels to have a similar range in 
women with ectopic pregnancy and ongoing pregnancies (i. e. threatened 
miscarriages). The mean fFN level was lower in the ectopic pregnancy group, 
though the range of values was greater. However, in their subjects, all women 
had a diagnosis at the time of sampling. I was interested to know whether there 
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were differences between women with ectopic pregnancy and women with 
normal early pregnancy at the stage when ultrasound findings are unhelpful. 
Women who presented with incomplete or complete miscarriage had the 
highest levels of fFN, but there was sufficient overlap with the ectopic 
pregnancy group to prevent it discriminating between the two. This group of 
women is not likely to cause major confusion as the symptoms associated with 
passage of trophoblast in miscarriage usually lead to clinical diagnosis. The 
greatest problem arises in those women who have lesser degrees of bleeding, 
with or without pain in whom an ultrasound scan does not make the diagnosis 
any clearer. 
The aim of this chapter is to measure levels of fFN found in women with 
suspected ectopic pregnancy and see if these levels differentiated them from 
women with normal pregnancy and miscarriage. 
7.2 Fetal Fibronectin in Ectopic Pregnancy 
7.2.1 Method 
Two groups of women were recruited: 
Group One: Women in first trimester in whom an ultrasound did not 
demonstrate an intra-uterine pregnancy. Although they presented with pain 
and/or vaginal bleeding, their symptoms were not consistent with a diagnosis of 
complete miscarriage. This group contained those pregnancies of primary 
interest in considering the use of fFN in the diagnosis of ectopic pregnancy. 21 
women were recruited. 
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Group Two: Symptomatic women seen in the Early Pregnancy Unit (EPU) or 
the Fertility Control Unit in whom a diagnosis of miscarriage was made at their 
first visit were recruited as a comparison group for my own assessment whether 
levels of fFN found in miscarrying women overlap with levels found in women 
with ectopic pregnancy, thus reducing its value as a diagnostic test.. In this 
group there was no diagnostic dilemma, all women clearly had miscarriages 
when ultrasound scan was performed and as such they differ from the women 
recruited from the RMC in chapter 6. Women in the RMC did not have 
symptoms of miscarriage at the time of sampling and their pregnancies were 
assumed to be ongoing. 13 women were recruited. 
Women recruited through the FCU had swabs taken prior to vaginal ultrasound. 
Women recruited through the EPU either had swabs taken at the time of 
speculum examination, if indicated, or prior to surgery. 
Samples were obtained from the endo-cervices of consenting women. Samples 
were taken by gently rolling the swab, taken from the collection system supplied 
with the assay, in the endocervix for 10 seconds. The swabs were immediately 
placed in the buffer solution. At the end of each session in which samples were 
taken, the swabs would be filtered and stored, as described in chapter fou. r. 
The major difference with this group of patients in comparison with the previous 
groups in previous chapters is that they were symptomatic, ie vaginal bleeding 
was present. This meant that the swabs were more likely to pick up blood in the 
sampling process, but this reflects the clinical reality. A note was made of any 
samples that were macroscopically contaminated with blood. 
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7.2.2 Results 
The outcomes of the 21 women in Group 1 are shown in Table 7.1. 
Table 7.1 Final outcome in women from group I 
outcome number 
Ectopic pregnancy confirmed 16 
Negative laparoscopy 3 
ongoing I 
Resolving trophoblast I 
Table 7.2 Final outcome in women from group 2 
outcome number 
Miscarriage - sac intact 11 
Complete miscarriage 2 
In 16 women, the diagnosis of ectopic pregnancy was confirmed 
laparoscopically. In three women laparoscopies were negative, as serum hCG 
levels were found to fall post-operatively, the presumed diagnosis was of 
complete miscarriage. One woman was subsequently found to have a normal 
intra-uterine pregnancy. One woman was managed conservatively, as her hCG 
levels fell, laparoscopy was not required and the site of trophoblast - tubal or 
intrauterine - was not confirmed. 
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The outcomes of the 13 women in Group two are shown in Table 7.2. 
In FCU patients, swabs were taken in symptomatic women before ultrasound 
scanning, therefore, two of the samples taken were from women who were 
found to have had complete miscarriages when scanned. 
The levels of fFN were expressed in a similar manner to previous chapters, 
three levels of fFN were considered - samples where no fFN was found 
(Omcg/ml fFN), samples where fFN was found, but at levels too small to 
measure (0-0.05mcg/ml) and samples with measurable levels of fFN 
(>0.05mcg/ml). Fig 7.1 displays the results from this chapter as a percentage of 
the total number of samples in each group. The complete table of assay results 
is found in appendix 8. Three groups are displayed - ectopic pregnancies, 
miscarriages and normal early pregnancy. The group of ectopic pregnancies 
were the samples taken form those women in whom a diagnosis of ectopic 
pregnancy was confirmed. The miscarriage group represents the samples taken 
from women with confirmed miscarriage discussed in this chapter. It does not 
include the women who miscarried after being seen in the RMC. Three groups 
are considered in the normal early pregnancy category - 
1. all the viable pregnancies sampled in the FCU. This has the 
disadvantage that the samples are taken from women at more than six 
weeks gestation, a stage of pregnancy when viability can be confirmed 
on ultrasound scan. 
2. the group of RMC patients in whom samples had been taken before six 
weeks gestation. As these women present as soon as pregnancy is 
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confirmed by pregnancy test, they are often seen at a stage when 
ultrasound confirmation of the pregnancy is not possible. However, 
because of their higher risk of first trimester loss, the levels of fFN may 
differ from low risk pregnancies at this gestation. 
3. because of this, the third group was included, this consisted of the 
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ongoing pregnancies of all gestations presenting through the RMC. 
Fig 7.1 Levels of fFN in ectopic pregnancy, miscarriage and normal early 
pregnancy displayed as a percentage of all the results in each group. See 
text for explanation of groupings. 
Considering the three groups of normal early pregnancy, they are broadly 
similar with the largest percentage of subjects having detectable, but not 
Fetal Fibronectin in Ectopic Pregnancy 184 
All ectopic pregnancies had some detectable fFN. 
The group in which a miscarriage was diagnosed had a larger proportion of 
subjects in which measurable levels of fFN were found, and a smaller 
proportion in which no fFN was detectable. 
7.2.3 Discussion 
Before starting this work, I had expected that the greater distance between the 
site of the pregnancy and the site of sampling, in ectopic pregnancy, would 
result in less fFN being present at the cervix. This is not the case. fFN was 
found in every sample taken from women with a diagnosis of ectopic pregnancy 
in my subjects. However, when the actual levels of fFN found in ectopic 
pregnancy and normal pregnancy are considered, this information is of no 
clinical value as the range of values is similar. 
Whilst samples from women with ectopic pregnancy all had detectable levels of 
fFN, many more samples taken from women with confirmed miscarriage had 
the higher levels of fFN. Again, because of the overlap in the measured levels, 
this is not clinically useful. 
If distance from the site of sampling does, in fact, make a difference to the 
amount of fFN detected, taking samples as close to the site of the ectopic 
pregnancy as endocervical samples are close to the site of a miscarriage might 
exaggerate the differences demonstrated in fig 7.1. 
As it is physically impossible to get at the fallopian tube without an invasive 
procedure, I decided to see how much fFN could be found in circulating blood. 
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Unlike hCG, which is secreted into the blood, fFN is produced to act locally, 
having a functional role in the attachment of the pregnancy. I was unsure 
whether any fFN would be detectable in the circulating blood. 
I had another concern. It would seem that the more bloody the first trimester 
complication, the greater were the amounts of fFN detected at the endocervix. 
The premise of this work is that the assay is specific to the onco-fetal form of 
fibronectin. I wished to explore whether contamination with blood might have an 
effect on the results. 
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Chapter 8- Fetal Fibronectin in Blood 
8.1 Introduction 
fFN is produced by the trophoblast, and so it is to be expected that it would be 
found locally to the pregnancy. The original hypothesis was that in ectopic 
pregnancy, which is situated at a distance from the cervix, less fFN would be 
found on endocervical sampling than would be found in an intrauterine 
pregnancy which is in closer proximity to the cervix. It was, therefore, an 
unexpected finding that fFN was detected in all cases of ectopic pregnancy and 
not all intrauterine pregnancies. Fibronectins are found in abundant quantities in 
the plasma and Feinberg and Wang (1994) raised concerns about the 
specificity of antibody raised against the FDC-6 epitope and the possibility of 
cross-reaction with plasma fibronectins. 
Levels of FDC-6 fibronectin have been noted to be raised in the plasma of 
women with pre-eclampsia (Paidas et at, 1994; Kupferminc et at, 1994). 
Increased amounts of circulating trophoblast have been suggested as the 
reason for this. 
Here are two possible concerns about using the fFN assay - 
I. The assay is not specific, and therefore contamination with blood will 
give unrealistically high levels of fFN as it detects other, plasma, 
fibronectins. 
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2. Pregnancy derived fFN is present in the blood, and therefore 
contamination with blood will increase the levels of fFN found in the 
cervix. 
The later point may cause difficulties in interpreting results obtained at the 
cervix in the presence of blood contamination, but circulating trophoblast 
reacting with the antibody to the FDC-6 epitope might open up other 
possibilities for screening for pregnancy complications. Would levels of 
circulating fFN differ in normal, stable pregnancy and abnormal, disrupted 
pregnancy? 
The next stage of my investigation was to explore testing of plasma samples 
with the quantitative assay. 
8.2. Levels of fFN found in plasma of pregnant women 
8.2.1 Method 
All women attending the FCU have blood taken for a full blood count and blood 
grouping. I took consent to take extra blood to measure levels of fFN to 
establish whether fFN could be detected in the plasma of pregnant women. A 
further 6mis of blood was taken in an EDTA tube for the purpose of this study. 
All women were scanned at the same visit so the pregnancy was confirmed, 
and its viability and gestation established. 
At the end of the clinic the samples were spun at 2200rpm for 10 minutes to 
separate the plasma from the blood cells. The plasma was then decanted and 
stored at -80°c until it was used for testing. I was unclear what to expect from 
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the plasma, all cervical samples are diluted in the buffer solution; the assay 
calculates the level of fFN in the secretions taking into account this dilutional 
factor. If only very small amounts of fFN were present in plasma, undiluted 
plasma might be required to obtain a measurable result. When calculating the 
final amount of fFN in the plasma, the results would have to be scaled down to 
allow for the omitted dilution. If fFN were present in plasma in similar amounts 
to the cervix, then the same dilution would be required to produce similar 
results. Therefore I stored and tested samples in two ways: 
1. Neat plasma. 
2. Plasma diluted in a similar way to the endocervical samples. A swab 
from the collection system was dipped into the plasma and left for 10 
seconds, to mimic collection conditions for the endocervical swabs. The 
swab was then inserted into the buffer system. The collecting system 
was then treated in a similar fashion to when endo-cervical swabs were 
processed. The transport tubes were then gently vortexed for 30 
seconds in a Gallenkamp mixer. Each swab was removed from its 
transport tube, the tip of the swab was squeezed against the transport 
tube to extract as much fluid as possible. The samples were then filtered 
in a similar fashion to the endo-cervical swabs. The filtrate was then 
decanted into a microcentrifuge tube for storage. 
8.2.2 Results 
All samples of undiluted plasma produced high levels of positivity, all recorded 
levels of >1.0µg/ml of fFN. As a result only the results obtained from the diluted 
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samples are considered. 30 samples of plasma from pregnant women were 
taken. The pregnancy outcome and level of fFN found are in Appendix 9. All the 
diluted samples of fFN gave results that were in the measurable range, with 
values between 0.2 and 0.8µg/ml of fFN. The scatter of results is shown in 
figure 8.1. Three additional samples were also taken from women with early 
pregnancy complications. These also had recordable levels of fFN falling within 
the same range. 
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Fig 8.1 Scatter graph of the levels of fFN found in the plasma of 
pregnant women 
8.2.3 Discussion 
It is clear that the assay is giving a positive result for fFN. What is unclear, 
however, is why the assay gives a positive result. Does the positive result 
represent circulating trophoblast or trophoblastically derived fFN, or is this a 
false positive result, representing cross-reaction of the assay with circulating 
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plasma fibronectins. Before spending any more time considering any 
application in pregnancy, I wished to re-run a similar series using samples from 
non-pregnant subjects. 
8.3 Levels of fFN found in plasma of non-pregnant subjects 
8.3.1 Method 
Samples were collected and processed in an identical manner to the samples in 
8.2 above. Five samples were obtained from non-pregnant women and a further 
two samples were obtained from men, to exclude any possible interference 
from past or current pregnancies. All samples were obtained from members of 
staff within the Department of Obstetrics and Gynaecology. 
8.3.2 Results 
Levels of fFN found in each subject are displayed in Appendix 10. 
Figure 8.2 displays the values of fFN obtained form non-pregnant subjects on a 
scatter graph. The levels obtained from the diluted plasma of pregnant subjects 
are displayed along-side. 
The scatter graph demonstrates a similar distribution of results in pregnant and 
non-pregnant sample groups. The values obtained for male subjects lie within 
the same distribution as the female subjects. 
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Fig 8.2 Levels of fFN found in the diluted plasma of non-pregnant (male 
and female) subjects displayed alongside the values obtained in pregnant 
subjects for comparison. Arrow denotes samples taken from male 
subjects. 
8.3.3 Discussion 
It is now clear that the assay is not as specific for fFN as claimed. It clearly 
cross-reacts with a substance in plasma. That could be either because the 
FDC-6 epitope is not as specific for the onco-fetal form of fibronectin, or that 
some of the onco-fetal form of fibronectin is present in plasma. 
If the positive results were because of the inappropriate use of the assay to 
measure fFN in blood, this would raise doubt about its use in any pregnancy in 
the presence of blood. Perhaps the correlation in third trimester of positive 
results with imminent labour owes more to the presence of blood, than the 
presence of fFN. 
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Contamination with blood might not be clinically significant, the amount of 
trophoblastic fFN far outweighing any small amounts of cross-reacting plasma 
fibronectin present at the cervix. To test this I tried sampling the cervices of 
non-pregnant women. 
8.4 fFN levels in endocervical samples from non-pregnant 
subjects. 
8.4.1 Method 
Women attending colposcopy clinics have a speculum examination as part of 
the colposcopy. This lent itself to taking a swab without requiring an 
examination that would not otherwise be required. Each woman was consented 
for a swab to be taken for research purposes before colposcopy was 
performed. Each woman was asked if she was pregnant, or might possibly be 
pregnant, before being recruited. Any woman in whom pregnancy was a 
possibility was excluded. 
Two types of swab were taken. 
1. Swabs were taken during loop biopsy of the cervix to mimic the heavy 
blood contamination that might occur during some early pregnancy 
complications. 
2. Swabs were taken immediately after insertion of the cuscos speculum 
so that swabs could also be taken from non-pregnant subjects when 
the only blood that could be present is that of contact bleeding of the 
cervix from the swab itself. 
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8.4.2 Results 
16 samples were taken. Five samples were taken during loop biopsies; all were 
heavily blood stained. 11 samples were taken in women who, either, were not 
having loop biopsies, or, prior to loop biopsy; three were visibly stained with 
blood. The complete table of fFN results is found in appendix 11 (colposcopy 
samples) and appendix 12 (loop biopsy samples). 
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Fig 8.3 Scattergraph of levels of fFN found during loop biopsies 
All the samples taken during loop biopsy had measurable levels of fFN, though 
slightly lower than those found in the plasma (range for loop biopsies: 0.07 to 
0.5 µg/ml, range for plasma: 0.213 to 0.76 [ig/ml). These results are displayed 
in the scattergraph figure 8.3. In the samples taken from cervices when a loop 
biopsy was not being performed, four samples detected the presence of fFN, in 
one of whom this levels was measurable. Interestingly, this was one of three 
samples that were macroscopically blood stained. These results are displayed 
in figure 8.4. These results are displayed as a bar chart, as in three positive 
results the levels were not high enough to quantify. 
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Fig. 8.4 Levels of fFN found in samples taken during colposcopy, but 
without loop biopsy. 
8.4.3 Discussion 
Although there are only small numbers, it is concerning that fFN can be 
detected in even such a small sample of non-pregnant subjects, the assay is 
clearly not specific for trophoblastic fibronectin. Either this represents cross 
reaction of the antibody produced to the FDC-6 epitope with plasma 
fibronectins, in which case an antibody produced to another epitope, more 
specific to the onco-fetal form of fibronectin may prove to be capable of 
differentiating different pregnancy complications in first trimester. It may also 
improve the specificity of fetal fibronectin in the detection of third trimester 
complications of pregnancy. Alternatively, quantifiable amounts of the onco-fetal 
form of fibronectin might be present in plasma of non-pregnant subjects. 
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All samples throughout this work had been examined for blood staining. 
Samples were considered to be blood stained if there was enough blood 
contamination to discolour the sample/buffer mixture. 27 out of 202 (13.4%) 
samples from women in early pregnancy were discoloured by blood. The actual 
levels found are recorded in Appendix 13. 
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Fig 8.5 The effect of blood staining (BS) on positive results for fFN in 
viable pregnancies, ectopic pregnancies and missed miscarriages. 
Results are expressed as a percentage of the total results in each 
grouping. 
Figure 8.5 above shows the proportion of positive results obtained in samples 
that were stained with blood and in samples in which there was no blood 
staining. Each of the pregnancy outcomes - viable pregnancy, ectopic 
pregnancy and missed miscarriage - is displayed. All samples in which there 
was some frank contamination with blood had detectable levels of fFN and in 
missed miscarriage, where contamination with blood might be expected to be at 
no BS BS no BS BS no BS BS 
viable ectopic missed miscarriage 
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its greatest, samples in which frank blood staining was found all had 
measurable levels of fFN. 
Feinberg et al. (1994) estimated that between 1 and 4% of circulating plasma 
fibronectin will bind FDC-6. They do not explore whether this is a cross reaction 
with a component of the plasma fibronectins, or whether fibronectins identical to 
the onco-fetal form are circulating in the plasma. Answering this question is 
crucial to any further exploration of the use of fFN in pregnancy as blood 
contamination can never be eliminated from samples taken from the pregnant 
cervix. 
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Chapter 9- Treating Ectopic Pregnancy 
9.1 Evaluating Treatment for ectopic oreanancy 
As discussed in chapter three, after an ectopic pregnancy, women are 
concerned about their future fertility and the risk of recurrence. This chapter 
discusses the treatment options for ectopic pregnancy and the impact on the 
woman's physical and psychological recovery, and the chances of a future 
normal pregnancy against the risk of a further ectopic pregnancy. 
In addition to producing a diagnostic guideline for ectopic pregnancy, I wished to 
produce a guideline covering the treatment of ectopic pregnancy. To help me 
achieve this, I explored two aspects that would influence care: 
1) does a woman's past history influence her choice of management of 
ectopic pregnancy? 
This was done using Conjoint Analysis, which is a tool used within Transport 
Studies to assess the trade offs people are prepared to make in the decision 
making process. The literature suggests that with ectopic pregnancy, there is a 
trade off between optimising future fertility and reducing the risk of further 
ectopic pregnancy. In order to study this, a Conjoint Analysis questionnaire was 
devised to see if women's prior experiences influenced their choice of treatment 
of a subsequent ectopic pregnancy. 
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2) does salpingotomy offer an advantage over salpingectomy? 
A pilot trial, randomising women to either salpingectomy or salpingotomy, was 
devised. Several outcome measures were to be considered - site of the next 
pregnancy, relative cost of the two treatments, impact on quality of life. If the 
trial had proven to be successful, it was to be used as a basis to apply for 
funding for a full-scale, multi-centre trial. 
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9.2 Conjoint Analysis - Women's Choices in the Management 
of Ectopic Pregnancy 
Conjoint Analysis, or Stated Preference, is a tool that has been used 
extensively in Transport Studies to establish priorities in the planning of public 
transport. It consists of a questionnaire that provides a series of options, the 
different options trade various advantages and disadvantages (attributes) 
against each other. By varying the degree to which one item is traded-off 
against another, it aims to establish how important one component is, relative to 
another, to different groups within the population. 
Conjoint Analysis has been used by health care providers to assess patient 
preferences - their priorities in the management of miscarriage (Ryan and 
Hughes, 1997), the management of menorrhagia (San Miguel et al., 1997) and 
in Primary Health Care (Ryan et al., 1998). 
Conjoint Analysis relies on an individual's willingness to trade one option 
against another. In the management of ectopic pregnancy, both conservative 
and radical surgery is considered to have advantages and disadvantages. 
Conservative management aims to improve the woman's future fertility because 
she retains both Fallopian tubes through which to conceive - this is at the cost 
of an increased risk of recurrent ectopic pregnancy, as the tube is damaged, 
and incomplete removal of trophoblast at the time of the primary procedure, 
which may require a second procedure to be performed. On the other hand, 
radical surgery has a lower risk of persistent and recurrent ectopic pregnancy, 
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but this might be at the cost of reduced fertility. Conjoint Analysis was used to 
examine these trade-offs in women with different experiences of pregnancy. 
9.2.1 Method - Constructing a Conjoint Analysis (San Miguel et al. 
1997) 
Stage I- Determination of the attributes 
The factors considered important to the respondents are selected. In the case 
of ectopic pregnancy, these were; 
1. chance in the future of normally placed pregnancy 
2. chance in the future of ectopically placed pregnancy 
3. chance of second operative procedure being required. 
Stage 2- Assigning levels to the attributes 
The levels should be "plausible, feasible and capable of being traded off against 
each other. " The review paper by Yao and Tulandi (1997) was used to judge 
plausible levels of risk 
"chance of needing more than one operation" 
was assigned 0% or 5% or 15% 
"chance of next pregnancy being in the right place" 
was assigned 40% or 60% 
"risk of a repeat ectopic" 
was assigned 10% or 20% 
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Stage 3- Definition of the scenarios to be presented 
Combinations of attributes at different levels produces many combinations 
would not require the respondent to trade e. g. 
"chance of needing more than one operation" 0% v 15% 
"chance of next pregnancy being in the right place" 60% v 40% 
"risk of a repeat ectopic" 10% v 20% 
The first option is clearly advantageous in comparison to the second; every 
respondent should choose it. Such scenarios are placed with the questionnaire 
as a test of respondent comprehension and some scenarios are repeated to 
test for consistency. 
In this questionnaire 28 scenarios were presented to the respondents to 
consider. An example follows (fig. 9.1). 
Chance of needing more than one operation for 0% 0% 
Chance of next Pregnancy to be in the right lace 40% 60% 
Risk of a repeat ectoDic 10% 20% 
What option would YOU choose? 
Figure 9.1 example of a conjoint analysis question 
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In this example the respondent is asked to trade a higher chance of a normally 
placed pregnancy against the risk of an ectopic pregnancy. The analysis 
assesses to what degree one attribute is weighted against another. 
Stage 4- Establishing preferences 
The questionnaire is given to the respondents to complete. 
Stage 5- Analysis of the data 
Analysis was performed within the Institute of Transport Studies at the 
University of Leeds using the ALOGIT package (Hague Consulting Group). 
The complete questionnaire is to be found in appendix 13. 
9.2.2 Results 
a) Characteristics of the Respondents 
108 questionnaires were completed by patients and nurses recruited, 
opportunistically, through general gynaecological, colposcopy, early pregnancy 
and recurrent miscarriage clinics to provide adequate power and control. 
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Figure 9.2 Source of respondent to questionnaire 
The analysis was done according to 5 criteria: 
(i) The source of the questionnaire 
Most women (89) were recruited from general gynaecology clinics. These 
women were not pregnant at the time of completing the questionnaire. 18 
women had encountered problems in early pregnancy with equal numbers 
having a history of recurrent miscarriage and ectopic pregnancy. The group of 
women with recurrent miscarriage was mixed, comprising both those who were 
currently pregnant and those who were being investigated prior to pregnancy. 
The women in the ectopic pregnancy group had all had a clinical diagnosis 
made and filled out the questionnaire whilst waiting to go to theatre. These two 
groups are similar in that they have both experienced early pregnancy losses 
and are both at risk their problem recurring in future pregnancies, but in women 
general gynae miscarriage ectopic 
clinic 
respondent 
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with recurrent miscarriage it is unlikely that their experience of miscarriage was 
life-threatening, unlike the ectopic pregnancy group. 
(ii) Experiences of a general anaesthetic 
If a woman is asked to choose between a procedure that might expose them to 
a second operation - salpingotomy carries a risk of persistent trophoblast - as 
opposed to a procedure that carries no such risk - salpingectomy - it might be 
expected that past experiences of general anaesthetics might influence their 
choice of treatment. 
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Figure 9.3 Past experience of a general anaesthetic 
(iii) Employment 
A woman's employment/family commitments might influence her decision, with 
women in employment or with young children being less able to commit to a 
procedure that requires repeated visits for follow-up, and might require 
readmission for management of persistent trophoblast, as is the case with 
salpingotomy. They may prefer a more definitive treatment. 
previous general 
anaesthetic 
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Figure 9.4 Respondents employment status 
(iv) Number of children 
Women with larger or complete families are likely to put less value on a 
procedure that increases their fertility at the expense of increasing the risk of 
another ectopic pregnancy (fig. 9.5). 
mum full time part time other 
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Figure 9.5 number of children of respondents 
(v) Age 
Women at the extremes of their reproductive life are less likely to be actively 
pursuing a pregnancy. It might be expected that these women would show less 
concern about future fertility and be more concerned about reducing the risk of 
another ectopic pregnancy. 
45 
40 
35 
30 
25 
20 
15 
10 
5 
0 
Figure 9.6 age of respondents 
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b) Results of Conjoint Analysis 
" The base model 
This examined the basic attributes of the Conjoint Analysis - the need for further 
operation and the future pregnancy - in isolation. It does not look for any effect 
of the past experiences of the respondents on the responses they give. Not 
surprisingly, respondents valued the next pregnancy being correctly sited and 
did not wish to have a further ectopic pregnancy or a second operative 
procedure. An attribute with a negative coefficient is an attribute the 
respondent would prefer to avoid, whilst a positive coefficient denotes a 
favourable attribute. The possibility of a further ectopic pregnancy has a greater 
negative value than the possibility of a second general anaesthetic - ie the 
respondents were slightly more concerned about another ectopic than a second 
anaesthetic. 
Attribute Coefficient 
further operation -0.0908 
intrauterine next 0.0588 
ectopic next -0.1169 
t-statistic 
-15.8 
16.9 
-16.7 
As would be expected, having the next pregnancy in the correct place has a 
positive coefficient - this is a desirable outcome, but the effect is about half that 
of the other two attributes, so, approximately speaking, a 10% chance of the 
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pregnancy being in the right place is valued equally to a 5% chance of a second 
ectopic pregnancy or a further operation. 
The t-statistics are taken directly from the ALOGIT package values of + or -2 
will indicate a significance at 5% on a Two Tailed Test. 
9 The full model 
This then introduces the variables that the respondents bring with them - 
employment, pregnancy history, and age. 
Firslty, the effect of each characteristic on the base coefficient is described. The 
base coefficient is described for a woman who is seen neither in the context of 
management of miscarriage or ectopic pregnancy, has not had a previous 
general anaesthetic, is either self-employed or a student, has had no children 
and is aged between 16 and 25. The difference between the baseline 
coefficient and the coefficient for any other given variable describes the effect of 
changing that variable on the responses given. This gives an indication of how 
important different influences are on the woman's choice compared to a 
participant with the baseline characteristics (Tables 9.1,9.2 and 9.3). 
The variable source of questionnaire was tested in isolation. Women who were 
questioned whilst being treated for an ectopic pregnancy always felt more 
strongly than others; they felt more strongly that they would want an intra- 
uterine pregnancy on the next occasion, and that they would not want a second 
operation or another ectopic pregnancy. 
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2"d operation next intrauterine next ectopic 
ectopic -0.1382 0.0764 -0.1823 
other -0.1251 0.0458 -0.1504 
Table 9.1 The effect of the different characteristics of participants on 
weight they attach to the possibility of a second operation being needed. 
Second 
operation 
operation 
Attribute level Coefficient t-statistic 
Base level -0.1109 -4.7 
Source of 
questionnaire 
Treatment for ectopic pregnancy -0.0131 -0.5 
Treatment for miscarriage 0.0080 0.4 
Previous general anaesthetic 0.0384 2.3 
employment 
mother 0.0274 1.2 
Part time 0.0210 1.0 
Full time 0.0010 0.1 
Number of 
1 0.0106 0.4 
pregnancies 2 0.0190 0.9 
3 or more 0.0417 2.0 
Age 
26 to 35 -0.0258 -1.6 
36 to 45 -0.0509 -3.0 
Over 45 -0.0094 -0.4 
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Table 9.2 The effect of the different characteristics of participants on 
weight they attach to the next pregnancy being intra-uterine. 
Next pregnancy 
intra-uterine 
Attribute level Coefficient t-statistic 
Base level 0.0783 5.5 
Source of Treatment for ectopic pregnancy 0.0306 2.0 
questionnaire Treatment for miscarriage 0.0038 0.3 
Previous general anaesthetic -0.0470 -4.7 
mother 0.0247 1.9 
employment Part time 0.0391 3.2 
Full time 0.0262 2.4 
1 -0.0580 -3.9 
Number of 
pregnancies 
2 -0.0502 -3.8 
3 or more -0.0273 -2.1 
26 to 35 -0.0007 -0.1 
Age 36 to 45 0.0049 0.5 
Over 45 -0.0534 -3.4 
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Table 9.3 The effect of the different characteristics of participants on 
weight they attach to the next pregnancy being ectopic. 
Further ectopic 
pregnancy 
Attribute level Coefficient t-statistic 
Base level -0.1554 -5.3 
Source of Treatment for ectopic pregnancy -0.0319 -1.1 
questionnaire Treatment for miscarriage -0.0305 -1.3 
Previous general anaesthetic 0.0496 2.4 
mother 0.0064 0.2 
employment Part time -0.0185 -0.7 
Full time 0.0004 0.0 
1 0.0714 2.4 
Number of 
pregnancies 
2 0.0816 3.0 
3 or more 0.0533 2.0 
26 to 35 -0.0668 -3.3 
Age 36 to 45 -0.0127 -0.6 
Over 45 0.0453 1.5 
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9.2.3 Discussion 
This was a first attempt at designing a conjoint analysis and at this stage 
hoped to explore its potential of discovering what women want from their 
management whilst gaining experience of the design process and use of this 
type of questionnaire. The fact that these results confirmed that women do 
make different decisions based on their past experiences and current life 
situation is a bonus and suggests that the development of this as a tool for 
assessing the decision making process in clinical care an exciting prospect. 
With thanks to Mr. G. Whelan and Dr. A. Fowkes, Institute of Transport 
Studies, University of Leeds, for their help in the analysis of the Conjoint 
Analysis. 
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9.3 Salpingectomy versus Salpinaotomy -a Pilot Trial to 
Compare Reproductive Outcome. 
9.3.1 Method 
When surgery was first used in the management of ectopic pregnancy, the aim 
was to save the woman's life by the cessation of the bleeding. This 
necessitated the removal of the fallopian tube along with the ectopic pregnancy. 
From the 1970's onwards, with earlier diagnosis, there was a move towards 
more conservative surgery with preservation of the fallopian tube, in the hope 
that this would improve the reproductive outcome. In their paper reviewing the 
management of ectopic pregnancy, Yao and Tulandi concluded that 
"conservative surgery may provide a subsequent intrauterine pregnancy rate 
that is at least as comparable to or possibly higher than that after radical 
surgery. Unfortunately, the recurrent ectopic pregnancy rate also may be higher 
after conservative surgery. "(Yao and Tulandi, 1997) Their review looked at nine 
retrospective studies, commenting that to determine the optimum treatment a 
trial randomising women to either conservative surgery - salpingotomy, or 
radical surgery - salpingectomy, would be needed. Such a trial has not yet been 
performed. 
I wished to examine the feasibility of such a trial and designed a pilot trial with a 
view to following women up post-operatively to determine the site of their next 
pregnancy. If the pilot trial proved to be successful, our aim was to design a 
large scale, multi-centre trial. 
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Inclusion criteria 
" Haemodynamically stable patients with their first ectopic pregnancy. 
" The ectopic pregnancy must be unruptured at the preliminary laparoscopy. 
"A healthy contra-lateral fallopian tube at the preliminary laparoscopy. 
" Written informed consent must be obtained. 
Exclusion criteria 
" Patients with a cornual ectopic pregnancy must not be entered into the trial 
9A fimbrial ectopic pregnancy (those feasible to being milked free of the 
fallopian tube 
9 An unhealthy contra-lateral tube (as defined by the presence of adhesions, 
visible tubal damage, nodularity and inability to inspect the fimbrial end of the 
tube). 
Women with a suspected ectopic pregnancy were recruited to the trial prior to 
going to theatre. Once the ectopic pregnancy was confirmed, a telephone 
randomisation line was contacted, resulting in the patient being randomised to 
either salpingotomy or salpingectomy. A postal questionnaire was to be sent out 
twelve months later to determine the number and site of pregnancies conceived. 
9.3.2 Results 
Recruitment required a detailed explanation of the aims of the trial: 
1. with salpingotomy the hope was that there would be a greater chance of 
a conception, as both tubes were preserved, but that this might be at the 
expense a greater risk of a further ectopic pregnancy 
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2. with salpingectomy the chance of a pregnancy in the future might be 
reduced as only one tube was preserved, but the risk of a second ectopic 
pregnancy might be less. 
Recruitment was between June and December 1999. In that time there were 47 
ectopic pregnancies. Two cases were not analysed their case notes were lost and 
A 
it was not possible to verify the inclusion criteria or treatment given. Of the 45 
women remaining, 40 were not recruited. In 37 their history and/or the findings 
from past laparoscopies clearly excluded them. The reasons are shown in Table 
9.4. 
Three women would have been suitable for the trial, but were not recruited. All 
other women either had a pre-operative or intra-operative exclusion factor, or 
did not wish to be randomised as they had a treatment preference pre- 
operatively. These women who did not wish to be randomised, fell into one of 
two groups; those with a prior history of subfertility chose salpingotomy, those 
with no history of subfertility chose salpingectomy. 
Five women were successfully recruited, but only one randomised (Table 9.5). 
Two were not randomised because of a failure in the randomisation line, one 
because of contra-lateral tubal damage and the other the surgeon 
misunderstood the aims of the trial. 
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Table 9.4 Reasons why women were not randomised to the trial of surgical 
management of ectopic pregnancy. More detail can be found in appendix 14 
where each patient is given with details of why they could not, or preferred 
not to be, randomised. 
Reasons for exclusion number 
PID/tubal damage/past sterilisation 9 
Patient requests salpingectomy 9 
Patient requests salpingotomy 6 
Family complete 2 
Ruptured ectopic 2 
Haemodynamically unstable 2 
Unicornuate system 1 
Previous ectopic pregnancy 1 
Ectopic pregnancy not found I 
Cornual ectopic 1 
Refused randomisation 1 
Failed recruitment 43 no discussion 
1 paranoid schizophrenic 
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Table 9.5 Women successfully recruited to the trial 
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956095 27.11.66 yes yes yes no no no yes 
958114 30.12.65 no line failure yes yes no no no yes 
904065 2.1.79 no line failure yes yes no no no yes 
848796 12.3.72 no left tubal disease yes yes no no yes no 
477143 5.2.63 no surgeon did not yes yes no no no yes 
randomise 
In summary, there were 47 ectopic pregnancies over the seven month period of 
the trial, it was possible to analyse the records of 45. Only seven women were 
suitable for randomisation during this time but only one was randomised. This 
was a great disappointment! 
When designing the trial it was estimated that approximately 800 women would 
need to be recruited. The number of patients was dictated by the assumption that 
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to demonstrate a 10% improvement in subsequent fertility is of clinical 
significance. Based on the evidence of the Yao and Tulandi (1997) review the 
subsequent fertility rate, with conservative surgery, was taken to be 57%. In order 
to demonstrate a 10% difference (with an 80% probability and 5% level of 
significance) 388 patients per trial arm would be needed. 
9.3.3 Discussion 
My attempts to recruit for the pilot trial of salpingectomy and salpingotomy were 
unsuccessful because either women were unwilling to be randomised or they 
were not clinically suitable. The recruitment required an explanation of the 
reasons for a trial - the desire to increase future fertility as much as possible 
whilst being aware of the possibility that tubal preservation might increase the 
risk of future ectopic pregnancy. If women had no prior history of infertility, they 
preferred to have radical surgery, apparently fearing the possibility of a future 
ectopic pregnancy above their fear of infertility. Those women who had 
conceived an ectopic pregnancy against a background of infertility chose 
conservative surgery, wishing to maximise their chances of achieving an intra- 
uterine pregnancy in the future. Their analysis of the situation is supported by 
the literature - women with a history of infertility prior to their ectopic pregnancy 
are least likely to achieve a subsequent intra-uterine pregnancy. The exceptions 
to this are the women who became pregnant through assisted conception who 
chose bilateral salpingectomy. They have accepted that natural conception is 
not an option for them and perceive a greater chance of successful assisted 
conception (and reduce the chance of ectopic implantation of an assisted 
conception) if as much of their tubes as possible have been removed. 
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A pragmatic approach to a trial comparing radical and conservative surgery for 
ectopic pregnancy - accepting that patients will choose their treatment, rather 
than agree to randomisation - would be inappropriate. The group most likely to 
choose conservative surgery is least likely to achieve an intra-uterine 
pregnancy and so a comparison with those choosing radical surgery would not 
be valid. From my experience, it would not seem possible to compare patient 
choices for surgical management. 
9.4 Summary 
Whilst my attempt at Conjoint Analysis was limited in what it showed, it did 
demonstrate that women do attach different weight to various outcomes. It is 
this very variation that meant ROCET failed - what was seen as a result in the 
Conjoint Analysis lead to a failure to recruit in ROCET ie women make choices 
when offered options, and those choices will differ according to her life 
experiences. 
This is why tools, such as conjoint analysis, that provide a way of measuring 
how much patients will trade the different advantages and disadvantages when 
choosing one treatment above another are interesting 
The ROCET pilot suggests that concerns about future fertility are not the only 
influence, and the fear of another ectopic pregnancy leads women, who have 
not been concerned about their fertility in the past, to trade a possible increase 
in the intra-uterine pregnancy rate for a reduced risk of another ectopic 
pregnancy. 
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Whilst I failed to shed any light on whether or not conservative management 
offers any advantages to women with an ectopic pregnancy, what is clear is that 
women can make decisions about what is "best" for them. "Best" might not be 
what the doctor considers to be most advantageous, but women can make 
decisions about what treatment addresses their own fears and aspirations for 
their own future pregnancies when they are given information and choice. Any 
protocol for the management of ectopic pregnancy should include a choice of 
management options and advice on when each option is appropriate. The 
protocol I wrote for use in the Early Pregnancy Unit in Leeds includes guidance 
on the management options that can be considered when an ectopic pregnancy 
is diagnosed (Appendix 14). 
Conclusions 
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Epidemiology of Ectopic Pregnancy 
9 There is a world-wide increase in the recorded incidence of ectopic 
pregnancy. Several factors account for this increase. 
  Better diagnostic tools leads to an increase in the number 
of ectopic pregnancies being detected. 
  Changes in patterns of sexual behaviour - for example a 
greater number of sexual partners, increases in the time 
between first intercourse and first pregnancy, greater 
spacing between pregnancies - means more women are 
either exposed to Chlamydia and have the opportunity to 
develop pelvic damage as a result of this exposure prior to 
conception. 
  Changes in reproductive practices, both the introduction of 
assisted conception techniques and the use of 
contraceptives that reduce the incidence of intra-uterine, 
but not extra-uterine pregnancies have an impact on the 
number of pregnancies that implant outside the endometrial 
cavity. 
As ectopic pregnancy has a significant associated mortality and morbidity, it is 
good that a greater number of ectopic pregnancies are detected. However, if 
increased detection leads to an increase in therapeutic procedures in women 
who would have previously never known that they had an ectopic pregnancy, 
that in turn have an associated morbidity and mortality, this is not desirable. It is 
as important to recognise when methods, other than surgery, would be more 
appropriate. As diagnostic methods improve detection, it is imperative that 
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management protocols are developed to ensure safe treatment, with full 
consideration to medical and conservative management options 
Reducing mortality and morbidity associated with ectopic pregnancy. 
There are two important components to this. 
" Increase awareness of pelvic infection particularly with Chlamydia 
both to reduce the incidence of infection, and to prompt rapid and 
effective treatment when infection has occurred. 
" Increase awareness of ectopic pregnancy amongst both patients 
and health care workers. 
Those countries that appear to have reduced the incidence of ectopic 
pregnancy have done so by tackling Chlamydia and the sequelae of this 
infection. This requires, firstly, population-wide knowledge of prevention of the 
infection, but secondly the importance of rapid treatment and screening for the 
asymptomatic infections. Prevention of chlamydial tubal disease will reduce the 
number of ectopic pregnancies that occur in the long-term. 
If an ectopic pregnancy occurs, early presentation widens the management 
options and reduces the risk of major haemorrhage before diagnosis and 
treatment. A wider general awareness of ectopic pregnancy and direct access 
to Early Pregnancy Units for women in early pregnancy would reduce some of 
the obstacles to early presentation. It is also important to increase awareness 
amongst health care professionals, so that the diagnosis is considered, 
particularly in General Practice and emergency medicine, where the possibility 
of pregnancy is not as high on the agenda as in gynaecology. 
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As recurrence is a complication of ectopic pregnancy, it is important that women 
are instructed to have an early scan when they next become pregnant, even 
when they are asymptomatic. They should have unrestricted, direct access to 
Early Pregnancy Units for this. 
Early Pregnancy Units allow organisation of services and expertise, facilitating 
rapid access to ultrasound and allow standards of diagnosis and management 
to be set. Protocols can set these standards and can be used as the basis to 
audit practice and ensure that these standards are met. They are the best place 
to deliver management choices to women. 
Diagnosis of ectopic pregnancy. 
Laparoscopy has been considered the gold standard for the diagnosis of 
ectopic pregnancy, as it allows direct visualisation of the ectopic itself. It is a 
management intervention in its own right; it is not 100% sensitive and has its 
own associated mortality and morbidity. If laparoscopy were required in the 
management of all ectopic pregnancies, it would be inappropriate to offer this in 
combination with either medical or expectant management, as this would 
expose the patient to the risks of two management options. If an ectopic 
pregnancy is diagnosed by laparoscopy it should be managed surgically. 
In reality, diagnosis is reached by a combination of clinical findings with 
ultrasound and biochemical (largely hCG levels, but progesterone has a similar 
role). None of these three are adequately accurate in isolation, and even 
together often resulting diagnostic uncertainty 
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" Clinical findings are neither sensitive, nor specific and can be misleading 
when taken in isolation 
" Transvaginal ultrasound is most useful when it excludes ectopic 
pregnancy. Whilst it can confirm the presence of an ectopic pregnancy, 
when a fetal heart pulsation is found in the adenexum, it more often just 
sets the level of suspicion by finding an adnexal mass. Endometrial 
stripe thickness is of no value in predicting ectopic pregnancy. Adnexal 
masses and fluid in the Pouch of Douglas both increase the probability of 
an empty uterus representing an ectopic pregnancy. 
" Biochemical testing - single hCG levels are of limited value. Their 
sensitivity can be increased at the expense of specificity by reducing the 
discriminatory zone. Paired levels, 48 hours apart, are the optimum 
method of using hCG estimations but ectopic pregnancies can give a 
normal rise. hCG estimations are only meaningful in the presence of an 
ultrasound scan when an intrauterine pregnancy (viable or non viable) is 
not found. 
If a laparoscopy is not performed, the woman being managed non-surgically, a 
histological diagnosis is not reached. In many cases an ectopic pregnancy 
would appear highly likely, in others there would be more doubt. A label of 
trophoblast of uncertain location might be used, but these women should 
always be thoroughly followed up as for an ectopic pregnancy, in the index and 
subsequent pregnancies. 
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An ideal diagnostic test would differentiate between ectopic pregnancy, normal 
early pregnancy and failing intrauterine pregnancy, and would achieve this at 
the first time of testing, it would reach diagnosis at an early stage, reducing the 
risk of cardiovascular compromise and would result in a reduction in 
unnecessary laparoscopies. 
The role of fetal fibronectin in early pregnancy 
The role of fetal fibronectin has been studied extensively in the latter stages of 
pregnancy, with premature labour beixj the main indication for its use. In this 
case a positive result not conclusive, but a negative result is reassuring, with 
there being a low chance of ensuing labour. Fetal fibronectin, as a predictor of 
premature labour, is available commercially, and is used world-wide in the 
prediction of premature labour. These commercially available kits use the 
antibody directed against the FDC-6 epitope, which is considered unique to the 
onco-fetal form of fibronectin. 
To date, two papers have been published which use this same assay to detect 
fetal fibronectin in early pregnancy. It was used at the time of acute 
presentation, and although some differences between uncomplicated and 
complicated early pregnancy were found, the differences were not useful in 
diagnosis. 
set out to see if fetal fibronectin might be useful as a predictive test to 
discriminate between normal and complicated early pregnancy, firstly to 
improve the detection of ectopic pregnancy and secondly to increase the 
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therapeutic options available to women in whom an ectopic pregnancy has 
been diagnosed by reaching a diagnosis at an early stage. 
Whilst the assay for fetal fibronectin is in wide use, my work shows either it 
does not specifically detect the onco-fetal form of fibronectin, or the onco-fetal 
form of fibronectin is found more widely than has been assumed before. Whilst I 
found higher levels in normal early pregnancy of less than 9 weeks, and that the 
assay was consistently positive, to varying degrees, when an ectopic pregnancy 
was found, it is not possible to say whether this reflects differing levels of fetal 
fibronectin, or is merely a feature of contamination with maternal blood. Nor 
does it differentiate between ectopic pregnancy and other pregnancies, as the 
assay was positive in at least a proportion of all pregnancy groups. 
Whether or not fetal fibronectin is useful in differentiating the complications of 
early pregnancy has not been answered. This would require an assay that was 
not positive in the presence of maternal blood. I attempted to acquire the 
antibody used in the work of Feinburg and Wang (1994), without success. 
The assay, itself, also proved problematic. If it had seemed that this assay might 
prove useful in differentiating the problems of early pregnancy it would have 
been important to explore these problems further. However, by the stage that 
the extent of the problem was apparent, it was also clear that any test using this 
antibody to detect fetal fibronectin would not be a useful diagnostic tool. 
As different early pregnancy diagnoses did result in differences in the levels of 
fetal fibronectin detected, it is possible that fetal fibronectin may yet prove 
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useful, if an appropriate assay is used, probably in combination with other 
markers. 
Management of Ectopic Pregnancy 
The primary objective in the managing of ectopic pregnancy is that the 
treatment used is safe i. e. that it avoids maternal death and minimizes 
morbidity, either from the complications of ectopic pregnancy or from the 
complications of treatment. Whilst ectopic pregnancy remains an important 
cause of maternal death, it is an uncommon complication, and most women 
who are faced with ectopic pregnancy will be more concerned with the 
associated morbidity. Ectopic pregnancy is associated with reduced subsequent 
fertility, recurrence of ectopic pregnancy in the future and persistence of ectopic 
pregnancy after treatment. The morbidity associated with the method of 
treatment must also be considered. 
Surgical Management 
Laparoscopic management has been conclusively shown to offer benefits over 
laparotomy to the patient, and should be considered the gold-standard for 
surgical management. These are short term benefits - with reduced blood loss, 
analgesic requirements and hospital stay. In the long-term, fertility and 
recurrence of ectopic pregnancy are similar for the two methods. There is a 
higher risk of persistent ectopic pregnancy with conservative laparoscopic 
management of ectopic pregnancy than with laparotomy. 
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When salpingectomy is compared with salpingotomy, there is no clear 
advantage of one procedure over the other, with similar long-term fertility and 
recurrent ectopic pregnancy rates, but there is a higher rate of persistent 
ectopic pregnancy. 
Medical Management 
Medical management predominantly uses methotrexate. It avoids the operative 
complications of surgical management and the recognised side-effects of 
therapy can be greatly reduced by single dose therapy. To be able to use 
medical management it must be possible to reach a diagnosis of ectopic 
pregnancy without resorting to laparoscopy, otherwise medical management will 
result in the patient being exposed to the potential complications of both 
treatments. Local infiltration with methotrexate, either laparoscopically or under 
ultrasound guidance, is to be discouraged as it has a lower success rate, whilst 
exposing the patient to similar systemic levels of the drug. 
The only factor that has been consistently shown to predict the outcome of 
medical management is the hCG level. If a cut off of 2,000miu/ml (3'd IS) is 
chosen, this not only has a 93% chance of success, but is also ties in with the 
discriminatory zone for an intra-uterine gestation sac on transvaginal 
ultrasound. Paired hCG levels should be used, as a sub-optimal rise gives 
further support to a non-viable pregnancy - to over-treat a miscarriage with 
methotrexate is acceptable, to miss a viable intra-uterine pregnancy and give 
methotrexate is not. Herein may lie the factor determining the success or not of 
medical management, it is not so much the actual level of hCG that determines 
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the success, or not, of medical treatment, but the rate of division of trophoblast 
reflected in the rate of change of hCG levels. Perhaps those ectopic 
pregnancies that can be successfully treated at higher hCG levels are those 
where the rate of change of hCG levels is low, many of which might be failing 
anyway. 
Expectant Management 
lt would appear that the natural history of ectopic pregnancy is to resolve in 
around 50% of cases. This is, however, at a high cost, with those women with 
failed expectant management frequently requiring emergency surgery; it is not 
an option that is suitable to offer to every woman. It appears to be most 
successful when the initial level of hCG is <2000mi/ml and the paired level 48 
hours later is seen to fall. 
All methods of management seem to have similar rates of subsequent intra- 
uterine pregnancy. The conservative treatments all appear to have similar rates 
of recurrent ectopic pregnancy, and this is higher than with radical surgery 
It should be remembered that persistent ectopic pregnancy is a potential 
complication of all management of ectopic pregnancy. In any case which is 
managed conservatively (conservative surgical, medical or expectant 
management), hCG levels should be tracked to non-pregnant levels. 
Each of the treatment options seem to result in similar subsequent fertility rates 
Whilst the primary aim is to ensure the woman is safe, there are a substantial 
number of occasions when there would be more than one appropriate treatment 
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option available to a woman. Women value choice and discussion of their 
choices, but also, my work demonstrates that they are able to weigh the 
implications of those choices in light of their own circumstances. 
Future work. 
Although the assay side of this thesis produced disappointing results, there was 
enough there to encourage me to think that there will be biochemical markers 
for early pregnancy problems, particularly ectopic pregnancy. Since I am now 
working in an early pregnancy unit, I am keen to continue this work by 
assessing different methods of sample collection and analysis. Although HVS 
sampling had a lower positive rate, it does have some advantages with the 
possibility of self testing. Other markers of trophoblast activity should be 
studied, particularly the cytokines and growth factors. 
I do not feel that this chapter is yet closed. 
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Appendix I 
HOSPITAL SURVEY OF EARLY 
PREGNANCY UNITS 
Thankyou for taking time to complete this questionnaire 
Name and address or 
¢ Does your hospital have an Early Pregnancy Assessment Unit (ie provision 
for women with problems in early pregnancy to be assessed without an 
inpatient admission)? 
yes / no please ring 
1. If your hospital does have an EARLY PREGNANCY 
UNIT: 
¢ please indicate when your Early Pregnancy Unit Is open and the times that 
ultrasound scanninn in available within the Fariv Praanancv Unit- 
Da Time Open Time Scanning Available 
Monda 
Tuesday 
Wednesday 
Thursday 
Friday 
Saturday 
_ Sunday 
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2. Thinking about ultrasound assessment in all units 
¢ If : 
0 either your unit does not have an Early Pregnancy Unit, 
" or, for units with an Early Pregnancy Unit, at times when this unit is closed, 
please indicate when you would expect to have access to ultrasound assessment: 
(eg scanning in the main ultrasound department, scanning on the ward which is 
dependent on whether an appropriately trained member of staff being on call) 
day Time scanning 
always available 
Time scanning 
might be available 
Monday 
Tuesday 
Wednesday 
Thursday 
Friday 
Saturday 
[Sunday 
¢ Does your unit have access to trans-vaginal ultra-sound scanning? 
Please tick the box closest to your situation 
Yes - whenever indicated 
Yes - limited access 
No 
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3. Thinking about ectopic pregnancy 
If a diagnosis of ectopic pregnancy is suspected in an asymptomatic patient, 
please indicate which of the following might be considered in your unit. 
Tick as many options as necessary 
d) 
N 
m :3 :3 
m 
Ö C N 
Z fA U) 
Ultrasound 
serum ßhCG level 
Urine ßhCG 
serum progesterone level 
¢ Does your unit have a written protocol for the diagnosis and management of 
ectopic pregnancy? 
yes / no please circle 
If your unit does have a written protocol, please could you enclose a copy. 
If an asymptomatic woman has a suspected ectopic pregnancy, but further review 
is indicated before a diagnostic procedure, how would she be managed In your 
unit: 
As an in-patient 
As an out-patient 
EEJ 
4. Medical Management of Ectopic Pregnancy 
Does your unit ever manage confirmed ectopic pregnancy medically? 
yes / no please circle 
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If ves. Dlease indicate the methodls used: 
Local methotrexate 
Systemic methotrexate, 
Other local agent Please seci 
Other systemic agent Please sspecify 
5. Surgical Management of Ectopic Pregnancy 
The next question is about the laparoscopic management, not 
diagnosis, of ectopic pregnancy 
¢ Does your unit manage confirmed ectopic pregnancies laparoscopically? 
Yes - if appropriate, always 
Yes - if appropriate, sometimes 
no 
Number in 
unit 
Number managing ectopic 
pregnancy la arosco icall 
Consultants 
Middle grades 
If yes, please indicate which doctors, In your unit, are able to manage 
ectooic oreanancies lanaroscopically 
If your unit manages ectopic pregnancy laparoscopicaily, but Is not able to 
do so on every appropriate occasion, please indicate why: 
(you may tick more than one) 
Appropriately trained staff not always 
available 
Facilities only available in normal working hours 
Facilities only available out of normal working hours 
¢ During the surgical diagnosis or management of ectopic pregnancy, Is it the policy 
of your unit to record the state of the patients affected tube? 
yes / no please circle 
¢ During the surgical diagnosis or management of ectopic pregnancy, is it the policy 
of your unit to record the state of the patients unaffected tube? 
yes / no please circle 
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If yes: 
" Would these findings be routinely discussed with the patient after the 
operation? 
yes / no please circle 
" Would the implications of these findings, with regard to her future fertility, 
be routinely discussed with her? 
Yes - post-operatively 
Yes - at an out-patient 
no 
6. Follow-up after an Ectopic Pregnancy 
If a woman has had an ectopic pregnancy, how long would you advise her to wait 
before trying for another oreanancv? in for another pregnancy 
No wait 
After next period 
Specified time Please indicate how long 
¢ Do you offer a follow-up out-patient appointment for women who have had an 
ectopic pregnancy? 
yes / no please circle 
¢ Do you offer an early pregnancy ultrasound scan, to women who have had an 
ectopic pregnancy, in their next pregnancy? 
yes / no please circle 
Is counselling offered to women who have had an ectopic pregnancy 
yes / no please circle 
" If you have answered yes, please state who does the counselling (eg 
Early Pregnancy Unit nurse, psychologist etc) 
------------------------- 
Is this person trained in counselling? 
yes / no please circle 
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¢ Does your unit have information leaflets for patients who have had an ectopic 
pregnancy? 
Yes - produced by the unit 
Yes - produced by an 
external agency Who? 
no 
¢ Are there support groups available to women in your area who have had ectopic 
pregnancies? 
yes / no please circle 
" If yes, please state the name(s) of this (these) support groups: 
local / national 
local / national 
local / national 
local / national 
" Is it the policy of your unit to pass on information about support groups to 
patients who have had an ectopic pregnancy? 
yes / no please circle 
¢ Are you aware of the existence of. 
The Miscarriage Association? yes / no 
The Ectopic Pregnancy Trust? yes / no 
please circle 
7. Research into Problems in Early Pregnancy 
Would your unit be interested in taking part in a trial looking at 
Ectopic pregnancy yes / no 
Miscarriage yes / no 
please circle 
" If you have answered yes to either of these, please could you Identify a 
person we could contact in your unit 
BEST COPY 
AVAILABLE 
Variable print quality 
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Research Questionnaire 
The Ectoptc Pregnancy Trust do Hillingdon Hospital, Maternity Unit 
Piela Heath Road Uxbridge. Middlesex, U68 3NN 
Re¢sioied Chary No %071 a1' Telephone 
No: 01695 238025 
f1. PERSONAL DETAILS 2. PREGNANCIES YOU HAVE HAb 
Neure: 
Add/HI'. 
{yo. r name ano address are 
useful for us to contact Yea 
In the future. Planara do not 
complete IF you wlsn to 
14mal, "no, ywat. I 
Dat. of P 41h. 
[Ihn¢ O,, yin: 
4"1 yhlc4 of both, bul In" 
"lhnlc plaup lo whldl yo. 
W1on9) 
Co You fine&q. 
Oo row know anyoM O1" 
pinonally whe has had an 
aclopic pmpnancy? 
Have you £utf. r. d from or 
mcNwd tn. tmont tOr *my of 
it'. bllowmp cantlilrons prior 
lo your Ill Ecloplc 
Pregnancy? 
Of you haw "acmed 'crt"hty 
.. [amen?, ' ma, be 
nRCt53ary (0 (On-'act you At IN 
i(er stage m . Had On ro tre 
"TOe Of `/carment va'. may 
have had 
luck Afr. esn Cl 
llact AfrO. CNi. O.  n O 
Fufopeýn O 
Ina) n O 
pJMlsYnl O 
!  noNdon O 
a lint. O 
M dlbrr nHn O 
Whu lOM. r O 
aln. r yrar... V. cýry 
Yaa 
No 
OIYOn Up 
Q 
O 
0 
L1 No 
Mother O 
DauQl r C 
Suar Q 
Olh4r flood RauUV" C 
Owor RNative C 
F, rd a 
Pelvic m4CNOn O 
CnAomlitrbSn 
nod a Coo (0001 C 
U.. d tn. U. Pol Q 
CnuTydi& O 
C.., av.. n äecI on D 
AppgnOKlht 0 
Abortion O 
Mlocarrna" O 
AbdornN4I {rVCC O 
Tubil sugary O 
FlitllIy Traahnant O 
aac d 
3w, -t- 0 
Now Many /n. nancba non y. na? 
TIP& of 
ºr. Enancy 
TOlal No. lehr. 
bl lclePýe 
No Alp,, 1*1 
EcIopI 
lclePKa 
Misc Sit elf 
siN 01nn. 
Tarn, mWona 
If Va. Aa.. fad men than lot 04116 
on. PCIA01º or"WNner 
plea4. Iwt them n d. 1. Ind Ort.: 
older 
$14 Dote 
4V. Oily 
3. EXPERIENCES OF YOUR IST 
ECTOPIC PREGNANCY 
1n, ro, *-R0 twºioN N. ,... I rvur .. p. d bc. .fy. W 1.1 i. 1. p. 
prederwº II yev V.. w hod mere the" One Celapic Pngn. nc. thin 
ý1ºýa. a. w. ý1.1. .. º. i. M H+.. 1 tar loll . n. Addltl. n. l hwtº can 
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0r90eewonal? 
Ye.. r'"y lick m.. Min we 
answer 
"btlamm"I Pal. 0 
vegemal aloadha Q 
S"MI ºrobI. 111a Q 
Fooling ºalnl Q 
V. mNNn/ Q 
Palo In M Ihoulder 
P. Mbis Unwell O 
pldntnp Q 
Lala p. no0 Q 
To report bhrp pol D0an1 O 
To ha.. $can because of 
PA+iouw . cwpic Q 
kbn f0Noring IVº or 
atl. r IN"IIIIIA. vrosi IM1 Q 
Sudd"o coII"p"" D 
PMU" ab. d"1"b. .1 "ny 
other lym loma row bui 
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py whlCh HuNh Cnra 
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Die your tuberuMor.? r.. 6. PREGNANCIES YOU HAD AFTER 
NO 0-1 THIS ECTOPIC Knvx "J 
Was your tube romovsV No c Plesie Ia .uM. bpUon, 
Porllspy rsmo+so O 
before 4180- 0-. 9 . vhn: A OM Is 
M. "m .d Complolsky J 
to yaw, artual1Dn. 
0. WIKnow C 
Which tubs W43 ofr t? Rpht O 
Loft 
Don't Kgow 
Do you 10.1 you wir. alvnn Yea 
an adequarp ellplsnatlon of No C 
Ma tttstmcn17 Don't Know O 
Ls. 
AFTER YOUR TREATMENT 
Wsn you Informed of the Yss I? ko O 
rtaki of future sctapIca9 
Wirte you advfaid to havrt to Yýý 
early dean whop you n. xt No O 
bace. d prnpnünl to C1140 It Don t know O 
weI in mo ripen piece1 11 
Have fau tuft&trd rm. a. r 
Did the health proioaslonai Yet 0I medical pioahma thci 
who boktd arter you. live having ypur actoplc that peu 
you InFormarlon about lobar No Q dm nor n Vs before and that 
or naBanal support prvupaT you food could 0* aoooculsd 
. "h rte... alopt 
9rºA^+ýcr a 
Wars you *Ivan any wr+ttrn vote O No D 
In lot"railon lOout actoplt. ill ya , rrom which 
Dfr9 *cu prior to Iitrrvm0 orwIs Alion) 
the noapiI&l? 
L-. I 
HOW HAS THE ECTOPIC PREGNANCY TRUST HELPED YOU? 
If you conlxcl. d tho Tmsl pMA$. 
Ied1CINS tl . by. I. wh, Ch 1biy 
hIlp. tl you? 
Ou you think rn. ri 14 o need to, 
the ectopic pregnancy Trust and 
IF H wnýl FvQ, P 00 o OYId (hey 
prowdv? 
Would you be nhrn. l. d In 
becoming a m. nbor of The 
Ectoplc Pregnancy Trust? 
Provided you with wttht. n udonnaHo. wh. ci you dW nN )lov. O 
Offered suppQti ever lot losepow-P7 13 
put you is touch *-Ih "aedonc me who 7t4,111 Moll On lcIopIC P. gnoncy b 
Infel Ttllgtt LM1t 0 
1. jppo 1 Afoi pi LCC/11V a 
. nloýmitierl 
0 
Rteearcn 0 
One tu One Conlicl pith other we. en the Aare h. d EcI IC6 
0 
oln. r (ples. 0 tpecIhl 
Yu 0 Pl.... t. 'tl ug An . prmcalgn form) 
No 0 
Would you hav* any objection to us contacting you in end tutu. a ahaud Wit ntajwe any ta. tho ^totmabpn in gbtqn to Nr anawoq you 
hava alvon in this quaadonnluoi 
yes O No C 
Appendix 2 
17. HOW HAS THE ECTOPIC PREGNANCY AFFECTED YOUR LIFE 
PIalaa ilal OR un MOat Imporbnl [nango to yowl gwdMty of Ido and wahleng Ui) harr n, MIItd 7mal VOW SCt9OI VnVMnCy. PlNaa 
start with IM ,. at ImaOMunt 4nanpua and canllnua cn a aaparan NFL d n«t, Hary 
Areal yoo --QMM canºlog, .,. - 
Phys. cal chengei -to abdanma1 pFFn. 
Cmotrunal Changes - ep worne. abaut bea0n1M9 PI*9nanl amain. 
Effeet en ynur fom, ly - of 0@, ual rdananihlp -th y.. pA., er 
MAY WE Tint 1n"S CPOQRTUNITV QO TMAl"'NG vOV OCR CCMP. ETIYG THIS QUCSTIONNA1RC AND $MOULD YOU HAVF ANY 0VIITION1 RElAT"dG `O 1 t«&N ILEA S6 , nNT&CT OUR Or, . CE EN COMPILINO THE DATA GIVEN IN THIS QUESTIONNAIIL IT IS HOPED THAI WE CAN HELP 10 DIAGNOSE rCTnr, S PROCNANCISS EARLIER AND MAKC ADVANCES IN THE TREATMENT AND MAMAQEMIENT Of LOTOPIC PREONANC: ES 
CO) 
x 
V 
c 
CL CL 
4 
ai 
ß 
'O 
.3 
C 
O 
.y 
ß 
ea 
E 
N 
H 
d a 
E 
co 
Co 
CD Ö Ö N Ö L1, ) 0 tx) 0 Ln 0 U') Ö 
Ö 
i 
Ö 
Ö o Co 
O 
Ö 
V V V 0 O 
p 
CD 
0 
V V O V 
C O O 
0 v- O Q O 
Co 0 
U' U) 
Ni 
T 
O 
O 
T 
N 
= V 
Ö 
T 
Co 
0 c» 
O 
M 
N 
Lf) 
z M 
(D 
Ö 
v 
N- 
LO LO W O 
to 
r 
LC) r 
ONO 
,, (Z) 0 ý 
ö ý 0 0 0 0 ö ý ° 0 0 ö N 
Z N 
O 
.. T 
Co , (0 ul C Ö Ö 0 
C 
Q v 43 
O O 
N 
O 
O oV 
r+ 
E 
En 
= 
CO 
N O 
M 
N A 
O CO 
0 N. N 
^ 
- 
O V O 
p Ö V Ö O O 
= N 
Q 
ý CD N. 1) n 
0 0 41 r"- o 
t 
T r O v, 
ci 0 0 C> CD 
A Co 0. M E N 
Co 
Co P. 
Q M Ö "" N M 
0 
N 
if 
T 
m 
O 
O) 
O 
O 
Co 
T 
m 
O 
e 
O 
2 
e 
r 
(C 
N 
M 
h 
O 
d 
O CO) 
Co 
9 M 
. 
N 
ýA 
ý 
Co 
M 
r l 
r 
r 
O O 
r O O r ( p O D C _ Ö N ýp en Ö - Ö ý{ N Ö S E . - 
r r gy r O t'7 le O I2 1, ý Co 
00 
O O LA 
o 
0 
N 
t- f- 
c D 
O 
M r 
e- 
r- 
e- 
r 
T 
N T M m 
Co 
r2 M 
O N f- O 
141 
N 
0 j tt') ýD 
1 
<O t0 (O f- f- t- 1. º1- 1- 
C 
CV) 
x 
ä 
Q o ö 
r 
ö ö 
e V 
°v n Q v 
ö 
v 
'a 
o ++ o 0 ö 
TI» 
ti 
ý 19) 
"0 Ln vi Lo 0 
oý V ^ ö o o 
ö o o o 
N 
lt) 
ý 
CY) 
in ö r, - 
N 
% -ab ý N o O O O O O O p 
V 
Z aý M U) N 
Iý r 
ý? 
O 4ýf p p 
. ý 
N O N 
O 
M 
Ö e O 0 O O 
O 0 O 
C N 
r O C ý 
O Ö 
ý 
Ö Ö 
N 
Ö Ö Ö 
A 
Ö 
N Ö Ö Ö 0 0 V OV 
V 
d 
O 
it) O LO 
O 
U) U) 
M 
ý+ O 
O 
V 
O 
V 
O 
V O V 
C 
E 
N M 
Co ^ 
OD 
Z 
01 
ai OD 
Co 
f0 
O 
1n 
0 
Iý r N Oý 
u3 
. - 
O 
00 
In 
Iý 
r 
eý 
(O 
(p 
O 
N 
M 
Q1 
119 
r O 
to 
- 
0ý 
N 
N 
O 
ß 
O O I 
M 
. yý 
00 
M O I-- 
(O 
N 
f, - 
O 
00 
u3 
r 
00 
N 
o 
r 
m 
e- 
ýp 
f7 
O fý O 
M 
7 
ti 
1 
00 N 
ºA S 
M N Co 00 
ONO 00 00 Co 000 O> m 01 cl (1 0 01 
(p 9 9 ä ~ 0 O 03 C 
Appendix 4 
Samples tested in duplicate at a single assay run 
number date value I 
absorbance nm 
value 2 
(absorbance nm 
960087 29/07/99 0.735 0.724 
952556 29/07/99 0.215 0.207 
952540 29/07/99 0.139 0.133 
947432 29/07/99 0.352 0.355 
943658 29/07/99 0.5 0.506 
941901 29/07/99 0.102 0.104 
932822 29/07/99 0.109 0.108 
880451 29/07/99 0.139 0.137 
796819 29/07/99 0.54 0.564 
772111 29/07/99 0.152 0.156 
702552 29/07/99 0.568 0.626 
698413 29/07/99 0.088 0.105 
560626 29/07/99 0.162 0.185 
524214 29/07/99 0.103 0.101 
493960 29/07/99 0.231 0.232 
429131 29/07/99 0.308 0.321 
407680 29/07/99 0.185 0.173 
397099 29/07/99 0.163 0.289 
312629 29/07/99 0.185 0.18 
111111 29/07/99 0.086 0.091 
968644 15/06/00 0.949 1.005 
965716 15/06/00 0.053 0.066 
952487 15/06/00 0.067 0.066 
946242 15/06/00 0.073 0.075 
934248 15/06/00 0.086 0.079 
910823 15/06/00 0.067 0.066 
903126 15/06/00 0.331 0.337 
871831 15/06/00 0.129 0.126 
713745 15/06/00 0.346 0.358 
646157 15/06/00 0.125 0.149 
619048 15/06/00 0.117 0.098 
582071 15/06/00 0.121 0.122 
497569 15/06/00 0.472 0.436 
331234 15/06/00 0.076 0.08 
Appendix 5 
Plasma samples tested in duplicate at a single assay run 
number date Value I (absorbance 
nm) 
Value 2 (absorbance 
nm) 
958421 28/01/00 0.145 0.147 
958384 28/01/00 0.174 0.16 
958370 28/01/00 0.14 0.127 
913149 28/01/00 0.306 0.297 
Appendix 6 
Samples from women attending the FCU. 
unit number date gestation fFN µg/ml 
674036 13.1.99 5-6 weeks 0 
435187 31.3.99 5-6 weeks <0.05 
491698 4.11.98 5-6 weeks <0.05 
238532 11.11.98 6-7 weeks 0 
943655 11.11.98 6-7 weeks 0 
871850 13.1.99 6-7 weeks <0.05 
941902 21.10.98 6-7 weeks <0.05 
941924 21.10.98 6-7 weeks <0.05 
943226 18.11.98 6-7 weeks <0.05 
702552 27.1.99 6-7 weeks 0.675 
943650 18.11.98 6-7 weeks 1 
945764 16.12.98 7-8 weeks 0 
455223 17.3.99 7-8 weeks <0.05 
784545 18.11.98 7-8 weeks <0.05 
902756 17.3.99 7-8 weeks <0.05 
942658 4.11.98 7-8 weeks <0.05 
944017 18.11.98 7-8 weeks <0.05 
945907 16.12.98 7-8 weeks <0.05 
946641 16.12.98 7-8 weeks <0.05 
948459 27.1.99 7-8 weeks <0.05 
953175 31.3.99 7-8 weeks <0.05 
381493 13.1.99 7-8 weeks 0.495 
243612 13.1.99 8-9 weeks 0 
733059 14.7.99 8-9 weeks 0 
959249 14.7.99 8-9 weeks 0 
959250 14.7.99 8-9 weeks 0 
445539 31.3.99 8-9 weeks <0.05 
493839 14.7.99 8-9 weeks <0.05 
528679 11.11.98 8-9 weeks <0.05 
544387 21.10.98 8-9 weeks <0.05 
547006 16.12.98 8-9 weeks <0.05 
601618 16.12.98 8-9 weeks <0.05 
611492 27.1.99 8-9 weeks <0.05 
667849 31.3.99 8-9 weeks <0.05 
671369 11.11.98 8-9 weeks <0.05 
771208 31.3.99 8-9 weeks <0.05 
942659 4.11.98 8-9 weeks <0.05 
943957 18.11.98 8-9 weeks <0.05 
947440 13.1.99 8-9 weeks <0.05 
947908 3.2.99 8-9 weeks <0.05 
948458 27.1.99 8-9 weeks <0.05 
959244 14.7.99 8-9 weeks <0.05 
890416 18.11.98 8-9 weeks 1 
Appendix 6 
unit number date gestation fFN gglml 
840368 17.3.99 9-10 weeks 0 
878917 13.1.99 9-10 weeks 0 
111119 3.2.99 9-10 weeks <0.05 
306308 16.12.98 9-10 weeks <0.05 
629887 3.2.99 9-10 weeks <0.05 
733823 4.11.98 9-10 weeks <0.05 
863524 13.1.99 9-10 weeks <0.05 
927226 17.3.99 9-10 weeks <0.05 
948511 3.2.99 9-10 weeks <0.05 
948542 3.2.99 9-10 weeks <0.05 
951762 17.3.99 9-10 weeks <0.05 
470749 21.10.98 9-10 weeks 0.065 
698413 13.1.99 9-10 weeks 0.075 
932822 11.11.98 9-10 weeks 0.115 
680294 16.12.98 9-10 weeks 0.765 
773649 27.1.99 9-10 weeks 1 
948454 27.1.99 9-10 weeks 1 
951765 17.3.99 9-10 weeks I 
951817 17.3.99 9-10 weeks 1 
751062 14.7.99 10-11 weeks 0 
794306 27.1.99 10-11 weeks 0 
804054 31.3.99 10-11 weeks 0 
941289 21.10.99 10-11 weeks 0 
578361 3.2.99 10-11 weeks <0.05 
945906 16.12.98 10-11 weeks <0.05 
946640 16.12.98 10-11 weeks <0.05 
948512 3.2.99 10-11 weeks <0.05 
948513 3.2.99 10-11 weeks <0.05 
959248 14.7.99 10-11 weeks <0.05 
941901 21.10.98 10-11 weeks 0.11 
943658 11.11.98 10-11 weeks 0.7 
959247 14.7.99 11-12 weeks 0 
353114 17.3.99 11-12 weeks <0.05 
947445 13.1.99 11-12 weeks <0.05 
948456 27.1.99 11-12 weeks <0.05 
948510 3.2.99 11-12 weeks <0.05 
951818 17.3.99 11-12 weeks <0.05 
947443 13.1.999 11-12 weeks 
IUCD in situ 
<0.05 
650626 3.2.99 11-12 weeks 0.075 
374314 21.10.98 11-12 weeks 1 
560408 16.12.98 12-13 weeks <0.05 
951764 17.3.99 12-13 weeks <0.05 
856525 18.11.98 13-14 weeks <0.05 
943656 11.11.98 13-14 weeks <0.05 
Appendix 6 
unit number date gestation fFN µg/ml 
952540 31.3.99 13-14 weeks 0.05 
952556 31.3.99 13-14 weeks 0.185 
692315 3.2.99 14-15 weeks 0 
544450 31.3.99 14-15 weeks <0.05 
L 959245 14.7.99 15-16 weeks 0 
Appendix 7 
Samples from women attending the recurrent miscarriage clinic 
number date gestation outcome absorban 
ce nm 
fFN 
mg/ml 
554699 15/06/99 3-4 miscarriage - FH not seen 0 0 
111114 29/12/98 4-5 miscarriage - FH not seen 0.018 <0.05 
949908 15/03/99 4-5 ongoing 0.036 <0.05 
772566 14/12/98 4-5 missed FH seen prior to loss 0.013 <0.05 
927417 19/10/99 4-5 ongoing 0.003 <0.05 
948758 27/04/99 4-5 ongoing 0.023 <0.05 
752238 12/01/98 4-5 miscarriage - FH not seen 0 0 
848172 08/02/99 4-5 ongoing 0.012 <0.05 
878675 02/11/99 4-5 ongoing 0.014 <0.05 
941055 22/02/99 4-5 ongoing 0.036 <0.05 
111254 26/07/99 4-5 ongoing 0.013 <0.05 
772566 05/10/99 4-5 missed FH seen prior to loss 0.016 <0.05 
948756 13/04/99 4-5 ongoing 0.009 <0.05 
524127 02/08/99 4-5 ongoing 0 0 
854108 06/07/99 4-5 ongoing 0.003 <0.05 
949910 14/06/99 4-5 ongoing 0 0 
949889 16/08/99 4-5 miscarriage - FH not seen 0.026 0.05 
938876 21/10/99 5-6 miscarriage - FH not seen 0.026 0.05 
111115 30/12/98 5-6 miscarriage - FH not seen 0.009 <0.05 
771068 09/03/99 5-6 ongoing 0.038 <0.05 
880451 05/07/99 5-6 ongoing 0.056 0.165 
917067 07/12/98 5-6 miscarriage - FH not seen 0 0 
511345 28/06/99 5-6 ongoing 0 0 
432113 23/08/99 5-6 miscarriage - FH not seen 0.169 0.35 
929722 17/08/99 5-6 ongoing 0.025 <0.05 
946242 15/05/00 5-6 ongoing 0.073 <0.05 
407680 12/07/99 5-6 ongoing 0.086 0.23 
713745 13/02/00 5-6 miscarriage - FH not seen 0.346 0.2 
943293 15/04/99 5-6 2nd sac collapsing, other 
ongoing 
0.007 <0.05 
329896 27/09/99 5-6 ongoing 0.005 <0.05 
658206 23/08/99 5-6 ongoing 0 0 
903126 14/02/00 5-6 ongoing 0.331 0.185 
582473 26/04/99 5-6 ongoing 0.032 <0.05 
646157 03/02/00 5-6 miscarriage - FH not seen 0.125 <0.05 
935712 04/05/99 5-6 ongoing (anencephalic) 0 0 
941059 07/12/98 5-6 missed FH seen prior to loss 0.008 <0.05 
917067 14/06/99 5-6 ongoing 0 0 
111113 26/11/98 5-6 miscarriage - FH not seen 0 0 
358083 15/03/99 5-6 ongoing 0 0 
Appendix 7 
number date gestation outcome absorban 
ce nm 
fFN 
mg/ml 
773736 17/05/99 5-6 ongoing 0.085 0.1 
949909 20/04/99 5-6 ongoing 0.013 <0.05 
963022 06/12/00 5-6 missed FH seen prior to loss 0 0 
33423 06/12/99 6-7 miscarriage - FH not seen 0.623 0.26 
876548 02/02/99 6-7 ongoing 0.026 <0.05 
241132 20/12/99 6-7 ectopic 0 <0.05 
889695 13/04/99 6-7 ongoing 0.026 <0.05 
935719 30/03/99 6-7 missed FH seen prior to loss 0.017 <0.05 
952487 20/03/00 6-7 ongoing 0.067 <0.05 
331234 20/03/00 6-7 ongoing 0.076 <0.05 
968644 14/02/00 6-7 ongoing 0.949 0.785 
945046 16/08/99 6-7 missed FH seen prior to loss 0 0 
144541 29/03/99 6-7 ongoing 0.008 <0.05 
144544 29/03/99 6-7 ongoing 0.08 <0.05 
564234, 13/12/99 6-7 ongoing 0.272 0.89 
910823 04/05/00 6-7 ongoing 0.067 <0.05 
861931 16/09/99 6-7 ectopic 0.015 <0.05 
619048 27/04/00 >7 ongoing 0.117 <0.05 
965716 24/01/00 >7 ongoing 0.053 0 
857265 06/12/00 >7 ongoing 0 0 
567373 06/12/99 >7 ongoing 0.041 0.105 
934248 10/04/00 >7 ongoing 0.086 <0.05 
420725 16/08/99 >7 ongoing 0.409 0.81 
836706 05/07/99 >7 ongoing 0.329 0.735 
871831 21/02/00 >7 missed FH seen prior to loss 0.129 <0.05 
582071 16/03/00 >7 ongoing 0.121 <0.05 
Appendix 8 
Samples taken from women in which there was either diagnostic 
dilemma, or a diagnosis of miscarriage had been made 
Group I 
number date source gestation outcome fFN 
mg/ml 
111111 11/12/98 EPU empty uterus ectopic 0.085 
111141 21/08/99 EPU empty uterus ectopic 0.145 
279294 15/12/98 EPU empty uterus ectopic <0.05 
293303 19/03/99 EPU empty uterus ectopic <0.05 
390717 18/08/99 EPU empty uterus ectopic <0.05 
455598 23/08/99 EPU empty uterus ectopic <0.05 
531846 21/10/99 EPU empty uterus ectopic 0.185 
750781 28/01/00 EPU empty uterus ectopic <0.05 
758313 29/11/98 EPU empty uterus ectopic 0.155 
788654 07/07/99 EPU empty uterus ectopic <0.05 
828446 03/02/99 EPU empty uterus ectopic <0.05 
848376 30/12/98 EPU empty uterus ectopic <0.05 
932829 03/07/99 EPU empty uterus ectopic <0.05 
945068 03/02/99 EPU empty uterus ectopic <0.05 
949892 08/02/99 EPU empty uterus ectopic <0.05 
955894 07/05/99 EPU empty uterus ectopic <0.05 
111 117 17/03/99 EPU empty uterus negative 
la arosco 
<0.05 
397 999 18/03/99 EPU empty uterus negative 
la arosco 
0.13 
429 331 09/04/99 EPU empty uterus negative 
la arosco 
0.215 
949880 10/02/99 EPU empty uterus resolving 
trophoblast 
<0.05 
111 331 22/04/99 EKUTý empty uterus - ongoing <0.05 
Appendix 8 
Group 2 
number date source gestation outcome fFN 
mg/ml 
291914 20/08/99 EPU missed miscarriage miscarriage 0.68 
317629 04/11/98 FCU missed miscarriage miscarriage 0.23 
524214 04/11/98 FCU anembryonic pregnancy miscarriage 0.08 
726060 16/12/99 FCU anembryonic pregnancy miscarriage <0.05 
772111 13/01/99 FCU anembryonic pregnancy miscarriage 0.145 
931596 26/11/98 FCU anembryonic pregnancy miscarriage 0.145 
947432 13/01/99 FCU anembryonic pregnancy miscarriage 0.375 
947461 03/02/99 FCU missed miscarriage miscarriage <0.05 
950032 17/03/99 FCU missed miscarriage miscarriage <0.05 
950051 17/03/99 FCU missed miscarriage miscarriage 0 
960087 14/07/99 FCU missed miscarriage miscarriage 0.925 
796819 04/11/98 FCU empty uterus complete 0.715 
948541 03/02/99 FCU empty uterus complete 0.12 
Appendix 9 
Levels of fEN found in plasma samples 
number source outcome Swab fFN µg/ml diluted plasma fFN µg/ml 
402070 FCU TOP 0.7 
460386 FCU TOP 0.665 
522935 FCU TOP 0.41 
658596 FCU TOP 0.44 
705765 FCU TOP 0.213 
736504 FCU TOP 0.734 
913149 FCU TOP 0.76 
958370 FCU TOP 0.5 
958384 FCU TOP 0.475 
958421 FCU TOP 0.39 
958423 FCU TOP 0.54 
958425 FCU TOP 0.47 
958428 FCU TOP 0.705 
958453 FCU TOP 0.5 
958524 FCU TOP 0.375 
493839 FCU TOP <0.05 0.49 
733059 FCU TOP 0 0.285 
751062 FCU TOP 0 0.285 
788654 EPU ectopic <0.05 0.6 
836706 RMC ongoing 0.735 0.59 
854108 RMC ongoing <0.05 0.426 
880457 RMC ongoing 0.165 0.285 
932829 EPU ectopic <0.05 0.42 
959244 FCU TOP <0.05 0.555 
959245 FCU TOP 0 0.44 
959247 FCU TOP 0 0.41 
959248 FCU TOP <0.05 0.555 
959249 FCU TOP 0 0.28 
959250 FCU TOP 0 0.295 
960087 EPU missed 0.925 0.455 
Appendix 10 
Levels of fFN found in non-pregnant subjects 
sample number sex of subject fFN µg/ml 
1 female 0.42 
2 female 0.67 
3 female 0.325 
4 female 0.5 
5 female 0.49 
6 male 0.42 
7 male 0.335 
Appendix 11 
Levels of fFN found in colposcopy subjects 
number sample visible blood staining fFN µg/ml 
039035 no loop 0 
104902 no loop <0.05 
289576 LLETZ yes 0.07 
322396 no loop yes 0 
390789 LLETZ yes 0.215 
408705 no loop <0.05 
409782 no loop yes 0 
563693 LLETZ yes 0.255 
640240 no loop 0 
640240 LLETZ yes 0.5 
674183 no loop <0.05 
719614 LLETZ yes 0.165 
824588 no loop yes 0.11 
887675 no loop 0 
912536 no loop 0 
968693 no loop 0 
Appendix 12 
Levels of fFN found in blood stained samples 
number outcome fFN mcg/ml 
111111 ectopic 0.085 
111141 ectopic 0.145 
291914 missed miscarriage 0.68 
544387 viable <0.05 
698413 viable 0.075 
758313 ectopic 0.155 
878917 viable <0.05 
903126 viable 0.185 
929722 viable <0.05 
931596 missed miscarriage 0.145 
943226 viable <0.05 
943293 viable <0.05 
944017 viable <0.05 
945068 ectopic <0.05 
947432 missed miscarriage 0.375 
947908 viable <0.05 
948758 viable <0.05 
949880 ectopic <0.05 
949892 ectopic <0.05 
949908 viable <0.05 
955894 ectopic <0.05 
960087 missed miscarriage 0.925 
Appendix 13 
Conjoint Analysis 
Dear patient, 
We would be most grateful to you if you would help us with a study about the treatment 
of ectopic pregnancies. 
" This will mean filling out the following questionnaire while you wait to see a doctor. 
" You do not need to have had an ectopic pregnancy. 
Your care will under no circumstances be affected by your participation or absence of 
participation with this study. 
What is an ectopic pregnancy? 
0 An ectopic pregnancy is a pregnancy that develops outside of the womb, usually in 
the fallopian tube. 
" It cannot lead to a live-birth of a baby. 
" It can cause a serious haemorrhage and treatment by surgery under a general 
anaesthetic is necessary. 
This involves: 
1. looking inside your tummy with a telescope (laparoscopy) 
2. either 
a. the fallopian tube that contains the ectopic pregnancy is removed 
-a single operation 
-2-3 day hospital stay or 
b. the fallopian tube is opened and the pregnancy removed from it. 
- follow-up and, possibly a second operation a few days later if 
the pregnancy is not completely removed the first time. 
Women who have had an ectopic pregnancy are more at risk of a further ectopic 
pregnancy than women who have never had an ectopic pregnancy. 
0 Some treatments for ectopic pregnancy increase this risk slightly, others 
reduce it slightly. 
" Some treatments slightly reduce the chances of a normal pregnancy next time 
whereas others don't. 
Appendix 13 
What is the purpose of this study? 
We are looking to see what patients take into consideration when choosing between 
different treatments for ectopic pregnancy 
¢ For the purpose of this study you have to IMAGINE that you have been diagnosed 
with an ectopic pregnancy and that you need surgery for it. 
¢ You have to decide between option I and option 2. Consider the advantages and 
disadvantages and then choose the option that you would want most. 
- for example 
Option A Option B 
Stay in hospital 10 days 1 day 
Surgery yes no 
Recovery from treatment 3 months 1 week 
Your choice 
¢ You have chosen option B 
If you have not been able to finish your questionnaires before you have been called to see 
the doctor, could you please be kind enough to complete it once you have been seen by 
the doctor. 
Thank you very much for your help 
Appendix 13 
Dilemma number 1 Option I Option 2 
Chance of needing more than one operation for treatment 0% 0% 
Chance of next pregnancy to be in the right place 40% 60% 
Risk of a repeat ectopic 10% 20% 
What option would YOU choose? 
Dilemma number 2 Option I Option 2 
Chance of needing more than one operation for treatment 0% 5% 
Chance of next pregnancy to be in the right place 40% 60% 
Risk of a repeat ectopic 10% 10% 
What option would YOU choose? 
Dilemma number 3 Option I Option 2 
Chance of needing more than one operation for treatment 0% O% 
Chance of next pregnancy to be in the right place 40% 60% 
Risk of a repeat ectopic 1 O% 1 O% 
What option would YOU choose? 
Appendix 13 
Dilemma number 4 Option I Option 2 
Chance of needing more than one operation for treatment 0% 5% 
Chance of next pregnancy to be in the right place 40% 60% 
Risk of a repeat ectopic 10% 20% 
What option would YOU choose? 
Dilemma number 5 Option I Option 2 
Chance of needing more than one operation for treatment O% 15% 
Chance of next pregnancy to be in the right place 40% 60% 
Risk of a repeat ectopic 1 O% 10% 
What option would YOU choose? 
Dilemma number 6 Option I Option 2 
Chance of needing more than one operation for treatment 0% 15% 
Chance of next pregnancy to be in the right place 40% 60% 
Risk of a repeat ectopic 10% 20% 
What option would YOU choose? 
Appendix 13 
Dilemma number 7 Option I Option 2 
Chance of needing more than one operation for treatment 0% 5% 
Chance of next pregnancy to be in the right place 40% 40% 
Risk of a repeat ectopic 20% 10% 
What option would YOU choose? 
Dilemma number 8 Option I Option 2 
Chance of needing more than one operation for treatment 0% 5% 
Chance of next pregnancy to be in the right place 40% 60% 
Risk of a repeat ectopic 20% 10% 
What option would YOU choose? 
Dilemma number 9 Option I Option 2 
Chance of needing more than one operation for treatment 0% 5% 
Chance of next pregnancy to be in the right place 40% 60% 
Risk of a repeat ectopic 20% 20% 
What option would YOU choose? 
Appendix 13 
Dilemma number 10 Option 1 Option 2 
Chance of needing more than one operation for treatment O% O% 
Chance of next pregnancy to be in the right place 40% 60% 
Risk of a repeat ectopic 10% 20% 
What option would YOU choose? 
Dilemma number 11 Option 1 Option 2 
Chance of needing more than one operation for treatment Q% 15% 
Chance of next pregnancy to be in the right place 40% 40% 
Risk of a repeat ectopic 20% 10% 
What option would YOU choose? 
Dilemma number 12 Option I Option 2 
Chance of needing more than one operation for treatment O% 15% 
Chance of next pregnancy to be in the right place 40% 60% 
Risk of a repeat ectopic 20% 20% 
What option would YOU choose? 
Appendix 13 
Dilemma number 13 Option I Option 2 
Chance of needing more than one operation for treatment 0% 5% 
Chance of next pregnancy to be in the right place 60% 40% 
Risk of a repeat ectopic 20% 10% 
What option would YOU choose? 
Dilemma number 14 Option I Option 2 
Chance of needing more than one operation for treatment O% 5% 
Chance of next pregnancy to be in the right place 60% 60% 
Risk of a repeat ectopic 20% 10% 
What option would YOU choose? 
Dilemma number 15 Option I Option 2 
Chance of needing more than one operation for treatment O% 15% 
Chance of next pregnancy to be in the right place 60% 40% 
Risk of a repeat ectopic 20% 1 O% 
What option would YOU choose? 
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Dilemma number 16 Option I Option 2 
Chance of needing more than one operation for treatment 0% 15% 
Chance of next pregnancy to be in the right place 60% 60% 
Risk of a repeat ectopic 10% 10% 
What option would YOU choose? 
Dilemma number 17 Option I Option 2 
Chance of needing more than one operation for treatment 0% 1 5% 
Chance of next pregnancy to be in the right place 60% 60% 
Risk of a repeat ectopic 20% 1 O% 
What option would YOU choose? 
Dilemma number 18 Option 1 Option 2 
Chance of needing more than one operation for treatment 5% 5% 
Chance of next pregnancy to be in the right place 40% 60% 
Risk of a repeat ectopic 10% 20% 
What option would YOU choose? 
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Dilemma number 19 Option I Option 2 
Chance of needing more than one operation for treatment 5% 15% 
Chance of next pregnancy to be in the right place 40% 60% 
Risk of a repeat ectopic 1 O% 1 O% 
What option would YOU choose? 
Dilemma number 20 Option 1 Option 2 
Chance of needing more than one operation for treatment 5% 15% 
Chance of next pregnancy to be in the right place 40% 60% 
Risk of a repeat ectopic 10% 20% 
What option would YOU choose? 
Dilemma number 21 Option I Option 2 
Chance of needing more than one operation for treatment O% 0% 
Chance of next pregnancy to be in the right place 40% 60% 
Risk of a repeat ectopic 10% 2O% 
What option would YOU choose? 
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Dilemma number 22 Option 1 Option 2 
Chance of needing more than one operation for treatment 5% 15% 
Chance of next pregnancy to be in the right place 40% 40% 
Risk of a repeat ectopic 20% 1 O% 
What option would YOU choose? 
Dilemma number 23 Option I Option 2 
Chance of needing more than one operation for treatment 5% 15% 
Chance of next pregnancy to be in the right place 40% 60% 
Risk of a repeat ectopic 20% 10% 
What option would YOU choose? 
Dilemma number 24 Option I Option 2 
Chance of needing more than one operation for treatment 5% 15% 
Chance of next pregnancy to be in the right place 40% 60% 
Risk of a repeat ectopic 20% 20% 
What option would YOU choose? 
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Dilemma number 25 
Option 1 Option 2 
Chance of needing more than one operation for treatment 5% 15% 
Chance of next pregnancy to be in the right place 60% 40% 
Risk of a repeat ectopic 
What option would YOU choose? 
20% 1 
O% 
Dilemma number 26 
Option I Option 2 
Chance of needing more than one operation for treatment 5% 
15% 
Chance of next pregnancy to be in the right place 60% 
60% 
Risk of a repeat ectopic 10% 
20% 
What option would YOU choose? 
Dilemma number 27 
Chance of needing more than one operation for treatment 
Option I 
5% 
Option 2 
15% 
Chance of next pregnancy to be in the right place 60% 
60% 
Risk of a repeat ectopic 20% 1 
O% 
What option would YOU choose? 
Appendix 13 
Dilemma number 28 Option 1 Option 2 
Chance of needing more than one operation for treatment 15% 15% 
Chance of next pregnancy to be in the right place 40% 60% 
Risk of a repeat ectopic 10% 20% 
What option would YOU choose? 
How easy or difficult have you found this questionnaire 
Very easy 12345 very difficult 
Please ring the number that indicates most closely, the lower 
numbers indicate that you found it easy, the higher numbers that you 
found it difficult 
And finally, please complete the questions overleaf to tell us about yourself. 
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PLEASE COULD YOU GIVE US SOME DETAILS 
ABOUT YOURSELF 
Your Age ý`ý 
For the following questions, please tick the correct box or fill in your answer. 
" Cou 
0 How 
Id you tell us about your plans for pregnancies in the future: 
Family complete 
I would like to become pregnant now, or in the future 
Do not wish to have children 
v man pregnancies nave you naa: 
Live births 
Miscarriages 
Ectopic pregnancies 
Still births 
Termination of pregnancy 
" Have you an history of difficulty with conceiving? 
No 
L_Jyes 
If you have had an ectopic pregnancy in the past, can you tell us how it 
was treated 
Tube removed 
L Tube saved 
L Don't know 
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Do you know anyone who has had an ectopic 
pregnancy. 
No 
yes 
Have you ever had any operation under general 
anaesthetic? 
No 
yes 
- if "yes", was this for a gynaecological 
reason? 
No 
yes 
- if yes - what was the operation 
Scrape /D& C 
H sterosco 
La arosco 
sterilisation 
hysterectomy 
repair 
caesarean section 
other 
what 
" Do ou work? 
No 
es 
- If yes - how do you work 
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Self-employed 
Full time-9to5 
Full time - shifts 
Part - time 
Please give the questionnaire back to the person at the 
registration desk. 
Thank you very much for your help. 
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Reasons why women were not recruited to the ROCET Trial 
Inclusion and exclusion 
criteria 
2 
J I 1 
m 
2 
- v 
C 
Reason why patient was C 
i" 
0 
E 
o E 
found unsuitable for or ä c 
m 
N declined randomisation :j 
m 4 
60624 21.6.65 no family complete yes yes no no no no 
461434 20.8.59 no ruptured ectopic yes yes no yes no no 
545583 16.9.68 considered known PID yes yes no no yes no 
912341 11.10.63 yes requested conservative no yes no yes no no 
138802 22.1.68 yes requested radical yes yes no no no yes 
404780 12.3.77 yes discussion not followed up yes yes no no no yes 
649925 23.1.75 yes didn't want randomising yes yes no no yes no 
702860 14.3.72 no unstable no yes yes no no no 
788654 25.4.66 yes requested radical yes yes no no no yes 
932829 6.7.58 no known PID yes yes no no yes no 
878782 27.10.64 no unicornuate uterus yes yes no yes no no 
133802 22.1.68 yes requested radical yes yes no no no yes 
127787 4.7.66 yes requested radical yes yes no no I no yes 
455598 21.6.76 no previous ectopic yes no no no yes no 
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Inclusion and exclusion 
criteria 
m 
C ° 
M P 
Reason why patient was to 
c Z" 
S 
E 
0 
ö c 
found unsuitable for or n M G1 
E 
y 
declined randomisation 
0 C m 
= LD v ° 2 ä ä 
941M -3. -8.66 no IVF, known PID - bilateral yes yes no no yes no 
salpingectomy 
367682 14.8.69 yes preferred salpingostomy no yes no no no yes 
886023 25.8.65 no yes yes no no no yes 
962921 25.4.77 no no ectopic pregnancy yes yes no EP no no 
800691 24.1.57 no ruptured ectopic yes yes no yes no no 
861931 16.9.71 yes requested radical yes yes no no no no 
965680 6.5.74 yes requested radical yes yes no no no Yes 
946243 13.2.77 no cornual ectopic, had yes yes no no no no 
requested radical 
281244 28.1.64 no sterilised yes yes no no no no 
893085 24.1.60 yes requested radical - pelvic yes yes no EP no 
ectopic 
871511 3.2-64 yes requested conservative yes yes no no yes no 
668491 23-8.69 no unilateral system yes no no no yes no 
531846 5.11.71 yes r equested conservative yes yes no no no yes 
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Inclusion and exclusion 
criteria 
ß >1 m 
_ 
U ö C m 
ä 
E 
Reason why patient was 
C 0 2" 
E 
' 
CL C 
V found unsuitable for or S c°, ' o m ,., 
E CO declined randomisation 
° 
ä i .- 
w 2 ä 
415627 5.6.79 considered not appropriate - paranoid yes yes no no yes no 
schizophrenic 
127015 29.12.70 yes requested conservative yes no no yes yes no 
739909 1.7.75 no yes yes no no no yes 
701120 5.10.71 no cornual ectopic yes yes no no no no 
824588 26.6.62 yes no further pregnancies yes yes no no no no 
desired 
526009 29.1.77 no previous sterilisation yes yes no no yes no 
658814 17.11.76 no tubal damage yes yes no no yes no 
911638 22.9.72 no tubal disease yes yes no no yes no 
502020 12.8.63 no chronic PID no yes no yes yes no 
284755 16.7.71 no known tuba) disease yes yes no no yes no 
630989 9.10.79 no Haemodynamically no yes no no no no 
unstable 
PfD - pelvic inflammatory disease 
IVF - in-vitro fertilisation 
Appendix 14 
Ectopic Pregnancy Protocols 
f Diagnosis is a combination of the clinical situation, ultrasound 
findings and biochemical parameters 
f If the woman is cardiovascularly unstable she needs 
immediate action ie resuscitation and diagnostic laparoscopy. 
However a serum hCG level should be taken with the pre- 
operative bloods in case an ectopic pregnancy is not found. 
f Most women who are being assessed with serial hCGs can be 
managed as outpatients if they are clinically stable. If there are 
worries about their clinical state they should be admitted. A 
woman who is being managed as an outpatient should be told 
to report any change in her symptoms - increase in pain, 
dizziness, fainting. She should be given the contact number of 
the EPU, or told to report to casualty out of normal hours. 
f hCG levels should be known pre-operatively so that medical or 
conservative management may be discussed if appropriate. It 
might also prevent a false negative laparoscopy 
f Remember - whatever way an ectopic pregnancy is managed, the 
woman will be at high risk of another ectopic pregnancy (about I in 16 
will have another ectopic pregnancy). She should be told to seek early 
review in her next pregnancy to confirm its location. 
f The Ectopic Pregnancy Trust is a support group for women who have 
had an ectopic pregnancy. Tel. 0189 5238025 
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Summary 
Ultrasound scan cannot be reasonably expected to be helpful before 6 weeks 
amenorrhoea. If there are indications for investigation before 6 weeks 
amenorrhoea - that would either be symptoms or a past history of ectopic 
pregnancy -a baseline hCG should be taken and the timing of the first scan 
arranged in the light of this. 
Procedure when a viable pregnancy cannot be confirmed 
Perform a pregnancy test. If positive she must remain under the care of the 
EPAU until the test becomes negative or a firm diagnosis is made. 
A. With an empty uterus and cardio-vascular instability: 
1. Needs diagnostic laparoscopy as soon as possible 
2. Pre-op hCG to be taken but do not wait for the result 
B. With an empty uterus and significant symptoms, particularly pain: 
1. Admit 
2. Alternate day hCG estimations 
- an abnormal rise in hCG over 48 hours would indicate a 
diagnostic laparoscopy is necessary 
3. If hCG levels rise appropriately and the clinical situation is stable 
repeat ultrasound I week after first scan 
4. If the patient's clinical picture is such that a diagnostic laparoscopy is 
indicated before the repeat scan 1 week later, repeat the scan early as 
demonstration of a viable intra-uterine pregnancy would avoid an 
unnecessary laparoscopy 
C. With an empty uterus and minor or no symptoms + no other scan 
findings 
1. Take hCG level 
2. Arrange for her to be rescanned in I week 
3. Explain what to look out for with ectopic pregnancy and give EPU 
number. 
4. If the repeat ultrasound is consistent with ectopic pregnancy, a repeat 
hCG should then be taken to help plan management. 
D. With an empty uterus and minor or no symptoms - adenexal mass/fluid in the POD 
1. Take hCG level and repeat at 48 hours 
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2. If the level is rising, arrange for her to be rescanned in 1 week. If the 
level is plateauing or falling seek senior review and repeat hCG in a 
week. 
3. Explain what to look out for with ectopic pregnancy and EPU number. 
4. If hCG levels are >2000 miu/ml, senior review required 
E. With an empty uterus following symptoms consistent with complete 
miscarriage 
1. Repeat urine pregnancy test 10 days later in EPAU. If this is positive, 
serial serum hCG should be initiated. 
F. If a gestation sac is found but viability is not confirmed 
1. Repeat ultrasound in 1 week 
2. hCG estimations are not indicated unless the sac is atypical and 
suggests the presence of a pseudosac. 
Sometimes, the repeat scan is still inconclusive - this tends to occur if there has been an appropriate increase in sac size but no yolk sac/fetal pole has been 
seen but the sac is not large enough to diagnose a missed miscarriage. In these 
cases a further scan should be arranged 
Remember 
- anti-D is required in rhesus negative women with ectopic 
pregnancy. 
3 
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Background 
Diagnosis 
Diagnosis of ectopic pregnancy has three components 
- clinical assessment 
- ultrasound assessment 
- biochemical assessment (ie largely hCG estimations) No single component is likely to diagnose an ectopic pregnancy in isolation - the 
whole picture is more important. 
" Clinical assessment. 
History of vaginal bleeding and pain - particularly unilateral pain - might suggest 
ectopic pregnancy, but also can be misleading. Equally, asymptomatic women 
may have an ectopic pregnancy. 
The date of the last menstrual period gives a guide to the gestation of the 
pregnancy. In assisted conceptions this date is likely to be reliable. In natural 
conceptions there is more scope for error in the gestational age, even with a 
reliable date of last menstrual period. 
Vaginal examination should be undertaken when there is an indication, not 
automatically. Women with an ectopic pregnancy might have a pre-disposing 
chlamydial infection and screening for chlamydia could be indicated. Chlamydia 
may be asymptomatic and still cause tubal damage. 
Cardiovascular instability should be taken seriously ie fainting, tachycardia, hypotension - women who die with ectopic pregnancy die of blood loss. In 
general this requires immediate action ie diagnostic laparoscopy. 
" Ultrasound assessment. 
The presence of an intra-uterine gestation sac excludes an ectopic pregnancy 
except: 
1. with a heterotrophic pregnancy, ie the presence of an ectopic 
pregnancy with a simultaneous intrauterine pregnancy. In spontaneous 
conceptions this occurs approximately once in 30,000 pregnancies. 
The current overall incidence of heterotrophic pregnancy is I in 7,000 - this indicates the impact of assisted conception on the incidence. 
Heterotrophic pregnancy is hard to diagnose, serum hCG levels are 
not helpful and ultrasound will only be diagnostic if an adenexal fetal 
heart pulsation/yolk sac is found on scan. It is something to be 
considered in a woman with persistent problems and an apparently 
normal intra-uterine pregnancy. In assisted conceptions the incidence 
of ectopic pregnancy, and heterotrophic pregnancy is higher than with 
natural conceptions. In assisted conceptions, the pregnancy is often 
monitored from a very early stage which is helpful for diagnosis. 
4 
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2. with a pseudo-gestational sac, this is the appearance of a 
gestational sac on ultrasound which is in reality a decidual cast and 
blood clot. A true gestation sac has a thick, bright rim, but the two can 
be mistaken. "Double ring sign" reliably predicts a gestation sac, but its 
absence does not exclude it. 
An empty uterus or an "early gestation sac" (ie where a fetal pole or yolk sac is 
not seen) may represent an early viable intra-uterine pregnancy, a non-viable 
intra-uterine pregnancy, a complete or incomplete miscarriage or an ectopic 
pregnancy. A baseline hCG level should be taken and a repeat ultrasound 
arranged for a week later. Medical staff should see the patient. 
An ectopic pregnancy can only be diagnosed with certainty by ultrasound if a 
fetal heart pulsation or a yolk sac is seen within the adenexa. This occurs in 
around 5% of ectopic pregnancies. 
Ultrasound Finding Likelihood ratio for ectopic pregnancy 
Ectopic mass, no fluid in POD 3.6 
Fluid in POD only 4.4 
Ecto is Mass and fluid in POD 9.9 
Mol et al, 1998 
Adenexal masses may represent corpus lutea, corpus luteal cysts, ruptured 
corpus lutea or hydrosalpinges - in isolation, fluid in the Pouch of Douglas is 
more predictive of ectopic pregnancy than an adnexal mass. If an adenexal mass 
or fluid in the POD is found, the hCG levels should be tracked at 48 hour 
intervals and the scan repeated after a week if she remains asymptomatic. 
If the ultrasound cannot be exclude an ectopic pregnancy, further diagnostic 
steps are required, this may not necessarily be a diagnostic laparoscopy at this 
stage, this will depend on the clinical and biochemical assessment of the woman. 
It is still more likely that this will not be an ectopic pregnancy. 
" Biochemical assessment 
hCG Currently, this means serum hCG estimations. Urine hCG (ie a pregnancy 
test) can confirm pregnancy but it is not quantifiable and, therefore, not useful in 
the further management of early pregnancy complications. If the urine test is 
positive and the serum negative, the serum result is the one to believe. 
Paired hCG levels (ie levels taken two days apart) are more useful than an 
isolated level - isolated levels have little value. 
- there is a wide variation of levels of hCG at any gestation 
- in normal early pregnancy the levels double approximately every 48 
hours 
- however the levels can double over 48 hours in ectopic pregnancy also 
- so remember to think about the whole picture, Shepherd et al (1990) 
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found a normal doubling of hCG levels in the early stages in 64% of 
women who eventually had ectopic pregnancy. The doubling time 
increased as the women became more symptomatic - be suspicious if 
the levels double and nothing is found on ultrasound. 
If the ultrasound shows an intra-uterine sac, no further hCG levels are 
needed. If a fetal heart has not been seen, the scan will need to be 
repeated 1 week later to confirm viability, not the hCG. 
On trans-vaginal scan, an intra-uterine pregnancy (defined as either an 
intradecidual sign or the presence of a yolk sac or a fetal pole with 
cardiac activity) should be expected by a level of `2000 miu/ml. Mehta 
et al (1997) and Mol et al (1998) suggested 1500 miu/ml if fluid in the 
PoD or an adenexal mass was found or 2000 miu/ml with no 
suspicious ultrasound findings. If the hCG level has reached 2000 
miu/ml and an intra-uterine pregnancy has not been found at 
ultrasound a senior doctor should be involved. 
* caution, normal pregnancies may not be apparent at higher levels and different laboratories 
use different assays giving different levels. Things are made more difficult by the different 
international standard used to measure hCG - when looking at the literature make sure you 
know which standard was used. 
an ectopic pregnancy might be missed at laparoscopy with very low 
levels of hCG, i. e. <500 miu/mI 
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Management Options 
1. Conservative management 
" If the hCG levels are falling no treatment may be required. 
" This is more likely to be successful if the initial hCG level is low ie <2000 
miu/ml. 
" The trophoblast might invade a blood vessel and cause major haemorrhage 
even when the levels are falling. Therefore, the woman must be warned to 
report any suspicious symptoms. This applies until hCG levels have reached 
non-pregnant levels. 
" She cannot be discharged from follow-up until hCGs have reached non- 
pregnant levels (ie<2miu/ml at SJUH, <5 miu/ml at LGI)). Once falling hCG 
levels have been demonstrated, weekly estimations are sufficient. 
" hCG levels need to be checked weekly until they reach non-pregnant levels. 
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Management Options 
2. Medical Management - methotrexate (single dose regime) 
"This decision must be made by a senior SpR or consultant. 
" Medical management can only be considered if the diagnosis of ectopic 
pregnancy can be reached without the need for laparoscopy. If she requires a 
general anaesthetic for diagnosis, a surgical procedure should be performed 
under that anaesthetic, and there is no place for laparoscopic infiltration of the 
ectopic pregnancy with methotrexate. Local methotrexate leads to similar 
systemic levels as systemic administration, this will expose the woman to the 
potential complications of both surgical and medical management) 
" Medical management works best in ectopic pregnancies where the hCG level 
is less than 2000 miu/ml and/or the hCG levels are plateauing. 
" The woman must be cardio-vascularly stable. The presence of pain does not 
contra-indicate the use of methotrexate if she is cardio-vascularly stable. 
However, if there were concerns about the degree of symptoms, it would be 
unwise to use medical management as it is action is not immediate. 
" She must be willing to attend for hCG follow-up until levels are <2miu/ml 
" Methotrexate should not be used in liver disease. 
"A baseline haemoglobin should be taken before treatment. If there are any 
post-treatment symptoms/signs of cardiovascular instability, a drop in the 
haemoglobin level is a further sign of intra-abdominal blood loss. 
"A dose of 50mg/m2 is used. Pharmacy can work out the body surface area if 
you give them the patient's height in metres and weight in kilograms. The 
methotrexate is given as a single IM dose. The woman should be warned 
- her pain might increase in the first 2-4 days 
- she may experience vaginal bleeding 
- she must be willing to attend for follow-up blood tests until non- 
pregnant levels are reached 
- she may require a second dose of methotrexate if the levels do not fall 
appropriately 
- she should avoid strong sunlight in the first 48 hours (because of 
photosensitivity) 
- she should avoid foods such as beans and cabbage (in the first 48 
hours because of flatulence) 
- she should avoid intercourse until hCG reaches non-pregnant levels 
- her hCG levels are likely to increase in the first few days 
Alopecia and neutropenia are not relevant in single dose regimes. 
" Treatment should be given in the EPU and the woman may be allowed home 
afterwards unless symptoms or her circumstances would make it advisable 
for her to be admitted. 
" hCG levels should be taken at 4 and 7 days post treatment. If the level at day 
4 has risen, this should not cause concern, in fact would be expected. The 
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day 4 hCG level should not be acted upon. The level at day 7 should be 15% 
lower than the level at day 4. 
" If levels are falling, repeat monitoring weekly until non-pregnant levels. If 
levels are not falling, a second dose of methotrexate may be required or 
consider surgery. 
" If we expect an increase in pain after the administration of methotrexate, it 
can be difficult to know when to intervene. Surgery is required if there are any 
cardio-vascular signs ie tachycardia, hypotension, fainting. The patient should 
be reviewed by senior medical staff. 
" The trophoblast might invade a blood vessel and cause major haemorrhage 
even when the levels are falling, therefore, the woman must be warned to 
report any suspicious symptoms until hCG levels have reached non-pregnant 
levels. 
" The woman should be advised to wait for two periods before trying to become 
pregnant. This is because of methotrexate is a folate antagonist but there are 
not clear guidelines on this. 
Contraindications to use of methotrexate 
A viable intrauterine pregnancy has been confirmed 
Clinically unstable or in severe pain 
History of liver disease 
Serum hCG more than 2000 miu/ml 
Patient not willing to return for serum hCG monitoring 
Appendix 14 
Management Options 
3. Surgical Treatment 
"A hCG level should be taken pre-operatively. Unless the patient is collapsed, 
the result should be known before she is taken to theatre. No randomised trial 
comparing salpingectomy (removal of the tube containing the ectopic 
pregnancy) with salpingotomy (removal of the ectopic pregnancy with 
preservation of the tube) has been successfully completed; therefore, it is not 
possible to say whether tubal preservation improves the chances of a 
successful intra-uterine pregnancy in the future. Review by Yao and Tulandi 
(1997) of the management of ectopic pregnancy suggest that conservative, in 
comparison to radical surgery, at best gives a small increase in the chance of 
an intra-uterine pregnancy in the future, however, the risk of a further ectopic 
pregnancy is increased. 
- Nine retrospective studies 
JUP Recurrent EP 
sal in ectom 49.3% 9.9% 
sal in otom 53.0% 14.8% 
- One prospective study 
IUP Recurrent EP 
salpingectomy 53.8% 7.7% 
salpingotomy 60% 18.3% 
" The RCOG guidelines for the surgical management of ectopic pregnancy 
recommend salpingectomy as the treatment of choice for a first ectopic 
pregnancy. This should be discussed with the woman pre-operatively so that 
her preferred treatment can guide surgical treatment. 
" Laparoscopic management is the preferred route for the surgical 
management of ectopic pregnancy. It shortens hospital stay, and reduces 
pain and blood loss. It appears to make little difference to future pregnancy 
outcome. Persistent trophoblast is more likely with laparoscopic management. 
" If salpingotomy is performed, whether as an open procedure or 
laparoscopically, persistent trophoblast is a possibility. hCGs should be 
tracked until they reach non-pregnant levels. If levels plateau or begin to rise 
again, methotrexate is indicated. 
" If diagnostic laparoscopy is negative, a diagnosis has not been made. The 
woman should be followed up until 
1. an intra-uterine pregnancy is found on ultrasound 
2. the hCG levels return to non-pregnant levels 
3. it becomes apparent that an ectopic pregnancy was 
present but not visualised at laparoscopy. (This might be 
10 
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because the ectopic pregnancy was too small to be 
visualised or it is located outside the tube). Treatment 
with methotrexate may be the best way of managing this 
situation. 
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